<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:enob="http://enochianbio.com/20211231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_enob_enochianbio.com_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20210701_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001527728 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DCurrentFiscalYearEndDate_06/30 -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DDocumentFiscalYearFocus_2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DDocumentFiscalPeriodFocus_Q2 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-07-01to2021-12-31" name="dei:EntityCentralIndexKey">0001527728</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-07-01to2021-12-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-07-01to2021-12-31" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate">06/30</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-07-01to2021-12-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-07-01to2021-12-31" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0049" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2021-06-30" id="xdx2ixbrl0101" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-12-31" id="xdx2ixbrl0118" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2021-12-31" id="xdx2ixbrl0127" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2021-06-30" id="xdx2ixbrl0128" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31" id="xdx2ixbrl0133" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-06-30" id="xdx2ixbrl0134" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossRealized" contextRef="From2021-10-012021-12-31" id="xdx2ixbrl0231" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-10-012021-12-31" id="xdx2ixbrl0251" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-07-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="enob:StockIssuedPursuantToWarrantsExercised" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="enob:StockIssuedPursuantToWarrantsExercised" contextRef="From2021-10-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="enob:SharesIssuedPursuantToLpcPurchaseAgreement" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="enob:SharesIssuedPursuantToLpcPurchaseAgreement" contextRef="From2021-10-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="enob:SharesIssuedForFullyVestedRsus" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="enob:SharesIssuedForFullyVestedRsus" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="enob:SharesIssuedForFullyVestedRsus" contextRef="From2021-10-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="enob:RestrictedSharesConvertedToSharesForServicesRendered" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="enob:RestrictedSharesConvertedToSharesForServicesRendered" contextRef="From2021-10-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="enob:RestrictedSharesConvertedToSharesForServicesRendered" contextRef="From2021-10-012021-12-31" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-07-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="enob:IssuanceOfCommitmentSharesRelatedToLpcPurchaseAgreementValue" contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="enob:IssuanceOfCommitmentSharesRelatedToLpcPurchaseAgreementValue" contextRef="From2020-07-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="enob:IssuanceOfCommitmentSharesRelatedToLpcPurchaseAgreementValue" contextRef="From2020-07-012020-09-30" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0408" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0436" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0438" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-10-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0442" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0443" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0445" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0449" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0450" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2020-07-012020-12-31" id="xdx2ixbrl0499" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2020-07-012020-12-31" id="xdx2ixbrl0526" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="enob:ContingentSharesIssuedPursuantToAcquisitionAgreement" contextRef="From2021-07-01to2021-12-31" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0678" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0680" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="enob:ContingentSharesIssuedPursuantToAcquisitionAgreement" contextRef="From2021-07-012021-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0684" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="enob:ContingentSharesIssuedPursuantToAcquisitionAgreement" contextRef="From2021-07-012021-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0686" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="enob:ContingentSharesIssuedPursuantToAcquisitionAgreement" contextRef="From2021-07-012021-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0688" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EquityFairValueAdjustment" contextRef="From2021-07-012021-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0690" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EquityFairValueAdjustment" contextRef="From2021-07-012021-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0692" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0696" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0698" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="AsOf2021-12-31" id="xdx2ixbrl0818" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="enob:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalIntrinsicValue" contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl1162" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl1164" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl1166" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl1168" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl1170" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl1172" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="enob:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl1174" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl1178" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="enob:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForExpiredInPeriodWeightedAverageIntrinsicValue" contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl1180" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-07-012021-12-31_custom_CommonStockPurchaseWarrantsMember" id="xdx2ixbrl1210" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-07-012021-12-31_custom_CommonStockPurchaseWarrantsMember" id="xdx2ixbrl1212" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2021-07-012021-12-31_custom_CommonStockPurchaseWarrantsMember" id="xdx2ixbrl1218" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2021-07-012021-12-31_custom_CommonStockPurchaseWarrantsMember" id="xdx2ixbrl1220" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2021-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1262" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-07-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1266" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="enob:WeightedAverageIntrinsicValueGranted" contextRef="From2021-07-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1268" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-07-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1272" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="enob:WeightedAverageIntrinsicValueExercised" contextRef="From2021-07-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2021-07-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1276" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2021-07-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1278" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="enob:WeightedAverageIntrinsicValueCancelledExpired" contextRef="From2021-07-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1280" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1288" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="enob-20211231.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-07-01to2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-02-152018-02-16_custom_AgreementAndPlanOfMergerAgreementAxisMember_custom_EBIAndWeirdScienceLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">enob:AgreementAndPlanOfMergerAgreementAxisMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">enob:EBIAndWeirdScienceLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-02-15</xbrli:startDate>
        <xbrli:endDate>2018-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-02-16_custom_AgreementAndPlanOfMergerAgreementAxisMember_custom_EBIAndWeirdScienceLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">enob:AgreementAndPlanOfMergerAgreementAxisMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">enob:EBIAndWeirdScienceLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_custom_AgreementAndPlanOfMergerAgreementAxisMember_custom_EBIAndWeirdScienceLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">enob:AgreementAndPlanOfMergerAgreementAxisMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">enob:EBIAndWeirdScienceLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_AcquisitionOfEnochianBiopharmaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">enob:AcquisitionOfEnochianBiopharmaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_custom_AcquisitionOfEnochianBiopharmaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">enob:AcquisitionOfEnochianBiopharmaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_custom_LabEquipmentAndInstrumentsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">enob:LabEquipmentAndInstrumentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_custom_LabEquipmentAndInstrumentsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">enob:LabEquipmentAndInstrumentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_LabEquipmentAndInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">enob:LabEquipmentAndInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_LabEquipmentAndInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">enob:LabEquipmentAndInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_AccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">enob:AccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_custom_AccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">enob:AccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_AccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">enob:AccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_LicensingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_LicensingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_GoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_GoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-11-012018-11-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-11-01</xbrli:startDate>
        <xbrli:endDate>2018-11-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-012019-06-19">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-01</xbrli:startDate>
        <xbrli:endDate>2019-06-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ConvertibleNotesPayablesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">enob:ConvertibleNotesPayablesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_custom_ConvertibleNotesPayablesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">enob:ConvertibleNotesPayablesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">enob:NotePayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_custom_NotePayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">enob:NotePayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-032021-11-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-03</xbrli:startDate>
        <xbrli:endDate>2021-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-08_custom_LincolnParksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">enob:LincolnParksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-21_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">enob:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_custom_LincolnParkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">enob:LincolnParkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_CommonStockMember543127406">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_us-gaap_CommonStockMember543127437">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_AgreementAndPlanOfMergerAgreementAxisMember_custom_EBIAndWeirdScienceLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">enob:AgreementAndPlanOfMergerAgreementAxisMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">enob:EBIAndWeirdScienceLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_DanDritDenmarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:DanDritDenmarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-02-06_custom_EquityIncentivePlan2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">enob:EquityIncentivePlan2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-02-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_custom_N2019EquityIncentivePlanMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">enob:N2019EquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_custom_N2019EquityIncentivePlanMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">enob:N2019EquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_custom_N2019EquityIncentivePlanMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">enob:N2019EquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-12-31_custom_N2019EquityIncentivePlanMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">enob:N2019EquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_custom_BoardOfDirectorsAndScientificAdvisoryMembersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:BoardOfDirectorsAndScientificAdvisoryMembersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_custom_BoardOfDirectorsAndScientificAdvisoryMembersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:BoardOfDirectorsAndScientificAdvisoryMembersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_custom_BoardOfDirectorsAndScientificAdvisoryMembersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:BoardOfDirectorsAndScientificAdvisoryMembersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-12-31_custom_BoardOfDirectorsAndScientificAdvisoryMembersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:BoardOfDirectorsAndScientificAdvisoryMembersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_custom_BlackScholesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">enob:BlackScholesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_EmployeeStockOptionOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">enob:EmployeeStockOptionOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_custom_EnochianBiosciencesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">enob:EnochianBiosciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_custom_EnochianBiosciencesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">enob:EnochianBiosciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_custom_EnochianBiosciencesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">enob:EnochianBiosciencesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_CommonStockPurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">enob:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_custom_CommonStockPurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">enob:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CommonStockPurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">enob:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_us-gaap_WarrantMember_custom_ExercisePriceRange4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember_custom_ExercisePriceRange4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_ExercisePriceRange5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_ExercisePriceRange5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">enob:ExercisePriceRange5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_custom_ConsultingAgreementMember_custom_GTechMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">enob:ConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:GTechMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_custom_ConsultingAgreementMember_custom_GTechMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">enob:ConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:GTechMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_custom_ConsultingAgreementMember_custom_GTechMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">enob:ConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:GTechMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-12-31_custom_ConsultingAgreementMember_custom_GTechMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">enob:ConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">enob:GTechMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-032019-11-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-03</xbrli:startDate>
        <xbrli:endDate>2019-11-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-12-31_us-gaap_ServiceAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 12pt; margin-bottom: 3pt"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 14pt Times New Roman, Times, Serif"><b>U.S.
SECURITIES AND EXCHANGE COMMISSION </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>Washington,
D.C. 20549 </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>FORM
<span id="xdx_908_edei--DocumentType_c20210701__20211231_zZeUs82PVlhb"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><span id="xdx_908_edei--DocumentQuarterlyReport_c20210701__20211231_zBdEPhoXrgY9"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span>&#160;QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
the quarterly period ended <b><span id="xdx_900_edei--DocumentPeriodEndDate_c20210701__20211231_z35o6IQiHUT4"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 31, 2021</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">OR</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><span id="xdx_907_edei--DocumentTransitionReport_c20210701__20211231_zg3zH3ncWcj8"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
the transition period from ________ to ________</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Commission
file number <span id="xdx_902_edei--EntityFileNumber_c20210701__20211231_zRqKlXTnXgmg"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" name="dei:EntityFileNumber">001-38758</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 24pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_900_edei--EntityRegistrantName_c20210701__20211231_z3XuWmrS1sg2"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" name="dei:EntityRegistrantName">Enochian Biosciences Inc.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 51%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20210701__20211231_zu6tC6m2xvdb"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span> </b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 48%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20210701__20211231_ziZaCziTH7Uf"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" name="dei:EntityTaxIdentificationNumber">45-2259340</ix:nonNumeric></span> </b></span></td></tr>
<tr>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction of </span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(I.R.S. Employer </span></td></tr>
<tr>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">incorporation or organization) </span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Identification Number) </span></td></tr>
<tr>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--EntityAddressAddressLine1_c20210701__20211231_zAoQzQ8ftBV1"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" name="dei:EntityAddressAddressLine1">2080 Century Park East</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressAddressLine2_c20210701__20211231_zZJCcteNSNQ7"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" name="dei:EntityAddressAddressLine2">Suite 906</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif"><br />
    <span style="font-size: 10pt"><span id="xdx_90C_edei--EntityAddressCityOrTown_c20210701__20211231_zsjUIyyv0Kdc"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" name="dei:EntityAddressCityOrTown">&#160;Los Angeles</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressStateOrProvince_c20210701__20211231_zfJWBnBS9Jdd"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></span></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_edei--EntityAddressPostalZipCode_c20210701__20211231_zvuZ1lKfN5Y"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" name="dei:EntityAddressPostalZipCode">90067</ix:nonNumeric></span></span></td></tr>
<tr>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Address of principal executive offices)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Zip Code)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">+1<span id="xdx_907_edei--CityAreaCode_c20210701__20211231_zIfdSQxqsnge"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" name="dei:CityAreaCode">(305)</ix:nonNumeric></span>
<span id="xdx_90F_edei--LocalPhoneNumber_c20210701__20211231_zd0i2SLMCaMe"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" name="dei:LocalPhoneNumber">918-1980</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">N/A</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Former
name, former address and former fiscal year, if changed since last report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; width: 40%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title
    of Each Class</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 20%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading
    Symbol</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 38%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name
    of Each Exchange on Which Registered</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--Security12bTitle_c20210701__20211231_zU599e8AltK6"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" name="dei:Security12bTitle">Common Stock, par value $0.0001 per
    share</ix:nonNumeric></span></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_edei--TradingSymbol_c20210701__20211231_zIYhebFCr1P8"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" name="dei:TradingSymbol">ENOB</ix:nonNumeric></span></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The <span id="xdx_901_edei--SecurityExchangeName_c20210701__20211231_ztM9qk4279Ba"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. <span id="xdx_90A_edei--EntityCurrentReportingStatus_c20210701__20211231_zDKRKzxJb3Ob"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files). <span id="xdx_90A_edei--EntityInteractiveDataCurrent_c20210701__20211231_zR2Vfa85Jcva"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;&#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging
growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting
company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 25%"><span style="font: 10pt Times New Roman, Times, Serif">Large accelerated filer </span></td>
    <td style="width: 25%"><span style="font: 10pt Times New Roman, Times, Serif">&#9744;</span></td>
    <td style="width: 25%"><span style="font: 10pt Times New Roman, Times, Serif">Accelerated filer </span></td>
    <td style="width: 25%"><span style="font: 10pt Times New Roman, Times, Serif">&#9744;</span></td></tr>
<tr>
    <td><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_edei--EntityFilerCategory_c20210701__20211231_zvqSIrN8D9Bj"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span> </span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#9746;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Smaller reporting company </span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_edei--EntitySmallBusiness_c20210701__20211231_z4tePE0WPNa1"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
<tr>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Emerging growth company</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20210701__20211231_zOyFi6Dq4eHi"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; <span id="xdx_906_edei--EntityShellCompany_c20210701__20211231_zbFsg0Vq07ug"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of February 14, 2022, the number of shares of the registrant&#8217;s common stock outstanding was <span id="xdx_90F_edei--EntityCommonStockSharesOutstanding_iI_c20220214_z4BoRH8WQpvf" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2022-02-14" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,633,267</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>- INDEX -</b>&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 10%">&#160;</td>
    <td style="width: 85%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 5%; text-align: center"><span style="font-size: 10pt"><b>Page</b></span></td></tr>
<tr>
    <td colspan="2"><span style="font-size: 10pt"><a href="#a_001">PART I &#8211; FINANCIAL INFORMATION:</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1</span></td></tr>
<tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
<tr>
    <td><span style="font-size: 10pt">Item 1.</span></td>
    <td><span style="font-size: 10pt"><a href="#a_002">Financial Statements (Unaudited):</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1</span></td></tr>
<tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="#a_003">Condensed Consolidated Balance Sheets as of December 31, 2021 (Unaudited) and June 30, 2021</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2</span></td></tr>
<tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="#a_004">Condensed Consolidated Statements of Operations&#160;for the Three and Six Months Ended December 31, 2021 and 2020 (Unaudited)</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">3</span></td></tr>
<tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="#a_005">Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended December 31, 2021 and 2020 (Unaudited)</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">4</span></td></tr>
<tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="#a_006">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three and Six Months Ended December 31, 2021 and 2020 (Unaudited)</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">5</span></td></tr>
<tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="#a_007">Condensed Consolidated Statements of Cash Flows&#160;for the Six Months Ended December 31, 2021 and 2020 (Unaudited)</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">6</span></td></tr>
<tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="#a_008">Notes to the Condensed Consolidated Financial Statements (Unaudited)</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">7</span></td></tr>
<tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
<tr>
    <td><span style="font-size: 10pt">Item 2.</span></td>
    <td><span style="font-size: 10pt"><a href="#a_009">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">22</span></td></tr>
<tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
<tr>
    <td><span style="font-size: 10pt">Item 3.</span></td>
    <td><span style="font-size: 10pt"><a href="#a_010">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">29</span></td></tr>
<tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
<tr>
    <td><span style="font-size: 10pt">Item 4.</span></td>
    <td><span style="font-size: 10pt"><a href="#a_011">Controls and Procedures</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">29</span></td></tr>
<tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
<tr>
    <td colspan="2"><span style="font-size: 10pt"><a href="#a_012">PART II &#8211; OTHER INFORMATION:</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">30</span></td></tr>
<tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
<tr>
    <td><span style="font-size: 10pt">Item 1.</span></td>
    <td><span style="font-size: 10pt"><a href="#a_013">Legal Proceedings</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">30</span></td></tr>
<tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
<tr>
    <td><span style="font-size: 10pt">Item 1A.</span></td>
    <td><span style="font-size: 10pt"><a href="#a_014">Risk Factors</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">30</span></td></tr>
<tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
<tr>
    <td><span style="font-size: 10pt">Item 2.</span></td>
    <td><span style="font-size: 10pt"><a href="#a_015">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">30</span></td></tr>
<tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
<tr>
    <td><span style="font-size: 10pt">Item 3.</span></td>
    <td><span style="font-size: 10pt"><a href="#a_016">Defaults Upon Senior Securities</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">30</span></td></tr>
<tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
<tr>
    <td><span style="font-size: 10pt">Item 4.</span></td>
    <td><span style="font-size: 10pt"><a href="#a_017">Mine Safety Disclosures</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">30</span></td></tr>
<tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
<tr>
    <td><span style="font-size: 10pt">Item 5.</span></td>
    <td><span style="font-size: 10pt"><a href="#a_018">Other Information</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">30</span></td></tr>
<tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
<tr>
    <td><span style="font-size: 10pt">Item 6.</span></td>
    <td><span style="font-size: 10pt"><a href="#a_019">Exhibits</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">30</span></td></tr>
<tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
<tr>
    <td colspan="2"><span style="font-size: 10pt"><a href="#a_020">Signatures</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">31</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_001"></span>PART I &#8211; FINANCIAL INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_002"></span>Item 1. Financial Statements.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The accompanying financial
statements have been prepared in accordance with generally accepted accounting principles for interim financial information and
in accordance with the instructions for Form 10-Q. Accordingly, they do not include all of the information and footnotes required
by generally accepted accounting principles for complete financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In the opinion of management,
the financial statements contain all material adjustments, consisting only of normal recurring adjustments necessary to present
fairly the financial condition, results of operations, and cash flows of the Company for the interim periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The results for the period
ended December 31, 2021 are not necessarily indicative of the results of operations for the full year. These financial statements
and related footnotes should be read in conjunction with the financial statements and footnotes thereto included in the Company&#8217;s
Form 10-K for the fiscal year ended June 30, 2021, filed with the Securities and Exchange Commission on September 24, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_003"></span>CONDENSED CONSOLIDATED BALANCE SHEETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_301_111_zdnfBjDQopcd" summary="xdx: Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20211231" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20210630" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">June 30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">(Unaudited)</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--AssetsAbstract_iB_zzAtC9GKJnM2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--AssetsCurrentAbstract_i01B_zqM8PqAFcQR3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzQot_z4DY1VPkVrV6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; width: 56%">Cash</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,707,907</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">$</td><td style="width: 12%; color: black; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,664,410</ix:nonFraction></td><td style="width: 1%; color: black; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--OtherReceivablesNetCurrent_i02I_maCzQot_zIJFRnBe85L2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0049">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,640</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--PrepaidExpenseCurrent_i02I_maCzQot_zkDLn57lB1Fd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Prepaid expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">910,637</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">232,943</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AssetsCurrent_i02TI_mtCzQot_maCzbrd_zhghd2WJQeyl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 30pt; text-align: left">Total Current Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,618,544</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,898,993</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzbrd_zZ5bgTkKNAu8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">668,723</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">719,364</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AssetsNoncurrentAbstract_i01B_zqd8ZU7a7B2c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">OTHER ASSETS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsNet_i02I_maCzUWw_z46KBIfM0Ny9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Definite life intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,413</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,906</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_i02I_maCzUWw_zYJfrsfm2e6i" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Indefinite life intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">154,824,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">154,824,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--Goodwill_i02I_maCzUWw_ze1bqYdjc0Pa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt">Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,640,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,640,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--DepositsAssetsNoncurrent_i02I_maCzUWw_ziWQEH4E4Rb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Deposits and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,494</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,984</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maCzUWw_zIuAxFWpX4e5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Operating lease rights-of-use assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,297,964</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,435,978</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--OtherAssetsNoncurrent_i02TI_mtCzUWw_maCzbrd_zalWozysA3vc" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 30pt; text-align: left">Total Other Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">167,848,871</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">167,986,868</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--Assets_iTI_mtCzbrd_zJLRa59ptUX5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">TOTAL ASSETS</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">183,136,138</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,605,225</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zhPWXypBGJr7" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--LiabilitiesCurrentAbstract_i01B_z0MI4X7QxHC8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--AccountsPayableTradeCurrent_i02I_pp0p0_maCzpiX_zEyihcgKkSQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Accounts payable &#8211; trade</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">166,750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">320,559</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzpiX_zGEQk4wXccRl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">504,383</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,182,323</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--OtherLiabilitiesCurrent_i02I_maCzpiX_zTMkz1yByz7l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,875</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,602</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--NotesPayableCurrent_i02I_maCzpiX_zY7BwKfR8HD8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Notes payable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,727,662</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0101">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCzpiX_zJJ7zbGazZm5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Current portion of operating lease liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">303,488</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">292,409</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--LiabilitiesCurrent_i02TI_mtCzpiX_maLzRUY_zppZbEjTK95f" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 30pt; text-align: left">Total Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,202,158</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,885,893</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zXmYAdjBU7Sg" style="vertical-align: bottom; background-color: White">
    <td>NON-CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_i02I_maLzRUY_zNVjJ5HEChUb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Contingent consideration liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,029,842</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,037,945</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--ConvertibleNotesPayable_i02I_maLzRUY_z1m9FpsS67Jh" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Convertible notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,200,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,200,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--NotesPayable_i02I_maLzRUY_zJNEcvrUe80a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Notes payable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0118">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,579,114</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maLzRUY_zN2GtDGf97E9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,084,675</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,239,334</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--Liabilities_i02I_mtLzRUY_maLASEzf4Y_zJo3orV3X0Bh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 30pt; text-align: left">Total Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,516,675</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,942,286</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--CommitmentsAndContingencies_i01I_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;Commitments and Contingencies</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0127">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0128">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">STOCKHOLDERS&#8217; EQUITY:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--PreferredStockValue_i02I_maCzzg5_z9LsFiUS5sQc" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Preferred stock, $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_c20211231_pp4d" title="Preferred stock, par value"><span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_c20210630_pp4d" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_c20211231_pdd" title="Preferred stock, shares authorized"><span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_c20210630_pdd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_do_c20211231_z1ewRawvvo7h" title="Preferred stock, shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20211231_zO1bfRQi7T53" title="Preferred stock, shares outstanding"><span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_do_c20210630_z39Hgpwf6O0b" title="Preferred stock, shares issued"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20210630_zNlf2J1qs9uk" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-06-30" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-06-30" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0133">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0134">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--CommonStockValue_i02I_maCzzg5_zqZrlMj4RMr7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Common stock, par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_c20211231_pp4d" title="Common stock, par value"><span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_c20210630_pp4d" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_c20211231_pdd" title="Common stock, shares authorized"><span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_c20210630_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_901_eus-gaap--CommonStockSharesIssued_c20211231_pdd" title="Common Stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_c20211231_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,633,267</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at December 31, 2021, and <span id="xdx_907_eus-gaap--CommonStockSharesIssued_c20210630_pdd" title="Common Stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_c20210630_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,219,661</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at June 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,263</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,222</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--AdditionalPaidInCapital_i02I_maCzzg5_zYYitNPfHfil" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">273,539,732</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">265,580,356</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCzzg5_zQd9xozlGbKa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">107,906,715</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">90,911,805</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40B_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_maCzzg5_z4zHCKWa22lf" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Accumulated other comprehensive loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,817</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,834</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_409_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtCzzg5_maLASEzf4Y_zoprMRWmWXE6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 30pt; text-align: left">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">165,619,463</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">174,662,939</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzf4Y_zEWMszQ46Bg7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">183,136,138</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">189,605,225</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to the unaudited condensed
consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_004"></span>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS<br />
(UNAUDITED)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_305_113_zG5DKKqvTPE2" summary="xdx: Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td id="xdx_49B_20211001__20211231_zz5rjHZ6IcKe" style="color: black; text-align: center">&#160;</td><td style="color: black; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20201001__20201231_zYm7i2a04q6d" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20210701__20211231_zxJ1Zf5ji3P1" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20200701_20201231" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">For the Six Months Ended</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--OperatingExpensesAbstract_iB_zTAiQfj4thgk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzjP4_zCu3OWQj3K9h" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; width: 40%; text-align: left">General and administrative</td><td style="width: 3%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">$</td><td style="width: 10%; color: black; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,154,901</ix:nonFraction></td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,939,988</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,621,598</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,717,911</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzjP4_zDoguZEo2Nig" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Research and development</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,144,085</ix:nonFraction></td><td style="color: black; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,334,468</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,150,328</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,384,844</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--DepreciationDepletionAndAmortization_i01_maCzjP4_z2JLwujCvp97" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Depreciation and amortization</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,805</ix:nonFraction></td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,760</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,538</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,218</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--OtherGeneralExpense_i01T_mtCzjP4_zTrjnAdQeb5a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Operating Expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralExpense" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,330,791</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralExpense" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,305,216</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralExpense" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,835,464</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralExpense" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,163,973</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--OperatingIncomeLoss_maCz4dz_zjw6Jl5O7EA5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">LOSS FROM OPERATIONS</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,330,791</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,305,216</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,835,464</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,163,973</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zLSMscW4kIWd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other Income (Expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--ChangeInFairValueOfContingentConsideration_i01_maCzNhG_zjcS79RXEap3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Change in fair value of contingent consideration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="enob:ChangeInFairValueOfContingentConsideration" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">167,255</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="enob:ChangeInFairValueOfContingentConsideration" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">493,411</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="enob:ChangeInFairValueOfContingentConsideration" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,991,897</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="enob:ChangeInFairValueOfContingentConsideration" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">920,811</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--InterestExpense_i01N_di_msCzNhG_zqM7pViQ0Z6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,382</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,426</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">183,121</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,739</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--ForeignCurrencyTransactionGainLossRealized_i01_maCzNhG_zH9D2Rq4Jrfc" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Gain on currency transactions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0231">&#151;</span>&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossRealized" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">32,289</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossRealized" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossRealized" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">32,289</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_407_eus-gaap--InvestmentIncomeInterest_i01_maCzNhG_zFuZ0J5t5mxa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Interest and other income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,487</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,066</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,597</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,372</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--NonoperatingIncomeExpense_i01T_mtCzNhG_maCz4dz_zvgr2e29Vqqj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total Other Income (Expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">252,150</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">370,762</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,159,412</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">710,155</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_iT_mtCz4dz_maCzyYf_zLqoK7FGwvf1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Loss Before Income Taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,582,941</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,934,454</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,994,876</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,453,818</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msCzyYf_zojWKthf6woj" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Income Tax (Provision) Benefit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0251">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,158</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">123,952</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--NetIncomeLoss_iT_mtCzyYf_z4OiLV73pfrc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">NET LOSS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,582,941</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,933,296</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,994,910</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,329,866</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--EarningsPerShareBasicAndDiluted_zWtkzRIVZTml" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">BASIC AND DILUTED LOSS PER SHARE</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.13</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.06</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.33</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.11</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_zOyk68AzDqS8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,321,982</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,660,304</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,270,821</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,632,711</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to the unaudited condensed
consolidated financial statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;<b><span id="a_005"></span>CONDENSED CONSOLIDATED STATEMENTS
OF COMPREHENSIVE LOSS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_302_113_zMfgZfG8L3Jh" summary="xdx: Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-top: 0; padding-right: 0; padding-left: 20pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49F_20211001_20211231" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20201001_20201231" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20210701_20211231" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20200701__20201231_zYylM7Cl0mze" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">For the Six Months Ended</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--NetIncomeLoss_maCznYg_zg4Skd3lr5I8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold; text-align: left">Net Loss</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,582,941</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,933,296</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,994,910</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,329,866</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_403_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_iN_di_msCznYg_zaq85WO8PhDg" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; font-weight: bold; text-align: left">Foreign Currency Translation, Adjustments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,990</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,933</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,983</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">38,322</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--ComprehensiveIncomeNetOfTax_iT_mtCznYg_zi09yIRK7Mbh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Comprehensive Loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,586,931</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,923,363</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,002,893</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,291,544</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to the unaudited condensed
consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_006"></span>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217;
EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_306_114_zNpwkSFuVWZb" summary="xdx: Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDER&apos;S EQUITY (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z2QKfa7jrAFi" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zDeXdN31uoal" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zlRTJmshUYnf" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zGTPGmS93Ufb" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B0_zW49go0ZEYE6" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center"># of Shares</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Common Shares</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Additional Paid-In Capital</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Accumulated Deficit</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Accumulated Other Comprehensive Income</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Total</td></tr>
<tr id="xdx_438_c20210701__20210930_eus-gaap--StockholdersEquity_iS_zF9uhwQqqBo" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">July 1, 2021</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLPIp49lgy51" title="Beginning balance, shares" style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,219,661</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,222</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">265,580,356</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">90,911,805</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,834</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">174,662,939</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_zvRZELbA6vY7" style="vertical-align: bottom; background-color: White">
    <td>Stock-based Compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0294">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,727,975</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0297">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,727,975</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net Loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0300">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0301">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,411,969</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0303">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,411,969</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_402_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_iN_pp0p0_di_zpeBELuujGoe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign Currency Translation Adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0308">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-07-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,993</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,993</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_432_c20211001__20211231_eus-gaap--StockholdersEquity_iS_zUwAwLyAn4F8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">September 30, 2021</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_c20211001__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3QqX1CYry1k" title="Beginning balance, shares" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,219,661</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,222</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">268,308,331</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">101,323,774</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,827</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,974,952</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--StockIssuedPursuantToWarrantsExercised_iP3us-gaap--SharesOutstanding_zjOLwDRUqWHi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock Issued Pursuant to Warrants Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--StockIssuedPursuantToWarrantsExercisedShares_iP3custom--StockIssuedPursuantToWarrantsExercised_c20211001__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8V8OrYDdAbf" title="Stock Issued Pursuant to Warrants Exercised, shares" style="text-align: right"><ix:nonFraction name="enob:StockIssuedPursuantToWarrantsExercisedShares" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="enob:StockIssuedPursuantToWarrantsExercised" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="enob:StockIssuedPursuantToWarrantsExercised" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,990</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0322">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="enob:StockIssuedPursuantToWarrantsExercised" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_ecustom--SharesIssuedPursuantToLpcPurchaseAgreement_iP3custom--StockIssuedPursuantToWarrantsExercisedShares_zLzOVz5FSebj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares Issued Pursuant to LPC Purchase Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--SharesIssuedPursuantToLpcPurchaseAgreementShares_iP3custom--SharesIssuedPursuantToLpcPurchaseAgreement_c20211001__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjZVPX8ShLR" title="Shares Issued Pursuant to LPC Purchase Agreement, shares" style="text-align: right"><ix:nonFraction name="enob:SharesIssuedPursuantToLpcPurchaseAgreementShares" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">277,340</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="enob:SharesIssuedPursuantToLpcPurchaseAgreement" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="enob:SharesIssuedPursuantToLpcPurchaseAgreement" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,048,311</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0331">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="enob:SharesIssuedPursuantToLpcPurchaseAgreement" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,048,339</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_zL2VlHGheay5" style="vertical-align: bottom; background-color: White">
    <td>Stock-Based Compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,043,292</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0338">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0339">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,043,292</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--SharesIssuedForFullyVestedRsus_iP3us-gaap--AllocatedShareBasedCompensationExpense_z2RGI17Pxrm4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued for fully vested RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--SharesIssuedForFullyVestedRsusShares_iP3custom--SharesIssuedForFullyVestedRsus_c20211001__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVSGS8K0th05" title="Shares issued for fully vested RSUs, shares" style="text-align: right"><ix:nonFraction name="enob:SharesIssuedForFullyVestedRsusShares" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,266</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="enob:SharesIssuedForFullyVestedRsus" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,811</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0344">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0345">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="enob:SharesIssuedForFullyVestedRsus" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,811</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--RestrictedSharesConvertedToSharesForServicesRendered_iP3custom--SharesIssuedForFullyVestedRsusShares_zozgNY1CGCg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted shares converted to shares for services rendered</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--RestrictedSharesConvertedToSharesForServicesRenderedShares_iP3custom--RestrictedSharesConvertedToSharesForServicesRendered_c20211001__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9a5hXQ92hPi" title="Restricted shares converted to shares for services rendered, shares" style="text-align: right"><ix:nonFraction name="enob:RestrictedSharesConvertedToSharesForServicesRenderedShares" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="enob:RestrictedSharesConvertedToSharesForServicesRendered" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="enob:RestrictedSharesConvertedToSharesForServicesRendered" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--NetIncomeLoss_zA3E7sEzxjc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net Loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0358">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0359">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,582,941</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0361">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,582,941</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_402_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_iN_pp0p0_di_zSn3wVIzqD8e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Currency Translations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0365">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-10-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,990</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,990</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_434_c20211001__20211231_eus-gaap--StockholdersEquity_iE_zlCUEnyRlmx2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">December 31, 2021</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_c20211001__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zETiI0obZoy8" title="Ending balance, shares" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,633,267</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,263</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">273,539,732</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">107,906,715</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,817</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,619,463</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"># of Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Additional Paid-In Capital</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Deficit</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Other Comprehensive Income</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr>
<tr id="xdx_436_c20200701__20200930_eus-gaap--StockholdersEquity_iS_zdPsKHEoO3L7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">July 1, 2020</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_c20200701__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zL1tpvlt6im5" title="Beginning balance, shares" style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,497,409</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,650</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,497,225</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">64,188,198</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">41,416</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,272,261</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_zT4mxBIEaEIg" style="vertical-align: bottom; background-color: White">
    <td>Stock-Based Compensation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">326,156</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0388">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">326,156</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--IssuanceOfCommitmentSharesRelatedToLpcPurchaseAgreementValue_iP3custom--RestrictedSharesConvertedToSharesForServicesRenderedShares_z38cMw1t70Gh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of Commitment Shares Related to LPC Purchase Agreement</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--IssuanceOfCommitmentSharesRelatedToLpcPurchaseAgreementShares_iP3custom--IssuanceOfCommitmentSharesRelatedToLpcPurchaseAgreementValue_c20200701__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zolF7xavln93" title="Issuance of commitment shares related to LPC purchase agreement,shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="enob:IssuanceOfCommitmentSharesRelatedToLpcPurchaseAgreementShares" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">139,567</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="enob:IssuanceOfCommitmentSharesRelatedToLpcPurchaseAgreementValue" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="enob:IssuanceOfCommitmentSharesRelatedToLpcPurchaseAgreementValue" contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0394">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0395">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0396">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--NetIncomeLoss_z1213JLM4oP6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net Loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0400">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0401">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,396,570</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,396,570</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_402_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_iN_pp0p0_di_zjbpW3Vjh7L5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Currency Translations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0406">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0407">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0408">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2020-07-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">28,389</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">28,389</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_435_c20201001__20201231_eus-gaap--StockholdersEquity_iS_zMHShAHLCfIh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">September 30, 2020</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20201001__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1Rs1bxC4fs5" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,636,976</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,664</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,823,367</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">66,584,768</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,027</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">164,230,236</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--StockIssuedPursuantToWarrantsExercised_zqm1C8yfoRze" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock Issued Pursuant to Warrants Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--StockIssuedPursuantToWarrantsExercisedShares_c20201001__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXorDEW8LCJ5" title="Stock Issued Pursuant to Warrants Exercised, shares" style="text-align: right"><ix:nonFraction name="enob:StockIssuedPursuantToWarrantsExercisedShares" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">63,122</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="enob:StockIssuedPursuantToWarrantsExercised" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="enob:StockIssuedPursuantToWarrantsExercised" contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,050</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="enob:StockIssuedPursuantToWarrantsExercised" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,056</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--ContingentShareIssuedPursuantToAcquisitionAgreement_iP3custom--StockIssuedPursuantToWarrantsExercisedShares_zu5mhwwCtXFf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Contingent Shares Issued Pursuant to Acquisition Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ContingentSharesIssuedPursuantToAcquisitionAgreementShares_iP3custom--ContingentShareIssuedPursuantToAcquisitionAgreement_c20201001__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFHNezxJ8lml" title="Contingent Shares Issued Pursuant to Acquisition Agreement, shares" style="text-align: right"><ix:nonFraction name="enob:ContingentSharesIssuedPursuantToAcquisitionAgreementShares" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">63,122</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="enob:ContingentShareIssuedPursuantToAcquisitionAgreement" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="enob:ContingentShareIssuedPursuantToAcquisitionAgreement" contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">192,516</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="enob:ContingentShareIssuedPursuantToAcquisitionAgreement" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">192,522</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_zHQLGBEwCWnj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Stock-based Compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0436">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">359,391</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0438">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0439">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">359,391</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--NetIncomeLoss_zBwI4pwzO4h7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net Loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0442">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0443">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,933,296</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0445">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,933,296</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_402_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_iN_pp0p0_di_zg7ccLtpG1je" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Currency Translations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0448">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0449">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0450">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2020-10-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">9,933</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">9,933</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_436_c20201001__20201231_eus-gaap--StockholdersEquity_iE_z6BFpM8Trbj6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">December 31, 2020</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_c20201001__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zttKByKfEl03" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,763,220</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,676</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">231,457,324</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">69,518,064</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,094</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,940,842</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to the unaudited condensed
consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_007"></span>CONDENSED CONSOLIDATED STATEMENTS OF CASH
FLOWS<br />
(UNAUDITED)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_112_ztCcoqZoYrPl" summary="xdx: Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20210701__20211231_zdfidwz7zxl4" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20200701__20201231_zlQhmqI0WIb3" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">For the
    Six Months Ended</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">December
    31,</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td></tr>
<tr id="xdx_409_eus-gaap--ProfitLoss_maCzPyy_z5CbFnN9bqP4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">NET
    LOSS</span></td><td style="width: 8%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,994,910</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 8%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,329,866</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_iB_zIJT3q7bxGDd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">ADJUSTMENTS
    TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--DepreciationAndAmortization_i01_maCzPyy_zUDCieFq4n1j" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Depreciation
    and amortization</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,538</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,218</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_i01N_di_msCzPyy_zKePOPWEMGm6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Change
    in contingent consideration liability</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,991,897</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">920,811</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40A_ecustom--NonCashCompensation_i01_maCzPyy_z83hhELr1J3i" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Stock
    based compensation expense</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="enob:NonCashCompensation" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,771,267</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="enob:NonCashCompensation" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">685,547</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_maCzPyy_zXq2wogzApT5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt"><span style="font: 10pt Times New Roman, Times, Serif">Right-of-use assets</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">138,014</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">132,611</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_ecustom--AmortizationOfDiscountOnNotePayable_i01N_di_msCzPyy_zs8VGCEoBuWd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Amortization
    of discount of notes payable</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="enob:AmortizationOfDiscountOnNotePayable" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">148,548</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="enob:AmortizationOfDiscountOnNotePayable" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">147,957</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zWaOcAFhAnLb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">CHANGES
    IN OPERATING ASSETS AND LIABILITIES:</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccountsAndOtherReceivables_i02N_di_msCzPyy_zOGCWVcyFwc3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Other
    receivables</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,640</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,982</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02N_di_msCzPyy_zkMh0MeYEnh6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt"><span style="font: 10pt Times New Roman, Times, Serif">Prepaid expenses/deposits</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,812</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">374,154</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maCzPyy_zWe0rRGfXjV4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Accounts
    payable</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">153,810</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">403,953</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40F_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_maCzPyy_z0FWqrxtlNc2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Accrued
    expenses</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">677,939</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">132,542</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--IncreaseDecreaseInOtherCurrentLiabilities_i02_maCzPyy_zbayEWi9G0dl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Other
    current liabilities</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,004</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0499">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--IncreaseDecreaseInOperatingLiabilities_i02_maCzPyy_zDe8PLLpKK6e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Operating
    lease liabilities</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLiabilities" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">143,580</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLiabilities" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">133,209</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtCzPyy_maCzInN_zhNMTc7oRRlb" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">NET
    CASH USED IN OPERATING ACTIVITIES</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,897,151</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,251,828</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_iB_zoomn7pSWDAa" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">CASH
    FLOWS FROM INVESTING ACTIVITIES:</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCzOCS_z2jLTZAigM86" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Purchase
    of property and equipment</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,156</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,721</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzOCS_maCzInN_zBZLEHlDNHya" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">NET
    CASH USED IN INVESTING ACTIVITIES</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,156</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,721</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_i01B_zA9znBqakXM5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">CASH
    FLOWS FROM FINANCING ACTIVITIES:</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--ProceedsFromWarrantExercises_i01_maNCPBUz8wO_z44VvKNQ8e61" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt"><span style="font: 10pt Times New Roman, Times, Serif">Proceeds from exercise
    of warrants</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,056</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--RepaymentsOfOtherDebt_i01N_di_msNCPBUz8wO_z1KkTXm9d7u3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Repayment
    of finance agreement</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RepaymentsOfOtherDebt" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,598</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RepaymentsOfOtherDebt" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,464</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_407_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_maNCPBUz8wO_zlqCbvbqzzVc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Proceeds
    from LPC equity agreement</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,048,339</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0526">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtNCPBUz8wO_maCzInN_zaYbc1vTpFh8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">NET
    CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,950,741</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,408</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--EffectOfExchangeRateOnCashAndCashEquivalents_maCzInN_zAUaGMFsoLd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Effect
    of exchange rates on cash</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,937</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,646</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCzInN_zzo27Qy9Mhj1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">NET
    CHANGE IN CASH</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,956,503</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,271,311</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iS_zss5QTX2HED8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">CASH,
    BEGINNING OF PERIOD</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,664,410</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,696,361</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iE_zjXE71GnREfc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">CASH,
    END OF PERIOD</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,707,907</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,425,050</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zdgpEmRI8qY2" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">SUPPLEMENTAL
    DISCLOSURES OF CASH FLOW INFORMATION</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_ecustom--CashPaidDuringPeriodsForAbstract_iB_zcsh4LUvlEPc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Cash
    paid during the quarter end for:</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--InterestPaidNet_z9CR4jtqcqrc" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt"><span style="font: 10pt Times New Roman, Times, Serif">Interest</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,462</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,365</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--IncomeTaxesPaidNet_z5oph2yrqEr8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Income
    Taxes</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>

<tr id="xdx_409_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zHjriaDx54O5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">SUPPLEMENTAL DISCLOSURES
    OF NON-CASH INVESTING AND FINANCING ACTIVITIES</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_ecustom--ContingentSharesIssuedPursuantToAcquisitionAgreement_i01_zcbZn9T74Ba8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Contingent Shares issued pursuant
    to Acquisition Agreement</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0558">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="enob:ContingentSharesIssuedPursuantToAcquisitionAgreement" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">192,522</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_ecustom--FinanceAgreementEnteredIntoInExchangeForPrepaidAssets_i01_zywhWFBcYD" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Finance agreement entered into in exchange
    for prepaid assets</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="enob:FinanceAgreementEnteredIntoInExchangeForPrepaidAssets" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">666,875</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="enob:FinanceAgreementEnteredIntoInExchangeForPrepaidAssets" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">607,250</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>



<p style="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0; text-indent: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to the unaudited condensed
consolidated financial statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_008"></span>NOTES TO UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_zzdz502NPVH1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 1 &#8212; <span id="xdx_82F_zGexzOid36kl">THE BUSINESS AND SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="enob:BusinessPolicyTextBlock"><p id="xdx_842_ecustom--BusinessPolicyTextBlock_zdpolIc4mLw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_866_zPz94g9XpuUd">Business</span>&#8211; </b>Enochian
Biosciences Inc., (&#8220;Enochian&#8221;, or &#8220;Registrant&#8221;, and together with its subsidiaries, the &#8220;Company&#8221;,
&#8220;we&#8221; or &#8220;us&#8221;) engages in the research and development of pharmaceutical and biological products for the
human treatment of HIV, HBV, influenza and coronavirus infections, and cancer with the intent to manufacture and commercialize
said products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z44w4TFoTuob" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_868_zgblHv37OGkf">Basis of Presentation</span>-
</b>The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in the United
States of America (&#8220;U.S. GAAP&#8221;) and follows the rules and regulations of the U.S. Securities and Exchange Commission
(&#8220;SEC&#8221;). The accompanying financial statements are unaudited. In the opinion of management, all adjustments (which
include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows
at December 31, 2021 and 2020 and for the periods then ended have been made. Certain information and footnote disclosures normally
included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited
condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included
in the Company&#8217;s June 30, 2021, audited financial statements. The results of operations for the periods ended December 31,
2021 and 2020 are not necessarily indicative of the operating results for the full year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zuauWDhCwQwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_868_zh15QYLSF0l3">Consolidation</span> </b>- For
the three and six months ended December 31, 2021 and 2020, the condensed consolidated financial statements include the accounts
and operations of the Registrant and its subsidiaries. All material inter-company transactions and accounts have been eliminated
in the consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_849_eus-gaap--UseOfEstimates_z5RNYMYm8Ybg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_868_z75HCR2nvWxi">Accounting Estimates</span>
</b>- The preparation of financial statements in conformity with generally accepted accounting principles requires management to
make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets
and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period.
Actual results could differ from those estimated. Significant estimates include the fair value and potential impairment of intangible
assets, and fair value of equity instruments issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="enob:CovidPolicyTextBlock"><p id="xdx_84E_ecustom--CovidPolicyTextBlock_zIvUHec4WOf9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_869_z7qORhNHxEKe">COVID-19</span> -</b> The pandemic
continues to evolve, and to date has led to the implementation of various mitigation responses, including government-imposed quarantines,
travel restrictions and other public health safety measures, as well as leading to reported adverse impacts on healthcare resources,
facilities and providers across the United States and in other countries. COVID-19 may cause delays in our research activities.
To date, it has not materially affected our operations; however, it has caused delays in the conduct of experiments due to limitations
of various organizations, in particular those conducting experiments related to COVID-19. There have also been increases in the
cost to conduct animal studies due to staffing and other limitations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The full extent to which
the COVID-19 pandemic may impact our business and operations is subject to future developments, which are uncertain and difficult
to predict. Further quarantines, shelter-in-place or similar restrictions and other actions taken or imposed by foreign, federal,
state and local governments could adversely impact our or our partners&#8217; clinical, research and development, regulatory and
manufacturing operations or timelines.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We continue to monitor the
impact of the COVID-19 pandemic on our business and operations and will seek to adjust our activities as appropriate. In addition,
the pandemic could result in significant and prolonged disruption of global financial markets, reducing our ability to access capital,
which could in the future negatively affect the financial resources available to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_84F_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zTfqQhPZHYxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86B_zWEDJJv1Q4i5">Functional Currency &amp;
Foreign Currency Translation</span> </b>- The functional currency of Enochian Denmark is the Danish Kroner (&#8220;DKK&#8221;). The Company&#8217;s
reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company&#8217;s balance sheet accounts
are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars
at the average exchange rates prevailing during the periods ended December 31, 2021 and 2020. Translation gains and losses are
deferred and accumulated as a component of other comprehensive income in stockholders&#8217; equity. Transaction gains and losses
that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included
in the statement of operations as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_237_z9OyUzQKsVqb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 9; Value: 1 -->
    <div id="xdx_236_zudA1YAHlg77" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23E_zlz2Tv4urGma" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_238_zUWf6HkjozH7" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_234_z38XqCl26PG9" style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zQG1k7ZV2Nzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_235_zce1d94G5fWl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES<br />
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </b></p></ix:exclude>

<ix:exclude><p id="xdx_234_zyN4jiBBIT79" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zFxkd5pqpneg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 &#8212; THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES (Continued) </b></p></ix:exclude>

<ix:exclude><p id="xdx_230_zHe1kUROet3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zTYSPqix6Uxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_864_z4Sj3OrGb24b">Cash and Cash Equivalents</span>
</b>&#8212;The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash
equivalents. The Company had balances held in financial institutions in Denmark and in the United States in excess of federally
insured amounts at December 31, 2021 and June 30, 2021 of $<span id="xdx_90D_eus-gaap--CashCashEquivalentsAndShortTermInvestments_c20211231_pp0p0" title="Cash held in financial institutions"><ix:nonFraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,423,820</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--CashCashEquivalentsAndShortTermInvestments_c20210630_pp0p0" title="Cash held in financial institutions"><ix:nonFraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,287,212</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zd8GfXoMhxu1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86D_zfdXtRfvVYL5">Property and Equipment</span>
</b>&#8212; Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives
of property and equipment are capitalized and depreciated upon being placed in service. Expenditures for maintenance and repairs
are charged to expense as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the
estimated useful lives of the assets, which range from four to ten years (see Note 3).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zhrExVzl5Tm" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_862_zUiwVU3DAIei">Intangible Assets</span> - </b>The
Company has both definite and indefinite life intangible assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Definite life intangible
assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards
Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 350, &#8220;Goodwill and Other Intangible
Assets&#8221;. Intangible assets are recorded at cost. Patent costs consist of costs incurred to acquire the underlying patent.
If it is determined that a patent will not be issued, the related remaining capitalized patent costs are charged to expense. Intangible
assets are amortized on a straight-line basis over their estimated useful life. The estimated useful life of patents is twenty
years from the date of application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Indefinite life intangible
assets include license agreements and goodwill. The Company accounts for indefinite life intangible assets in accordance with ASC
350, &#8220;Goodwill and Other Intangible Assets&#8221;. License agreement costs represent the fair value of the license agreement
on the date acquired and are tested annually for impairment, as well as whever events or changes in circumstances indicate the
carrying value may not be recoverable. The fair value analysis performed on the license agreements, and the fair value analysis
performed on goodwill supported that both indefinite life intangible assets are not impaired as of June 30, 2021 (see Note 4.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock"><p id="xdx_840_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zGalthAb5iA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_860_ziWxEqeINWV4">Goodwill</span> </b>&#8212;Goodwill
is not amortized but is evaluated for impairment annually as of June 30<sup>th</sup> of each fiscal year or whenever events or
changes in circumstances indicate the carrying value may not be recoverable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"><p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zWjoTOGacHR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><b><span id="xdx_867_zCiz5qNWgNLk">Impairment of Goodwill and Indefinite Lived
Intangible Assets</span> </b>&#8211; We test for goodwill impairment at the reporting unit level, which is one level below the operating
segment level. Our detailed impairment testing involves comparing the fair value of each reporting unit to its carrying value,
including goodwill. Fair value reflects the price a market participant would be willing to pay in a potential sale of the reporting
unit and is based on discounted cash flows or relative market-based approaches. If the carrying value of the reporting unit exceeds
its fair value, we record an impairment loss for such excess. The carrying value of in-process research and development (&#8220;IPR&amp;D&#8221;)
and goodwill at December 31, 2021, were $<span id="xdx_90F_ecustom--InProcessResearchAndDevelopment_c20211231_pp0p0" title="In-Process Research &amp; Development"><ix:nonFraction name="enob:InProcessResearchAndDevelopment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">154,824,000</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--Goodwill_c20211231_pp0p0" title="Goodwill"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,640,000</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">For indefinite-lived intangible assets, such
as licenses acquired as an IPR&amp;D asset, on an annual basis we determine the fair value of the asset and record an impairment
loss, if any, for the excess of the carrying value of the asset over its fair value. The fair value analysis performed on the license
agreement, and the annual fair value analysis performed on goodwill supported that both indefinite life intangible assets are not
impaired as of June 30, 2021, and no impairment is deemed necessary as of December 31, 2021 (see Note 4.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_23A_zUselEkq9kUc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 10; Value: 1 -->
    <div id="xdx_234_z4PZyvDQFFq5" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23B_z8ofzZ85fbmg" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_23D_zGAg8OvEY4a9" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_23E_zZDKx0TGBA3b" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zNBMl8rMNty5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_234_zbdkVhsPzp5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES<br />
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </b></p></ix:exclude>

<ix:exclude><p id="xdx_232_zotVrQOvTwJj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zoFo3qpuDDrh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 &#8212; THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_231_zdIT0EdlMTUl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zBxGHuIrTSL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86B_zbdLP2VdhMYk">Impairment of Long-Lived
Assets</span> - </b>Long-lived assets, such as property and equipment and definite life intangible assets are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances
which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant
adverse changes in the business climate or legal factors; current period cash flow or operating losses combined with a history
of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will
more likely than not be sold or disposed of significantly before the end of its estimated useful life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Recoverability of assets
to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows
expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows,
an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.
Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or
fair value less costs to sell and would no longer be depreciated. The depreciable basis of assets that are impaired and continue
in use are their respective fair values.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_z2aYjPqqXOF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_862_zgSprQwTzQYj">Leases</span> </b>&#8212; In
accordance with ASC Topic 842, the Company determined the initial classification and measurement of its right-of-use assets and
lease liabilities at the lease commencement date and thereafter. The lease terms include any renewal options and termination options
that the Company is reasonably assured to exercise, if applicable. The present value of lease payments is determined by using the
implicit interest rate in the lease, if that rate is readily determinable; otherwise, the Company develops an incremental borrowing
rate based on the information available at the commencement date in determining the present value of the future payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Rent expense for operating
leases is recognized on a straight-line basis, unless the operating lease right of use assets have been impaired, over the reasonably
assured lease term based on the total lease payments and is included in operating expense in the condensed consolidated statements
of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease
right-of-use assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative
expenses in the unaudited condensed consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company has elected
the practical expedient to not separate lease and non-lease components. The Company&#8217;s non-lease components are primarily
related to property maintenance, insurance and taxes, which vary based on future outcomes, and thus are recognized in general and
administrative expenses when incurred (see Note 5.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zYuQpJN8vsQ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86D_zukdRxntuqwb">Research and Development
Expenses</span> </b>&#8212; The Company expenses research and development costs incurred in formulating, improving, validating, and creating
alternative or modified processes related to and expanding the use of the HIV, HBV, Coronaviruses and Oncology therapies and technologies
for use in the prevention, treatment, amelioration of and/or therapy for HIV, HBV, Coronaviruses and Oncology. Research and development
expenses for the three and six months ended December 31, 2021, amounted to $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20211001__20211231_zjeRdy0U9eD" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,144,085</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210701__20211231_zY37w59lUwkl" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,150,328</ix:nonFraction></span>, respectively. Research and
development expenses for the three and six months ended December 31, 2020, amounted to $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20201001__20201231_z94YRd531qja" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,334,468</ix:nonFraction></span>, and $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20200701__20201231_zVQfu3qJbaz7" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,384,844</ix:nonFraction></span>, respectively</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zlpG7yzaXXpk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_866_zLb5hBHNwvi2">Income Taxes</span> </b>&#8212;
The Company accounts for income taxes in accordance with FASB ASC Topic 740, &#8220;Accounting for Income Taxes&#8221;, which requires
an asset and liability approach for accounting for income taxes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zMwRJBXAPz7l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_864_zJzWw1xhMtW2">Loss Per Share</span> </b>&#8212;
The Company calculates earnings/ (loss) per share in accordance with FASB Topic ASC 260, &#8220;Earnings Per Share&#8221;. Basic
earnings per common share (EPS) are based on the weighted average number of shares of Common Stock outstanding during each period.
Diluted earnings per common share are based on shares outstanding (computed as under basic EPS) and potentially dilutive shares
of Common Stock. Potential shares of Common Stock included in the diluted earnings per share calculation include in-the-money stock
options that have been granted but have not been exercised. Because of the net loss for the three and six months ended December
31, 2021 and 2020, the dilutive shares for both periods were excluded from the Diluted EPS calculation as the effect of these potential
shares of Common Stock is anti-dilutive. The Company had <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20211231_pdd" title="Potential dilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,125,894</ix:nonFraction></span> and <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20201231_pdd" title="Potential dilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,072,275</ix:nonFraction></span> potential shares of Common Stock excluded from
the Diluted EPS calculation as of December 31, 2021 and December 31, 2020, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_232_zUIvKxHh1EH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 11; Value: 1 -->
    <div id="xdx_239_zmRNktvHlITd" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_232_zZrVaGJIc5z6" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_239_zu9vIIzXITSc" style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_238_zVJbi8q2AE6b" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_23A_zWue3vhgOshe" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zeSGaaSxIT4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zyExGflddddc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES<br />
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zlIWGMhqsi96" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zRoJjfjJ2o0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 &#8212; THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES (Continued) </b></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zRi0aHxBuewa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zyNS8xl0P4Q" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86F_zgx33xd7Rwof">Fair Value of Financial
Instruments</span> </b>&#8212;The Company accounts for fair value measurements for financial assets and financial liabilities in accordance
with FASB ASC Topic 820, &#8220;Fair Value Measurements&#8221;. The authoritative guidance, which, among other things, defines
fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability
category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing
the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between
market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market
participants would use in pricing an asset or liability (see Note 2.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="enob:StockOptionsAndWarrantsPolicyTextBlock"><p id="xdx_84D_ecustom--StockOptionsAndWarrantsPolicyTextBlock_zVfjHwEq0vpj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;<b><span id="xdx_86B_zSbDJYrbbASj">Stock Options and
Restricted Share Units</span></b>&#8212;The Company has granted stock options, restricted share units (&#8220;RSUs&#8221;) and warrants.
The Company accounts for options in accordance with the provisions of FASB ASC Topic 718, &#8220;Compensation - Stock Compensation&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z1lwzMnNmu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86D_zBp4v59jdKYg">Stock-Based Compensation</span></b>&#8212;The
Company records stock-based compensation in accordance with ASC Topic 718, &#8220;Compensation - Stock Compensation&#8221;. All
transactions in which goods or services are the consideration received for the issuance of equity instruments&#160;are accounted
for based on the fair value of the&#160;consideration received or the&#160;fair value of the equity instrument issued, whichever
is more reliably measurable. Equity instruments issued to consultants and the cost of the services received as consideration are
measured and recognized based on the&#160;fair value of the equity instruments issued and are recognized over the required service
period, which is generally the vesting period. Stock based compensation costs for the vesting of options and RSUs granted for the
three and six months ended December 31, 2021, were $<span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0p0_c20211001__20211231_zXT8OEJk0Bz2" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,043,292</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20210701__20211231_zHzKa0ibD4Oi" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,771,267</ix:nonFraction></span>, respectively. Stock-based compensation costs for
the vesting of the options and RSUs granted for the three and six months ended December 31, 2020 were $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_pp0p0_c20201001__20201231_zIwCbzChZujd" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">359,391</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20200701__20201231_ztX2TG23X0y1" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">668,482</ix:nonFraction></span>, respectively.
(see Note 7.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="enob:NewAccountingPronouncementsNotYetAdoptedPolictTextBlock"><p id="xdx_84E_ecustom--NewAccountingPronouncementsNotYetAdoptedPolictTextBlock_zsowdzcGXFV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86F_zWpRK5RUedFc">Recently Adopted Accounting
Pronouncements</span></b>&#8212;<b> </b>Recent accounting pronouncements issued by the FASB do not or are not believed by management to
have a material impact on the Company&#8217;s present or future financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_230_zcmrzjNdYl22" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 12; Value: 1 -->
    <div id="xdx_231_z7ptIWDdFXPd" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_238_zOu5A9yf0Ntk" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_232_zbLNjUCQh7cg" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_230_zoyGSQFetZAe" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zhrafMGNi89l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_238_zDgE7upBNLfa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES<br />
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_232_zKoHJcLQElee" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p></ix:exclude>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="enob:FairVakueMeasurementTextBlock"><p id="xdx_802_ecustom--FairVakueMeasurementTextBlock_z8pvGDoNoAJ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>NOTE 2 &#8212; <span id="xdx_820_zXDZPO1ydac">FAIR VALUE
MEASUREMENTS</span> </b>&#8212; The Company accounts for fair value measurements for financial assets and financial liabilities in accordance
with FASB ASC Topic 820, &#8220;Fair Value Measurements&#8221;. The authoritative guidance, which, among other things, defines
fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability
category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing
the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between
market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market
participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes
a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities; </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">There were no Level 1, 2
or 3 assets, nor any Level 1 or 2 liabilities as of December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Level 3 liabilities held
as of December 31, 2021 consisted of a contingent consideration liability related to the February 16, 2018 acquisition of Enochian
Biopharma Inc. (the &#8220;Acquisition&#8221;). As consideration for the Acquisition, the stockholders of Enochian Biopharma received
(i) <span id="xdx_90F_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20180215__20180216__us-gaap--TypeOfArrangementAxis__custom--AgreementAndPlanOfMergerAgreementAxisMember__us-gaap--BusinessAcquisitionAxis__custom--EBIAndWeirdScienceLLCMember_pdd" title="Shares issued on business combination"><ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="From2018-02-152018-02-16_custom_AgreementAndPlanOfMergerAgreementAxisMember_custom_EBIAndWeirdScienceLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,081,962</ix:nonFraction></span> shares of Common Stock, and (ii) the right to receive contingent shares pro rata upon the exercise of warrants,
which were outstanding at closing. The contingent consideration liability was recorded at fair value of $<span id="xdx_901_eus-gaap--BusinessCombinationContingentConsiderationLiability_c20180216__us-gaap--TypeOfArrangementAxis__custom--AgreementAndPlanOfMergerAgreementAxisMember__us-gaap--BusinessAcquisitionAxis__custom--EBIAndWeirdScienceLLCMember_pp0p0" title="Contingent consideration liability"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2018-02-16_custom_AgreementAndPlanOfMergerAgreementAxisMember_custom_EBIAndWeirdScienceLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,516,000</ix:nonFraction></span> at the time
of acquisition and is subsequently remeasured to fair value at the end of each reporting period. At December 31, 2021, there were
<span id="xdx_90A_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20210701__20211231__us-gaap--TypeOfArrangementAxis__custom--AgreementAndPlanOfMergerAgreementAxisMember__us-gaap--BusinessAcquisitionAxis__custom--EBIAndWeirdScienceLLCMember_pdd" title="Shares issued on business combination"><ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="From2021-07-012021-12-31_custom_AgreementAndPlanOfMergerAgreementAxisMember_custom_EBIAndWeirdScienceLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></span> contingent shares were issuable in connection with the Acquisition of Enochian Biopharma.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The fair value of the contingent
consideration liability is estimated using an option-pricing model. The key inputs to the model are all contractual or observable
with the exception being volatility, which is computed, based on the Company&#8217;s underlying stock. The key inputs to valuing
the contingent consideration liability as of December 31, 2021, include the Company&#8217;s stock price on the valuation date of
$<span id="xdx_90B_eus-gaap--SharePrice_c20211231__us-gaap--BusinessAcquisitionAxis__custom--AcquisitionOfEnochianBiopharmaMember_pdd" title="Stock price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-12-31_custom_AcquisitionOfEnochianBiopharmaMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.29</ix:nonFraction></span>; the exercise price of the warrants of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20211231__us-gaap--BusinessAcquisitionAxis__custom--AcquisitionOfEnochianBiopharmaMember_pdd" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-31_custom_AcquisitionOfEnochianBiopharmaMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.30</ix:nonFraction></span>, the risk-free rate of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210701__20211231__us-gaap--BusinessAcquisitionAxis__custom--AcquisitionOfEnochianBiopharmaMember_ziWEEoYv1qw6" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-07-012021-12-31_custom_AcquisitionOfEnochianBiopharmaMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.20</ix:nonFraction></span>% the expected volatility of the Company&#8217;s
Common Stock of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210701__20211231__us-gaap--BusinessAcquisitionAxis__custom--AcquisitionOfEnochianBiopharmaMember_zeJqOzcO9p0b" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-07-012021-12-31_custom_AcquisitionOfEnochianBiopharmaMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">88.4</ix:nonFraction></span>%, the digital call rate of <span id="xdx_90B_ecustom--DigitalCallRate_dp_c20210701__20211231__us-gaap--BusinessAcquisitionAxis__custom--AcquisitionOfEnochianBiopharmaMember_zGwESQ7nWYjl" title="Digital call rate"><ix:nonFraction name="enob:DigitalCallRate" contextRef="From2021-07-012021-12-31_custom_AcquisitionOfEnochianBiopharmaMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">99</ix:nonFraction></span>%, and the <span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesContingentlyIssuable_c20210701__20211231__us-gaap--BusinessAcquisitionAxis__custom--AcquisitionOfEnochianBiopharmaMember_pdd" title="Outstanding contingent shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable" contextRef="From2021-07-012021-12-31_custom_AcquisitionOfEnochianBiopharmaMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></span> contingent shares remaining at the end of the period. Fair
Value measurements are highly sensitive to changes in these inputs and significant changes in these inputs could result in a significantly
higher or lower fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Unless otherwise disclosed,
the fair value of the Company&#8217;s financial instruments including cash, accounts receivable, prepaid expenses, investments,
accounts payable, accrued expenses, capital lease obligations and notes payable approximate their recorded values due to their
short-term maturities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The following table sets
forth the Level 3 liability at December 31, 2021, which is recorded on the balance sheet at fair value on a recurring basis. As
required, this liability is classified based on the lowest level of input that is significant to the fair value measurement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zTjjbhSqpNRg" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8BA_zHVdf2TSxoei" style="display: none">Summary of significant to the fair value measurement</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements at<br /> Reporting Date Using</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted Prices in <br /> Active Markets for Identical Assets Inputs</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other <br /> Observable Inputs</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other Unobservable Inputs</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">The roll forward of the contingent consideration liability is as follows:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 46%">Balance June 30, 2021</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--BusinessCombinationContingentConsiderationLiabilityCurrent_iS_pp0p0_c20210701__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zuwdfkRWDRl8" title="Balance at beginning" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0678">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--BusinessCombinationContingentConsiderationLiabilityCurrent_iS_pp0p0_c20210701__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxC8LmKuQ12" title="Balance at beginning" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0680">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiabilityCurrent_iS_pp0p0_c20210701__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0QaAKnWrjFc" title="Balance at beginning" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,037,945</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Contingent Shares issued pursuant to the Acquisition Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ContingentSharesIssuedPursuantToAcquisitionAgreement_c20210701__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Contingent Shares issued pursuant to the Acquisition Agreement" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0684">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ContingentSharesIssuedPursuantToAcquisitionAgreement_c20210701__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" title="Contingent Shares issued pursuant to the Acquisition Agreement" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0686">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ContingentSharesIssuedPursuantToAcquisitionAgreement_c20210701__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Contingent Shares issued pursuant to the Acquisition Agreement" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0688">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Fair value adjustment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--EquityFairValueAdjustment_c20210701__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Fair value adjustment" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0690">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--EquityFairValueAdjustment_c20210701__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" title="Fair value adjustment" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0692">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--EquityFairValueAdjustment_c20210701__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Fair value adjustment" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EquityFairValueAdjustment" contextRef="From2021-07-012021-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,991,897</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Contingent Consideration Liability at December 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--BusinessCombinationContingentConsiderationLiabilityCurrent_iE_pp0p0_c20210701__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zcdpwonFLbcg" title="Balance at end" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0696">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--BusinessCombinationContingentConsiderationLiabilityCurrent_iE_pp0p0_c20210701__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zgl9NActEUH3" title="Balance at end" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0698">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--BusinessCombinationContingentConsiderationLiabilityCurrent_iE_pp0p0_c20210701__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z563wQXU3qk3" title="Balance at end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,029,842</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_23E_zpbHGKzH2P5c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 13; Value: 1 -->
    <div id="xdx_23B_zHF9J7P2kiab" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23B_zKakAQ3NCX7e" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_23D_zjHAuhYul2pb" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_237_zHuU0xO39JLb" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zEJPTRXoQra3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zF56SxfzD3r3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES<br />
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_230_zkNm3wLab3uk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zrnIvvd9yX66" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 3 &#8212; <span id="xdx_825_zykff6PDW36e">PROPERTY AND EQUIPMENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--PropertyPlantAndEquipmentTextBlock_zWcedNjTUQEf" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -7.5pt; padding-left: 7.5pt"><span id="xdx_8B7_zxKHNJzzHbY7" style="display: none">Summary of property and equipment</span></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2021</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left; text-indent: -7.5pt; padding-left: 7.5pt">Lab Equipment and Instruments</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 11%; text-align: center"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210701__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember__srt--RangeAxis__srt--MinimumMember_zpKQWC00Suli" title="Useful Life"><ix:nonNumeric contextRef="From2021-07-012021-12-31_custom_LabEquipmentAndInstrumentsMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">4</ix:nonNumeric></span>-<span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210701__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember__srt--RangeAxis__srt--MaximumMember_ziZZBe1k5Sx5" title="Useful Life"><ix:nonNumeric contextRef="From2021-07-012021-12-31_custom_LabEquipmentAndInstrumentsMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: center">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_pp0p0" title="Total" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_custom_LabEquipmentAndInstrumentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">583,421</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_pp0p0" title="Total" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-06-30_custom_LabEquipmentAndInstrumentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">583,421</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -7.5pt; padding-left: 7.5pt">Leasehold Improvements</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210701__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zYcCAbWT9mzc" title="Useful Life"><ix:nonNumeric contextRef="From2021-07-012021-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric></span></td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">224,629</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-06-30_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">224,629</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -7.5pt; padding-left: 7.5pt">Furniture Fixtures and Equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210701__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_z3pjFCvL7Emc" title="Useful Life"><ix:nonNumeric contextRef="From2021-07-012021-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">4</ix:nonNumeric></span>-<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210701__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zkWjEUOWHTl3" title="Useful Life"><ix:nonNumeric contextRef="From2021-07-012021-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric></span></span></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">177,131</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-06-30_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">171,975</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -7.5pt; padding-left: 7.5pt">Total</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_c20211231_pp0p0" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">985,181</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_c20210630_pp0p0" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">980,025</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -7.5pt; padding-left: 7.5pt">Less Accumulated Depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20211231_z6CnnBl0RdI8" title="Less Accumulated Depreciation" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">316,457</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20210630_zeNsI3VboTQc" title="Less Accumulated Depreciation" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">260,661</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -7.5pt; padding-left: 7.5pt">Net Property and Equipment</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentOther_c20211231_pp0p0" title="Net Property and Equipment" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOther" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">668,723</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentOther_c20210630_pp0p0" title="Net Property and Equipment" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOther" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">719,364</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Depreciation expense amounted
to $<span id="xdx_909_eus-gaap--Depreciation_pp0p0_c20211001__20211231_zyiRKKFUp8g" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,990</ix:nonFraction></span>, and $<span id="xdx_907_eus-gaap--Depreciation_pp0p0_c20210701__20211231_zNcQUldeObvl" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">55,796</ix:nonFraction></span> for the three and six months ended December 31, 2021 respectively, and $<span id="xdx_90B_eus-gaap--Depreciation_pp0p0_c20201001__20201231_zvxjT4AQ9Rdd" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,813</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--Depreciation_pp0p0_c20200701__20201231_zTHeP1tpQHA4" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">53,358</ix:nonFraction></span> for the three
and six months ended December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_806_eus-gaap--IntangibleAssetsDisclosureTextBlock_zstOGDEyIikd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 4 &#8212;<span id="xdx_827_zUk1eA1JCalj">INTANGIBLE ASSETS</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">At December 31, 2021 and
June 30, 2021, definite-life intangible assets, net of accumulated amortization, consisted of patents on the Company&#8217;s products
and processes of $<span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsNet_c20211231_pp0p0" title="Definite-life intangible assets"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">55,413</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsNet_c20210630_pp0p0" title="Definite-life intangible assets"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">65,906</ix:nonFraction></span>, respectively. The patents are recorded at cost and amortized over twenty years from the date
of application. Amortization expense for the three and six months ended December 31, 2021, was $<span id="xdx_90E_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20211001__20211231_z5fZHosT9nBk" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,814</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20210701__20211231_zQzuZMCr9DB" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,741</ix:nonFraction></span>, respectively.
Amortization expense for the three and six months ended December 31, 2020 was $<span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20201001__20201231_zX5UtBvi0FJ" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,947</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20200701__20201231_zmzqh3s7abk9" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,859</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">At December 31, 2021 and
2020, indefinite life intangibles assets consisted of a license agreement classified as In-Process Research and Development (&#8220;IPR&amp;D&#8221;)
intangible assets, which are not amortizable until the intangible asset provides economic benefit, and goodwill.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">At December 31, 2021 and
June 30, 2021, definite and indefinite-life intangible assets consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zSXDurIZel69" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8B8_zZps8ooZkYSl" style="display: none">Schedule of life intangible assets</span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,<br /> 2021</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Period Change</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Effect of Currency Translation</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31&#160;,<br /> 2021</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Definite Life Intangible Assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 24%">Patents</td><td style="width: 2%">&#160;</td>
    <td style="width: 10%; text-align: center; padding-left: 5.4pt"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210701__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zXfvvmFhDRvi" title="Useful Life"><ix:nonNumeric contextRef="From2021-07-012021-12-31_us-gaap_PatentsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">20</ix:nonNumeric></span> Years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" title="Definite-life intangible assets" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2021-06-30_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">316,115</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--PeriodChange_pp0p0_d0_c20210701__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zlFeIImgW87e" title="Period Change" style="width: 12%; text-align: right"><ix:nonFraction name="enob:PeriodChange" contextRef="From2021-07-012021-12-31_us-gaap_PatentsMember" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_c20210701__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" title="Effect of Currency Translation" style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" contextRef="From2021-07-012021-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">14,145</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" title="Definite-life intangible assets" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2021-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">301,970</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less Accumulated Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; padding-left: 18pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_pp0p0" title="Accumulated Amortization" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2021-06-30_custom_AccumulatedAmortizationMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">250,209</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--PeriodChange_c20210701__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_pp0p0" title="Period Change" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="enob:PeriodChange" contextRef="From2021-07-012021-12-31_custom_AccumulatedAmortizationMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">7,741</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_c20210701__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_pp0p0" title="Effect of Currency Translation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" contextRef="From2021-07-012021-12-31_custom_AccumulatedAmortizationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,393</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_pp0p0" title="Accumulated Amortization" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2021-12-31_custom_AccumulatedAmortizationMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">246,557</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net Definite-Life Intangible Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 18pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210630_pp0p0" title="Definite-life intangible assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">65,906</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--PeriodChange_c20210701__20211231_pp0p0" title="Period Change" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="enob:PeriodChange" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">7,741</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_c20210701__20211231_pp0p0" title="Effect of Currency Translation" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,752</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_c20211231_pp0p0" title="Definite-life intangible assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">55,413</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="padding-left: 5.4pt; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Indefinite Life Intangible Assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">License Agreement</td><td>&#160;</td>
    <td style="padding-left: 5.4pt; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--OtherIndefiniteLivedIntangibleAssets_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_pp0p0" title="Indefinite Life Intangible Assets" style="text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2021-06-30_us-gaap_LicensingAgreementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">154,824,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--OtherIndefiniteLivedIntangibleAssets_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_pp0p0" title="Indefinite Life Intangible Assets" style="text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2021-12-31_us-gaap_LicensingAgreementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">154,824,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Goodwill</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--OtherIndefiniteLivedIntangibleAssets_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_pp0p0" title="Indefinite Life Intangible Assets" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2021-06-30_us-gaap_GoodwillMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,640,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--OtherIndefiniteLivedIntangibleAssets_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_pp0p0" title="Indefinite Life Intangible Assets" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2021-12-31_us-gaap_GoodwillMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,640,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total Indefinite Life Intangible Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--OtherIndefiniteLivedIntangibleAssets_c20210630_pp0p0" title="Indefinite Life Intangible Assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">166,464,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--OtherIndefiniteLivedIntangibleAssets_c20211231_pp0p0" title="Indefinite Life Intangible Assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">166,464,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AD_zW1NHL31Vjh7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Expected future amortization
expense is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zqvh9DSS4IR3" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span id="xdx_8B7_z65Xmkx2eaM5" style="display: none">Schedule of expected future amortization expense</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20211231_zXEaRT8NdqR5" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Year ending June 30,</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_maFLIANz0Vs_zHRgdVqyacni" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 73%; text-align: left; padding-left: 10pt">2022</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,661</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_maFLIANz0Vs_zoBnKXTYiRV8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,154</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_maFLIANz0Vs_z7glYpfWMGei" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,154</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_maFLIANz0Vs_zs3P0w4tCJA4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,154</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0_maFLIANz0Vs_zFeZT7QauFpd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,290</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pp0p0_maFLIANz0Vs_zgUZH4GB4IZg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0818">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANz0Vs_zjOOtRWmC7Xe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 10pt"><span style="font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">55,413</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A0_zw8n8391uzc2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">During February 2018, the
Company acquired a License Agreement (as licensee) to an HIV therapy which consists of a perpetual, fully paid-up, royalty-free,
sub-licensable, and sole and exclusive worldwide license to research, develop, use, sell, have sold, make, have made, offer for
sale, import and otherwise commercialize certain intellectual property in cellular therapies for the prevention, treatment, amelioration
of and/or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans. Because the
HIV License Agreement is considered an IPR&amp;D intangible asset it is classified as an indefinite life asset that is tested annually
for impairment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Impairment &#8211; Following
the fourth quarter of each year, management performs its annual test of impairment of intangible assets by performing a quantitative
assessment and determines if it is more likely than not that, the fair value of the asset is greater than or equal to the carrying
value of the asset. The results of the quantitative assessment supported Management&#8217;s conclusion that an impairment adjustment
was not required as of June 30, 2021, and no impairment is deemed necessary as of December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_23F_zynOTAByKSAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 14; Value: 1 -->
    <div id="xdx_234_zd7LZ1bYGtHd" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_237_zm93bqgRJ9we" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_230_z8ZDUrfgeVy6" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_23F_zJSCqlUoPll4" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zuLlxBxr3nC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zvmehwFAIoT4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES</b>&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zMct5iTMkXCc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_230_zhScbkx2Z7wd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:OperatingLeasesOfLessorDisclosureTextBlock"><p id="xdx_80A_eus-gaap--OperatingLeasesOfLessorDisclosureTextBlock_zEWpykzw9RV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 5 &#8212; <span id="xdx_823_zdTfcgeKlOj1">LEASES</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><b>Operating
Leases </b>&#8212; <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDescription_c20181101__20181113" title="Lease premises, description"><ix:nonNumeric contextRef="From2018-11-012018-11-13" name="us-gaap:LesseeOperatingLeaseDescription">On November 13, 2017, Enochian entered into a Lease Agreement for a term of five years and two months from November
1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company (the &#8220;Landlord&#8221;), as landlord,
pursuant to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increases
by 3% each year, and ranges from approximately $8,719 per month for the first year to $10,107 per month for the two months of the
sixth year</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span id="xdx_903_eus-gaap--LesseeOperatingLeaseDescription_c20190601__20190619" title="Lease premises, description"><ix:nonNumeric contextRef="From2019-06-012019-06-19" name="us-gaap:LesseeOperatingLeaseDescription">On June 19, 2018, the Registrant
entered into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc.,
pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, the Registrant entered
into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to
include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from
$17,770 per month for the first year to $23,186 per month for the tenth year. The equalized monthly lease payment for the term
of the lease is $20,050</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company identified and
assessed the following significant assumptions in recognizing the right-of-use asset and corresponding liabilities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Expected lease term</i></b>
&#8212; The expected lease term includes both contractual lease periods and, when applicable, cancelable option periods when it
is reasonably certain that the Company would exercise such options. The Company&#8217;s leases have remaining lease terms between
12 months and 68 months. As of December 31, 2021, the weighted-average remaining term is <span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_zgEbjBnOaXC5" title="Weighted-average remaining term"><ix:nonNumeric contextRef="AsOf2021-12-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">5.28</ix:nonNumeric></span> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Incremental borrowing
rate</i></b> &#8212; The Company&#8217;s lease agreements do not provide an implicit rate. As the Company does not have any external
borrowings for comparable terms of its leases, the Company estimated the incremental borrowing rate based on the U.S. Treasury
Yield Curve rate that corresponds to the length of each lease. This rate is an estimate of what the Company would have to pay if
borrowing on a collateralized basis over a similar term in an amount equal to the lease payments in a similar economic environment.
As of December 31, 2021, the weighted-average discount rate is <span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20211231_zyzvDcX2C3l2" title="Weighted-average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.01</ix:nonFraction></span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Lease and non-lease
components</i></b> &#8212; In certain cases the Company is required to pay for certain additional charges for operating costs,
including insurance, maintenance, taxes, and other costs incurred, which are billed based on both usage and as a percentage of
the Company&#8217;s share of total square footage. The Company determined that these costs are non-lease components and they are
not included in the calculation of the lease liabilities because they are variable. Payments for these variable, non-lease components
are considered variable lease costs and are recognized in the period in which the costs are incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Lease expense charged&#160;to
general and administrative expenses for the three and six months ended December 31, 2021, amounted to $<span id="xdx_906_eus-gaap--OperatingLeaseExpense_pp0p0_c20211001__20211231_z54bxWL5eXs" title="Lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">84,113</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--OperatingLeaseExpense_pp0p0_c20210701__20211231_zU0vaj4YDTr5" title="Lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">168,196</ix:nonFraction></span>, respectively.
Lease expense charged&#160;to general and administrative expenses for the three and six months ended December 31, 2020 amounted
to $<span id="xdx_902_eus-gaap--OperatingLeaseExpense_pp0p0_c20201001__20201231_zF2iFWijwcBa" title="Lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">88,690</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--OperatingLeaseExpense_pp0p0_c20200701__20201231_zLUDaEaimCT" title="Lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">178,374</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Below are the lease commitments
for the next 5 years and thereafter:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--LesseeOperatingLeasesTextBlock_znwLr0iWgTg3" summary="xdx: Disclosure - LEASES (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span id="xdx_8BC_zORvcL9Gwwnl" style="display: none">Lease commitments</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20211231_zGhdnM8to0yk" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Year Ending June 30<sup>th</sup></b></span></td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Lease Expense</td></tr>
<tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueCurrent_iI_pp0p0_maOLFMPzcSt_zR1Vla4PzxZh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 73%; text-align: left; padding-left: 10pt">2022</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">175,419</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_pp0p0_maOLFMPzcSt_z3qzAbaEJHj6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">298,305</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_pp0p0_maOLFMPzcSt_zDedyaPRoE26" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">246,004</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_iI_pp0p0_maOLFMPzcSt_ztkcV9rmAqf6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">253,384</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFiveYears_iI_pp0p0_maOLFMPzcSt_zI9KBKybueL3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">260,985</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueThereafter_iI_pp0p0_maOLFMPzcSt_zGHUJ8uN2XHg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">313,836</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--LessImputedInterest_iNI_pp0p0_di_msOLFMPzcSt_zKhxrjJz2E7g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 10pt">Less imputed interest</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="enob:LessImputedInterest" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">159,770</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_pp0p0_mtOLFMPzcSt_zs292F34IGkf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 10pt"><span style="font-size: 10pt"><b>Total</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,388,163</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><p id="xdx_23D_zM0eznn9dp4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 15; Value: 1 -->
    <div id="xdx_239_z8vs1xxw6UQd" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23F_zw0bd0nyhLoi" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_232_zlL52CNC2Qya" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_23C_zxGevsEGczBk" style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_z9Jl16sbVP4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_234_zQVnvTMG5XQa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES<br />
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zRxjcP34IA0k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_802_eus-gaap--DebtDisclosureTextBlock_z7rAbfppylz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 6 &#8212; <span id="xdx_82E_zq90731vb54g">NOTES PAYABLE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Convertible Notes Payable </b>&#8212; On
February 6, 2020, the Company issued two Convertible Notes (the &#8220;Convertible Notes&#8221;) to an existing stockholder of
the Company each with a face value amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayablesMember_pp0p0" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-12-31_custom_ConvertibleNotesPayablesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">600,000</ix:nonFraction></span>, convertible into shares of the Company&#8217;s Common Stock. The outstanding
principal amount of the Convertible Notes is due and payable on <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_c20210701__20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayablesMember" title="Maturity date"><ix:nonNumeric contextRef="From2021-07-012021-12-31_custom_ConvertibleNotesPayablesMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">February 6, 2023</ix:nonNumeric></span>. Interest on the Convertible Notes commenced accruing
on the date of issuance at six percent (<span id="xdx_901_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20210701__20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayablesMember_z0bu65PAoOY2" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2021-07-012021-12-31_custom_ConvertibleNotesPayablesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>%) per annum, computed on the basis of twelve 30-day months, and is compounded monthly
on the final day of each calendar month based upon the Principal and all accrued and unpaid interest outstanding as of such compound
date. The interest is payable in cash on a semi-annual basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The holder of the Convertible
Notes had the right at any time prior to the date that is twelve months from issuance to convert all or any part of the outstanding
and unpaid principal and all unpaid interest into shares of the Company&#8217;s Common Stock. The conversion price is equal to
$<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayablesMember_pdd" title="Debt Instrument, Convertible, Conversion Price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2021-12-31_custom_ConvertibleNotesPayablesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></span> per share of Common Stock. The holder did not exercise the conversion feature that expired on February 6, 2021. The Company
evaluated the Convertible Notes in accordance with ASC 470-20 and identified that they each contain an embedded conversion feature
that shall not be bifurcated from the host document (i.e., the Convertible Notes) as they are not deemed to be readily convertible
into cash. All proceeds received from the issuance have been recognized as a liability on the balance sheet. The Convertible Notes
balance as of December 31, 2021 and 2020 was $<span id="xdx_90B_eus-gaap--ConvertibleLongTermNotesPayable_c20211231_pp0p0" title="Convertible Notes Payable, Noncurrent"><span id="xdx_908_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20201231_zYue5k8TDz9j" title="Convertible Notes Payable, Noncurrent"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,200,000</ix:nonFraction></ix:nonFraction></span></span>. As of December 31, 2021 and 2020, the Company recorded accrued interest
in the amount of $<span id="xdx_901_eus-gaap--OtherAccruedLiabilitiesCurrent_c20211231_pp0p0" title="Accrued interest"><span id="xdx_900_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_c20201231_zB1HCXm204oi" title="Accrued interest"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,181</ix:nonFraction></ix:nonFraction></span></span>, which is included in accrued expenses for each period. For the three and six months ended December 31,
2021 and 2020, the interest expense related to the Convertible Notes amounted to $<span id="xdx_909_eus-gaap--InterestExpenseOther_pp0p0_c20211001__20211231_zreY2m3Psli9" title="Interest Expense, Other"><span id="xdx_90E_eus-gaap--InterestExpenseOther_pp0p0_c20201001__20201231_zyhkuwheCk85" title="Interest Expense, Other"><ix:nonFraction name="us-gaap:InterestExpenseOther" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:InterestExpenseOther" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,181</ix:nonFraction></ix:nonFraction></span></span> and $<span id="xdx_909_eus-gaap--InterestExpenseOther_pp0p0_c20210701__20211231_zYeuBhktNRqj" title="Interest Expense, Other"><span id="xdx_903_eus-gaap--InterestExpenseOther_c20200701__20201231_pp0p0" title="Interest Expense, Other"><ix:nonFraction name="us-gaap:InterestExpenseOther" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:InterestExpenseOther" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">36,453</ix:nonFraction></ix:nonFraction></span></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note Payable </b>&#8212; On March 30, 2020
(the &#8220;Issuance Date&#8221;), the Company issued a Promissory Note in the principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_c20211231__us-gaap--LongtermDebtTypeAxis__custom--NotePayableMember_pp0p0" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-12-31_custom_NotePayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction></span> (the &#8220;Unsecured
Note&#8221;) to Paseco APS, a Danish limited company and an existing stockholder of the Company. The principal amount of the Note
was originally payable on <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_c20210701__20211231__us-gaap--LongtermDebtTypeAxis__custom--NotePayableMember" title="Maturity date"><ix:nonNumeric contextRef="From2021-07-012021-12-31_custom_NotePayableMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">November 30, 2021</ix:nonNumeric></span> (the &#8220;Maturity Date&#8221;) and bears interest at a fixed rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20210701__20211231__us-gaap--LongtermDebtTypeAxis__custom--NotePayableMember_zrzCAEynTGX" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2021-07-012021-12-31_custom_NotePayableMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% per annum,
computed based on the number of days between the Issuance Date and the Maturity Date, which was prepaid by the Company in full
on the Issuance Date through the issuance of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210701__20211231__us-gaap--LongtermDebtTypeAxis__custom--NotePayableMember_pdd" title="Stock issued for debt conversion, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2021-07-012021-12-31_custom_NotePayableMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">188,485</ix:nonFraction></span> shares of the Company&#8217;s Common Stock based on the closing market price
on that date for a total value of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20210701__20211231__us-gaap--LongtermDebtTypeAxis__custom--NotePayableMember_pp0p0" title="Stock issued for debt conversion"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-07-012021-12-31_custom_NotePayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">501,370</ix:nonFraction></span>. The Company evaluated the Unsecured Note and PIK interest in accordance with ASC 470-Debt
and ASC 835-Interest, respectively. Pursuant to ASC 470-20, proceeds received from the issuance are to be recognized at their relative
fair value, thus the liability was shown net of the corresponding discount of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210701__20211231__us-gaap--LongtermDebtTypeAxis__custom--NotePayableMember_pp0p0" title="Issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-07-012021-12-31_custom_NotePayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">493,192</ix:nonFraction></span>, which is the relative fair value of the
shares issued for the PIK interest on the closing date using the effective interest method. The discount of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20210701__20211231__us-gaap--LongtermDebtTypeAxis__custom--NotePayableMember_zMOi0EUmejHj" title="Issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-07-012021-12-31_custom_NotePayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">493,192</ix:nonFraction></span> is being accreted
over the life of the Unsecured Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On February 11, 2021, the
Company entered into an amendment to the Unsecured Note in the principal amount of $<span id="xdx_90A_eus-gaap--DebtInstrumentAnnualPrincipalPayment_c20210211_pp0p0" title="Unsecured note principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentAnnualPrincipalPayment" contextRef="AsOf2021-02-11" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction></span> that extends the Maturity Date out
to November 30, 2022. All other terms of the Unsecured Note remain the same. The change in Maturity Date required an additional
year of interest at the fixed rate of <span id="xdx_90A_eus-gaap--DerivativeFixedInterestRate_iI_dp_c20210211_zebjhCVTMENe" title="Interest at the fixed rate"><ix:nonFraction name="us-gaap:DerivativeFixedInterestRate" contextRef="AsOf2021-02-11" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% per annum, which was prepaid by the Company in full on the date of the amendment through
the issuance of <span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210701__20211231_pp0p0" title="Issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">74,054</ix:nonFraction></span> shares of the Company&#8217;s Common Stock based on the closing market price on that date for a total value
of $<span id="xdx_908_ecustom--MarketPrice_c20211231_pp0p0" title="Market price"><ix:nonFraction name="enob:MarketPrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">298,178</ix:nonFraction></span>. For the three and six months ended December 31, 2021, respectively, discount amortization of $<span id="xdx_909_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20211001__20211231_z6WfdLUtvfM4" title="Discount amortization"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">74,274</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20210701__20211231_zu84WxT6F22a" title="Discount amortization"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">148,548</ix:nonFraction></span>
was charged to interest expense. For the three and six months ended December 31, 2020, discount amortization of $<span id="xdx_903_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20201001__20201231_zjEnshogAah5" title="Discount amortization"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">73,979</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--AmortizationOfDebtDiscountPremium_c20200701__20201231_pp0p0" title="Discount amortization"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">147,958</ix:nonFraction></span>,
respectively was charged to interest expense. The Unsecured Note balance, net of discount at December 31, 2021 was $<span id="xdx_901_ecustom--UnsecuredNoteBalanceNetOfDiscount_c20210701__20211231_pp0p0" title="Unsecured note balance, net of discount"><ix:nonFraction name="enob:UnsecuredNoteBalanceNetOfDiscount" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,727,662</ix:nonFraction></span>,
and is reflected in current liabilities</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Finance Agreement </b>&#8212; On November
30, 2021, the Company entered into a premium finance agreement (the &#8220;Agreement&#8221;) with a principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pp0p0_c20211130_zgPjPJ3AjL62" title="Unsecured note principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentAnnualPrincipalPayment" contextRef="AsOf2021-11-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">666,875</ix:nonFraction></span>
at <span id="xdx_904_eus-gaap--DerivativeFixedInterestRate_iI_dp_c20211130_zdyp727uK6Vf" title="Interest at the fixed rate"><ix:nonFraction name="us-gaap:DerivativeFixedInterestRate" contextRef="AsOf2021-11-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.99</ix:nonFraction></span>% interest per annum. The repayment of the Agreement will be made in nine equal monthly installments of $<span id="xdx_90B_ecustom--MonthlyInstallments_pp0p0_c20211103__20211130_zUBJxg7TdYef" title="Monthly installments"><ix:nonFraction name="enob:MonthlyInstallments" contextRef="From2021-11-032021-11-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">56,469</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">For the three and six months
ended December 31, 2021, the Company recorded total interest expense in the amount of $<span id="xdx_90C_eus-gaap--InterestExpenseRelatedParty_c20210701__20211231_pp0p0" title="Interest expense related to agreement"><ix:nonFraction name="us-gaap:InterestExpenseRelatedParty" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">927</ix:nonFraction></span>. This amount is reflected in other income
and expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Total interest expense recorded
for the three and six months ended December 31, 2021, was $<span id="xdx_906_eus-gaap--InterestExpenseDebt_pp0p0_c20211001__20211231_z1a1D18Q08L2" title="interest expense"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">93,382</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--InterestExpenseDebt_pp0p0_c20210701__20211231_zvACts2aXoi5" title="interest expense"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">183,121</ix:nonFraction></span>, respectively. Interest expense recorded for the
three and six months ended December 31, 2020, $<span id="xdx_90B_eus-gaap--InterestExpenseDebt_pp0p0_c20201001__20201231_zeKit7sUWoMh" title="interest expense"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">93,426</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--InterestExpenseDebt_c20200701__20201231_pp0p0" title="interest expense"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">185,739</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_23D_zejPtFOgydS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 16; Value: 1 -->
    <div id="xdx_238_zo2dQ0Bt8qS9" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_239_zlwuY83PWMCj" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_237_zSP1a8idYEd1" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_232_z8R7dYyx4NN" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zjVQXaKfZAY" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zwZJCvua2EG6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES<br />
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_z1DuPpotoZkg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_801_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zRpONSawuVBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 7 &#8212; <span id="xdx_82F_zchxEtTOcI5i">STOCKHOLDERS&#8217; EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Preferred Stock </b>&#8212;The
Company has <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_zhg9EzZQxmu4" title="Preferred Stock, Shares Authorized"><span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20210630_zJRDWRXE9Pwc" title="Preferred Stock, Shares Authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> authorized shares of Preferred Stock, par value $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pp4d_c20211231_z2ODsj1Q15te" title="Preferred Stock, Par or Stated Value Per Share"><span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pp4d_c20210630_zJJa0CKK7jz3" title="Preferred Stock, Par or Stated Value Per Share"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> per share. At December 31, 2021 and June 30, 2021,
there were zero shares issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Common Stock </b>&#8212;The
Company has <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zmq89pemgY5" title="Common stock, shares authorized"><span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20210630_zwmysohii5A9" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> authorized shares of Common Stock, par value $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pp4d_c20211231_zSbCkkP5lCBe" title="Common stock, par value"><span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pp4d_c20210630_zE4sITYN27mk" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> per share. At December 31, 2021 and June 30, 2021,
there were <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20211231_z9UmXseavHtf" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_z7AtUQbZ1vPc" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,633,267</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_c20210630_zd2LwIi4MNQ6" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20210630_z5qV66Nsf8qh" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,219,661</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding, respectively</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Voting &#8212; </b>Holders
of Common Stock are entitled to one vote for each share held of record on each matter submitted to a vote of stockholders, including
the election of directors, and do not have any right to cumulate votes in the election of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Dividends &#8212; </b>Holders
of Common Stock are entitled to receive ratably such dividends as the Board from time to time may declare out of funds legally
available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Liquidation Rights &#8212;</b>
In the event of any liquidation, dissolution or winding up of affairs of the Company, after payment of all of our debts and liabilities,
the holders of Common Stock will be entitled to share ratably in the distribution of any of our remaining assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><b><i>Purchase Agreement with Lincoln Park Capital</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On July 8, 2020, we entered
into a purchase agreement (the &#8220;Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;),
pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $<span id="xdx_90D_eus-gaap--PurchaseObligation_c20210708_pp0p0" title="Obligation to purchase"><ix:nonFraction name="us-gaap:PurchaseObligation" contextRef="AsOf2021-07-08" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000,000</ix:nonFraction></span>
of shares of our Common Stock from time to time through August 1, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Under the Purchase Agreement,
we may direct Lincoln Park, at our sole discretion subject to certain conditions, to purchase up to <span id="xdx_90E_ecustom--PurchaseOfShares_c20210708_pdd" title="Purchase of shares"><ix:nonFraction name="enob:PurchaseOfShares" contextRef="AsOf2021-07-08" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span> shares of Common Stock
on any business day (a &#8220;Regular Purchase&#8221;). The amount of a Regular Purchase may be increased under certain circumstances
up to <span id="xdx_900_ecustom--PurchaseOfShares_c20210708__srt--TitleOfIndividualAxis__custom--LincolnParksMember_pdd" title="Purchase of shares"><ix:nonFraction name="enob:PurchaseOfShares" contextRef="AsOf2021-07-08_custom_LincolnParksMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,000</ix:nonFraction></span> shares of Common Stock, provided that Lincoln Park&#8217;s committed obligation for Regular Purchases on any business
day shall not exceed $<span id="xdx_902_ecustom--ExceedAmount_c20210708_pp0p0" title="Exceed amount"><ix:nonFraction name="enob:ExceedAmount" contextRef="AsOf2021-07-08" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,000,000</ix:nonFraction></span>. In the event we direct&#160;Lincoln Park to purchase the full amount allowed for a Regular Purchase
on any given business day, we may also direct Lincoln Park to purchase additional amounts as accelerated and additional accelerated
purchases. The purchase price of shares of Common Stock related to the future funding will be based on the then prevailing market
prices of such shares at the time of sales as described in the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our sale of shares of Common
Stock to Lincoln Park subsequent to the Amendment Date is <span id="xdx_900_ecustom--PurchaseAgreementDescription_c20210701__20211231" title="Purchase agreement description"><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" name="enob:PurchaseAgreementDescription">limited to 12,016,457 shares of Common Stock, representing 19.99%</ix:nonNumeric></span> of
the shares of the Common Stock outstanding on the Amendment Date unless (i) stockholder approval is obtained, (ii) the average
price of all applicable sales to Lincoln Park under the Purchase Agreement equals or exceeds the lesser of (A) the closing price
of the Common Stock on the Nasdaq Capital Market immediately preceding the date of the Purchase Agreement or (B) the average of
the closing prices on the Nasdaq Capital Market for the five Business Days immediately preceding the date of the Purchase Agreement
or (iii) to the extent it would cause Lincoln Park to beneficially own more than 9.99% of the Company&#8217;s outstanding shares
of Common Stock at any given time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In consideration for entering
into the Purchase Agreement, we issued <span id="xdx_906_eus-gaap--SharesIssued_c20200721__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_pdd" title="Issued shares"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2020-07-21_custom_PurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">139,567</ix:nonFraction></span> shares of Common Stock to Lincoln Park as a commitment fee on July 21, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">During the three and six
months ended December 31, 2021, we issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211001__20211231_z3vaD0r7Exwb" title="Number of shares issued"><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210701__20211231_zlACNdXLd1dh" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">277,340</ix:nonFraction></ix:nonFraction></span></span> shares of Common Stock to Lincoln Park under the Purchase Agreement for a purchase
price of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210701__20211231__us-gaap--RelatedPartyTransactionAxis__custom--LincolnParkMember_zmEMn9rOiYvd" title="Number of shares purchase"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-07-012021-12-31_custom_LincolnParkMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,048,339</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_23E_zo0csudz0vGl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 17; Value: 1 -->
    <div id="xdx_231_zmfqqYMBU09k" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23C_zNZiS3T0j3ie" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_23A_zTl9p8dFmIte" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_236_zKj7hBxwOcmc" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zW6fTPLbY886" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_z1VNYil6XoJi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES<br />
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_znRSQCqAAE67" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zQp9xseSI6F2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 7 &#8212; STOCKHOLDERS&#8217; EQUITY
(Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zoWmOp9C6jf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Common Stock Issuances
&#8212; </b>In the three and six months ended December 31, 2021, there were <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesOther_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember_zFxGzl143kQ1" title="Number of shares issued"><span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesOther_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember_zmIG8Mfe29bh" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember543127406" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2021-07-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">413,606</ix:nonFraction></ix:nonFraction></span></span> shares of Common Stock issued, respectively.
In the three and six months ended December 31, 2020, there were <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesOther_c20201001__20201231__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember_zplibotYvl6c" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember543127437" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">126,244</ix:nonFraction></span> and <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesOther_c20200701__20201231__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember_zBz2EO6ikkpk" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2020-07-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">265,811</ix:nonFraction></span> shares of Common Stock issued, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Acquisition of Enochian
Biopharma Inc. / Contingently issuable shares <i>&#8212; </i></b>On February 16, 2018, the Acquisition was completed when the subsidiary
merged with and into Enochian Biopharma, with Enochian Biopharma as the surviving corporation. As consideration for the Acquisition,
the stockholders of Enochian Biopharma received (i) 18,081,962 shares of Common Stock, and (ii) the right to receive contingent
shares pro rata upon the exercise or conversion of warrants, which were outstanding at closing. At December 31, 2021, <span id="xdx_903_ecustom--BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable_c20211231__us-gaap--TypeOfArrangementAxis__custom--AgreementAndPlanOfMergerAgreementAxisMember__us-gaap--BusinessAcquisitionAxis__custom--EBIAndWeirdScienceLLCMember_pdd" title="Common shares contingently issuable"><ix:nonFraction name="enob:BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable" contextRef="AsOf2021-12-31_custom_AgreementAndPlanOfMergerAgreementAxisMember_custom_EBIAndWeirdScienceLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></span>
contingent shares are issuable in connection with the Acquisition of Enochian Biopharma.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Acquisition of Enochian
Denmark <i>&#8212; </i></b>At December 31, 2021 and June 30, 2021, the Company maintained a reserve of <span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20211231_pdd" title="Common stock reserved for issuance"><span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20210630_pdd" title="Common stock reserved for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,414</ix:nonFraction></ix:nonFraction></span></span> shares of Common
Stock of the Registrant held in escrow according to Danish law (the &#8220;Escrow Shares&#8221;), , all of which are reflected
as issued and outstanding in the accompanying financial statements. The Escrow Shares are reserved to acquire the shares of Enochian
Denmark held by non-consenting shareholders of Enochian Denmark on both December 31, 2021 and June 30, 2021, in accordance with
Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark. There have been <span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DanDritDenmarkMember_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31_custom_DanDritDenmarkMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">167,639</ix:nonFraction></span> shares of Common
Stock issued to non-consenting shareholders of Enochian Denmark as of December 31, 2021. During the three and six months ended
December 31, 2021, the Company issued zero shares of Common Stock to such non-consenting shareholders of Enochian Denmark. There
is no impact on outstanding shares as these shares are reflected as issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_23E_znagcACLJDki" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 18; Value: 1 -->
    <div id="xdx_237_zFAfSbp6Qgzl" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23A_zHHIc52foMz4" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_232_zuMxlSisR0I2" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_23D_zK4mEvksU8sk" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zwaxbBbiK56e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_238_zesf9XlD9PG3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES<br />
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_zDiVpTOJGWej" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zUrjlamGYysf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 7 &#8212; STOCKHOLDERS&#8217; EQUITY (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_zPgsmocw1536" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Stock-based Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company recognizes compensation
costs for stock option awards to employees and directors based on their grant-date fair value. The value of each stock option is
estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate
the fair values of the stock options granted using the Black-Scholes option-pricing model are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellspacing="0" cellpadding="0" id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zMARfchKnSEi" summary="xdx: Disclosure - STOCKHOLDERS&apos; EQUITY (Details)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 7.5pt; text-indent: -7.5pt"><span id="xdx_8B4_zPluloJ5iofk" style="display: none">Summary of weighted-average assumptions used to estimate the fair values of the stock options granted</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 7.5pt; text-align: center; text-indent: -7.5pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Enochian</b></span><br />
<span style="font-size: 10pt"><b>Biosciences Inc.</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; padding-left: 7.5pt; text-indent: -7.5pt"><span style="font-size: 10pt">Expected term (in years)</span></td>
    <td style="width: 10%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: center"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210701__20211231__dei--LegalEntityAxis__custom--EnochianBiosciencesMember__srt--RangeAxis__srt--MinimumMember_zJMbd5kMZiGh" title="Expected term (in years)"><ix:nonNumeric contextRef="From2021-07-012021-12-31_custom_EnochianBiosciencesMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.0</ix:nonNumeric></span> &#8211; <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210701__20211231__dei--LegalEntityAxis__custom--EnochianBiosciencesMember__srt--RangeAxis__srt--MaximumMember_zz3uNWTil5b9" title="Expected term (in years)"><ix:nonNumeric contextRef="From2021-07-012021-12-31_custom_EnochianBiosciencesMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.5</ix:nonNumeric></span></span></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 7.5pt; text-indent: -7.5pt"><span style="font-size: 10pt">Volatility</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210701__20211231__dei--LegalEntityAxis__custom--EnochianBiosciencesMember__srt--RangeAxis__srt--MinimumMember_zhXF1mKRISK9" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-07-012021-12-31_custom_EnochianBiosciencesMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">82.39</ix:nonFraction></span>%-<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210701__20211231__dei--LegalEntityAxis__custom--EnochianBiosciencesMember__srt--RangeAxis__srt--MaximumMember_zr8Ep8qOSDpa" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-07-012021-12-31_custom_EnochianBiosciencesMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">90.21</ix:nonFraction></span>%</span></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 7.5pt; text-indent: -7.5pt"><span style="font-size: 10pt">Risk free interest rate</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210701__20211231__dei--LegalEntityAxis__custom--EnochianBiosciencesMember__srt--RangeAxis__srt--MinimumMember_zep5BnkQQpUj" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-07-012021-12-31_custom_EnochianBiosciencesMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.77</ix:nonFraction></span>%-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210701__20211231__dei--LegalEntityAxis__custom--EnochianBiosciencesMember__srt--RangeAxis__srt--MaximumMember_z95HqdJ9h0Z" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-07-012021-12-31_custom_EnochianBiosciencesMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.33</ix:nonFraction></span>%</span></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 7.5pt; text-indent: -7.5pt"><span style="font-size: 10pt">Dividend yield</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210701__20211231__dei--LegalEntityAxis__custom--EnochianBiosciencesMember_zt4MhpOYK7e1" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-07-012021-12-31_custom_EnochianBiosciencesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>%</span></td>
    <td>&#160;</td></tr>
</table>
</ix:nonNumeric><p id="xdx_8AF_zVaHhNtpV1Ha" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company recognized stock-based compensation expense related
to the options of $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0p0_c20211001__20211231_zV7YXWOcTXrb" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,043,292</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_c20210701__20211231_pp0p0" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,771,267</ix:nonFraction></span> for the three and six months ended December 31, 2021, respectively. The Company recognized
stock-based compensation expense related to the options of $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20201001__20201231_zAbnhuc7dlGb" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">359,391</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0p0_c20200701__20201231_zlX320f2Wsi8" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-07-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">668,482</ix:nonFraction></span> for the three and six months ended December 31,
2020, respectively. At December 31, 2021, the Company had approximately $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20211231_pp0p0" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,571,250</ix:nonFraction></span> of unrecognized compensation cost related to
non-vested options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Plan Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On February 6, 2014, the
Board adopted the Company&#8217;s 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;), and the Company had reserved <span id="xdx_90F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20140206__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014Member_pdd" title="Common stock reserved for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2014-02-06_custom_EquityIncentivePlan2014Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,206,000</ix:nonFraction></span>
shares of Common Stock for issuance in accordance with the terms of the 2014 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On October 30, 2019, the
Board approved and on October 31, 2019, the Company&#8217;s shareholders adopted Enochian&#8217;s 2019 Equity Incentive Plan (the
&#8220;2019 Plan&#8221;), which replaced the 2014 Plan. The 2019 Plan authorized options to be awarded to not exceed the sum of
(1) 6,000,000 new shares of Common Stock, and (2) the number of shares of Common Stock available for the grant of awards as of
the effective date under the 2014 Plan that, after the effective date of the 2019 Plan, expires, or is terminated, surrendered,
or forfeited for any reason without issuance of shares. The remaining shares of Common Stock available for grant related to the
2014 Plan was&#160;655,769 as of the effective date; this amount along with the new 6,000,000 shares totals 6,655,769 shares of
Common Stock were available to grant immediately after the effective date of the 2019 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Pursuant to the 2019 Plan,
the Company granted options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20211001__20211231__us-gaap--PlanNameAxis__custom--N2019EquityIncentivePlanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember_z187zHsj7q7b" title="Options Granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2021-10-012021-12-31_custom_N2019EquityIncentivePlanMember_custom_EmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,900</ix:nonFraction></span>
and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210701__20211231__us-gaap--PlanNameAxis__custom--N2019EquityIncentivePlanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember_pdd" title="Options Granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2021-07-012021-12-31_custom_N2019EquityIncentivePlanMember_custom_EmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,130,200</ix:nonFraction></span>
shares of Common Stock to employees with a <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20211001__20211231__us-gaap--PlanNameAxis__custom--N2019EquityIncentivePlanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember_zC7RPoQJcaw3" title="Options vesting period" style="display: none"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20211231__us-gaap--PlanNameAxis__custom--N2019EquityIncentivePlanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember_zVvokd1olf41" title="Options vesting period"><ix:nonNumeric contextRef="From2021-10-012021-12-31_custom_N2019EquityIncentivePlanMember_custom_EmployeesMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"><ix:nonNumeric contextRef="From2021-07-012021-12-31_custom_N2019EquityIncentivePlanMember_custom_EmployeesMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">3</ix:nonNumeric></ix:nonNumeric></span></span>
three-year vesting period during the three and six months ended December 31, 2021, respectively. For the three and six months ended
December 31, 2020, the Company granted options to purchase <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20201001__20201231__us-gaap--PlanNameAxis__custom--N2019EquityIncentivePlanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember_zpMk2ZzHD3P5" title="Options Granted"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20200701__20201231__us-gaap--PlanNameAxis__custom--N2019EquityIncentivePlanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember_zdWhsS18knO7" title="Options Granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2020-10-012020-12-31_custom_N2019EquityIncentivePlanMember_custom_EmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2020-07-012020-12-31_custom_N2019EquityIncentivePlanMember_custom_EmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,201</ix:nonFraction></ix:nonFraction></span></span>
shares of Common Stock to employees with a <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20201001__20201231__us-gaap--PlanNameAxis__custom--N2019EquityIncentivePlanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember_zioVMrN8mXzc" title="Options vesting period" style="display: none"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200701__20201231__us-gaap--PlanNameAxis__custom--N2019EquityIncentivePlanMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember_zSQZ4iy7VXYe" title="Options vesting period"><ix:nonNumeric contextRef="From2020-10-012020-12-31_custom_N2019EquityIncentivePlanMember_custom_EmployeesMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"><ix:nonNumeric contextRef="From2020-07-012020-12-31_custom_N2019EquityIncentivePlanMember_custom_EmployeesMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">3</ix:nonNumeric></ix:nonNumeric></span></span> three-year vesting period. Options are exercisable at the market price of the
Company&#8217;s Common Stock on the date of the grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">During the three and six
months ended December 31, 2021, the Company granted options to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20211001__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BoardOfDirectorsAndScientificAdvisoryMembersMember_z6JXWagqeLh" title="Options Granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2021-10-012021-12-31_custom_BoardOfDirectorsAndScientificAdvisoryMembersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,727</ix:nonFraction></span> and <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210701__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BoardOfDirectorsAndScientificAdvisoryMembersMember_pdd" title="Options Granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2021-07-012021-12-31_custom_BoardOfDirectorsAndScientificAdvisoryMembersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">63,462</ix:nonFraction></span> shares of Common stock, respectively,
to the Board of Directors and Scientific Advisory Board Members with a one-year vesting period. For the three and six months ended
December 31, 2020, the Company granted annual options to purchase <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20201001__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BoardOfDirectorsAndScientificAdvisoryMembersMember_zXbWlqRmztR1" title="Options Granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2020-10-012020-12-31_custom_BoardOfDirectorsAndScientificAdvisoryMembersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">63,435</ix:nonFraction></span> and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20200701__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BoardOfDirectorsAndScientificAdvisoryMembersMember_zkyZMi0EoBJk" title="Options Granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2020-07-012020-12-31_custom_BoardOfDirectorsAndScientificAdvisoryMembersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">87,631</ix:nonFraction></span> shares of Common Stock, respectively to members
of the Board of Directors and Scientific Advisory Board with a one-year vesting period. Options are exercisable at the market price
of the Company&#8217;s Common Stock on the date of the grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company issued options
to purchase <span id="xdx_904_ecustom--NumberOfOptionIssued_c20210701__20211231__us-gaap--AwardTypeAxis__custom--BlackScholesMember_pdd" title="Number of option issued"><ix:nonFraction name="enob:NumberOfOptionIssued" contextRef="From2021-07-012021-12-31_custom_BlackScholesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,979</ix:nonFraction></span> shares of Common Stock with immediate vesting, issued options to purchase <span id="xdx_900_ecustom--VestingForServices_c20210701__20211231__us-gaap--AwardTypeAxis__custom--BlackScholesMember_pp0p0" title="Vesting for services"><ix:nonFraction name="enob:VestingForServices" contextRef="From2021-07-012021-12-31_custom_BlackScholesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,500</ix:nonFraction></span> shares of Common Stock with
a one-year vesting period, and issued options to purchase <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20211001__20211231_zUMkU74uUtIk" title="Number of shares issued options to purchase"><span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210701__20211231_zk07jX41Y5R9"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000</ix:nonFraction></ix:nonFraction></span></span> shares of Common Stock with a three-year vesting period for consulting
services during the three and six months ended December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">To date the Company has
granted options under the Plan (&#8220;Plan Options&#8221;) to purchase <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Options Granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,629,294</ix:nonFraction></span> shares of Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_230_zbHTBesB9Tye" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 19; Value: 1 -->
    <div id="xdx_238_z83mZ1FqVeH6" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_237_zTKMdWqFazz3" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_233_z8JmROVFWML3" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_237_zYVNFXQuSSCi" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zel0xTMhSJWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zwNDF0DzxuF8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES<br />
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_zyeOW2lmzwP9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zY2bGt19Xkqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 7 &#8212; STOCKHOLDERS&#8217; EQUITY
(Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_234_znH3aGtpu01g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">A summary of the status
of the Plan Options outstanding at December 31, 2021 is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock"><table cellspacing="0" cellpadding="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z8ACgamL0QO4" summary="xdx: Disclosure - STOCKHOLDERS&apos; EQUITY (Details 1)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 7.5pt; text-indent: -7.5pt"><span id="xdx_8B8_zoC2DlBLkZZh" style="display: none">Summary of stock option activity</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="16" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Options Outstanding</b>&#160;</span></td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Options Exercisable</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 7.5pt; text-align: center; text-indent: -7.5pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Exercise Price Ranges</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Number Outstanding</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average Remaining Contractual Life&#160;(years)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average Exercise Price</b></span></td>
    <td colspan="2" style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Number Exercisable</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average Remaining Contractual Life&#160;(years)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average Exercise Price</b></span></td></tr>
<tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; width: 10%; padding-left: 7.5pt; text-indent: -7.5pt">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; width: 10%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_ecustom--ExercisePrices_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member__srt--RangeAxis__srt--MinimumMember_pdd" title="Exercise Prices"><ix:nonFraction name="enob:ExercisePrices" contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction></span>&#8211;<span id="xdx_906_ecustom--ExercisePrices_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercise Prices"><ix:nonFraction name="enob:ExercisePrices" contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.50</ix:nonFraction></span></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_pdd" title="Options Outstanding, Number Outstanding" style="vertical-align: top; width: 10%; text-align: right"><span style="font-size: 10pt">&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">285,043</ix:nonFraction> </span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 10%; text-align: right"><span style="font-size: 10pt">&#160;<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zo4upC4jDvS4" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.69</ix:nonNumeric></span> </span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_ztEWyn0fTNh4" title="Options Outstanding, Weighted Average Exercise Price" style="vertical-align: top; width: 10%; text-align: right"><span style="font-size: 10pt">&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.23</ix:nonFraction> </span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_z6qRcgqfkfv5" title="Options Exercisable" style="vertical-align: top; width: 10%; text-align: right"><span style="font-size: 10pt">&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">197,637</ix:nonFraction> </span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 10%; text-align: right"><span style="font-size: 10pt">&#160;<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_z5AdLIbkHqBg" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">8.49</ix:nonNumeric></span> </span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zO697q3HlfR3" title="Options Exercisable, Weighted Average Exercise Price" style="vertical-align: bottom; width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.12</ix:nonFraction></span></td></tr>
<tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 7.5pt; text-indent: -7.5pt">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_ecustom--ExercisePrices_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member__srt--RangeAxis__srt--MinimumMember_pdd" title="Exercise Prices"><ix:nonFraction name="enob:ExercisePrices" contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.51</ix:nonFraction></span>&#8211;<span id="xdx_907_ecustom--ExercisePrices_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercise Prices"><ix:nonFraction name="enob:ExercisePrices" contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.50</ix:nonFraction></span></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_pdd" title="Options Outstanding, Number Outstanding" style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,538,330</ix:nonFraction> </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#160;<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_z14iy5CNwmW4" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.21</ix:nonNumeric></span> </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_pdd" title="Options Outstanding, Weighted Average Exercise Price" style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.80</ix:nonFraction> </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_pdd" title="Options Exercisable" style="vertical-align: top; text-align: right"><span style="font-size: 10pt">&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">455,999</ix:nonFraction> </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#160;<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_z6hb5FiwHuC8" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">7.09</ix:nonNumeric></span> </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_pdd" title="Options Exercisable, Weighted Average Exercise Price" style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.16</ix:nonFraction></span></td></tr>
<tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; padding-left: 7.5pt; text-indent: -7.5pt">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_ecustom--ExercisePrices_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member__srt--RangeAxis__srt--MinimumMember_pdd" title="Exercise Prices"><ix:nonFraction name="enob:ExercisePrices" contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.51</ix:nonFraction></span>&#8211;<span id="xdx_904_ecustom--ExercisePrices_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercise Prices"><ix:nonFraction name="enob:ExercisePrices" contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.00</ix:nonFraction></span></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: windowtext 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_pdd" title="Options Outstanding, Number Outstanding" style="border-bottom: windowtext 1pt solid; vertical-align: top; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">797,521</ix:nonFraction> </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: windowtext 1pt solid; vertical-align: top; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zRdv0BtZiDI3" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.70</ix:nonNumeric></span> </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_pdd" title="Options Outstanding, Weighted Average Exercise Price" style="border-bottom: windowtext 1pt solid; vertical-align: top; text-align: right"><span style="font-size: 10pt">&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.95</ix:nonFraction> </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_pdd" title="Options Exercisable" style="border-bottom: windowtext 1pt solid; vertical-align: top; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">556,094</ix:nonFraction> </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: windowtext 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zY5BNDPcXLz8" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">8.20</ix:nonNumeric></span></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_pdd" title="Options Exercisable, Weighted Average Exercise Price" style="border-bottom: windowtext 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.93</ix:nonFraction></span></td></tr>
<tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 7.5pt; text-indent: -7.5pt"><span style="font-size: 10pt">Total</span></td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; padding-left: 7.5pt; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; padding-left: 7.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zWEN7BW69sSg" title="Options Outstanding, Number Outstanding" style="border-bottom: black 2.25pt double; vertical-align: top; padding-left: 7.5pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,620,894</ix:nonFraction> </span></td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; padding-left: 7.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: top; padding-left: 7.5pt; text-align: right"><span style="font-size: 10pt">&#160;<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zV5JpwoDFIWf" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.09</ix:nonNumeric></span> </span></td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zkXYMPtCIAWl" title="Options Outstanding, Weighted Average Exercise Price" style="border-bottom: black 2.25pt double; vertical-align: top; padding-left: 7.5pt; text-align: right"><span style="font-size: 10pt">&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.25</ix:nonFraction> </span></td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; padding-left: 7.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">&#160;</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zCVl9EDaP2D4" title="Options Exercisable" style="border-bottom: black 2.25pt double; vertical-align: top; padding-left: 7.5pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,209,730</ix:nonFraction> </span></td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; padding-left: 7.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom; padding-left: 7.5pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zqsI27FQD1ha" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">7.83</ix:nonNumeric></span> </span></td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; padding-left: 7.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zCkcY2MKdIj4" title="Options Exercisable, Weighted Average Exercise Price" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.48</ix:nonFraction></span></td></tr>
</table>
</ix:nonNumeric><p id="xdx_8A3_z2fuOeMb5T7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">A summary of the status
of the Plan Options at December 31, 2021 and changes since July 1, 2021 are presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellspacing="0" cellpadding="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zEenDTWZveFl" summary="xdx: Disclosure - STOCKHOLDERS&apos; EQUITY (Details 2)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: white">
    <td><span id="xdx_8BE_zS2fYwxPVxQ6" style="display: none">Summary of stock option activity</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Shares</b></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average Exercise</b></span><br />
<span style="font-size: 10pt"><b>Price</b></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Average Remaining Life</b></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average Intrinsic</b></span><br />
<span style="font-size: 10pt"><b>Value</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 32%"><span style="font-size: 10pt">Outstanding at beginning of period</span></td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zKCWmIgzCJDd" title="Options Outstanding at beginning of period" style="width: 12%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,329,153</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zsnIJLJAViR5" title="Weighted Average Exercise Price, Outstanding at beginning of period" style="width: 12%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.24</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne_dtY_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zmo4Ckbcsmvh" title="Weighted Average remaining life, Outstanding at beginning of period"><ix:nonNumeric contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="enob:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne">8.42</ix:nonNumeric></span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z8t3ijQMIPGc" title="Weighted Average Intrinsic Value, Outstanding at beginning of period" style="width: 12%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">511,239</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Options Outstanding, Granted" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,300,141</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Weighted Average Exercise Price, Granted" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.85</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_za4gtZNLy8l" title="Weighted Average remaining life, Granted"><ix:nonNumeric contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="enob:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm1">10.0</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$&#160;</span></td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalIntrinsicValue_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zzsm4V2uJdFk" title="Weighted Average Intrinsic Value, Granted" style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1162">&#8212;</span></span></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Exercised</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Options Outstanding, Exercised" style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1164">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1166">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pp0p0" title="Weighted Average Intrinsic Value, Exercised" style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1168">&#8212;</span></span></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Forfeited</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Options Outstanding, Forfeited" style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1170">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Weighted Average Exercise Price, Forfeited" style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1172">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z5scAemAX6u9" title="Weighted Average Intrinsic Value, Forfeited" style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1174">&#8212;</span></span></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Expired</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-bottom: 1pt">&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z3wSQV8EjqDh" title="Options Outstanding, Expired" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,400</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)&#160;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Weighted Average Exercise Price, Expired" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1178">&#8212;</span></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForExpiredInPeriodWeightedAverageIntrinsicValue_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pp0p0" title="Weighted average intrinsic value, Expired" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1180">&#8212;</span></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Outstanding at end of period</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt">&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zcHNYzQUjQ21" title="Options Outstanding at end of period" style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,620,894</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zN188tdhdKuj" title="Weighted Average Exercise Price, Outstanding at end of period" style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.25</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zrRpgiEKyUk1" title="Weighted Average remaining life, Outstanding at end of period"><ix:nonNumeric contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.09</ix:nonNumeric></span></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zd6iArfByita" title="Weighted Average Intrinsic Value, Outstanding at end of period" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,997,233</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Exercisable end of period</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Options Exercisable" style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,209,730</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Options Exercisable, Weighted Average Exercise Price" style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.48</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zpRD4Nfl7PUk" title="Weighted Average Remaining Life, Exercisable end of period"><ix:nonNumeric contextRef="From2021-07-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">7.83</ix:nonNumeric></span></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pp0p0" title="Weighted Average Intrinsic Value, Exercisable end of period" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,352,948</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
</ix:nonNumeric><p id="xdx_8A4_zVEWFyfhItW1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">At December 31, 2021, the
Company had <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Options Exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,209,730</ix:nonFraction></span> exercisable Plan Options outstanding. The total intrinsic value of options exercisable at December 31, 2021,
was $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_c20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionOneMember_pp0p0" title="Intrinsic value of stock option"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="AsOf2021-12-31_custom_EmployeeStockOptionOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,352,948</ix:nonFraction></span>. Intrinsic value is measured using the fair market value at the date of exercise (for shares exercised) or at December
31, 2021 (for outstanding options), less the applicable exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common Stock Purchase Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">A summary of the warrants
outstanding at December 31, 2021, are presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="enob:CommonStockPurchaseWarrantsOutstandingTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--CommonStockPurchaseWarrantsOutstandingTableTextBlock_zTJsuIaCtMCd" summary="xdx: Disclosure - STOCKHOLDERS&apos; EQUITY (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -7.5pt; padding-left: 7.5pt"><span id="xdx_8B1_zZqaD6O9Vk25" style="display: none">Summary of common stock purchase warrants outstanding</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Shares</b></span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise<br /> Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining<br /> Life</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-indent: -7.5pt; padding-left: 7.5pt">Outstanding at beginning of period</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_ecustom--CommonStockPurchaseWarrants_iS_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_znKzrWZPm2h1" title="Outstanding at beginning of period" style="width: 11%; text-align: right"><ix:nonFraction name="enob:CommonStockPurchaseWarrants" contextRef="AsOf2021-06-30_custom_CommonStockPurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,350,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--CommonStockPurchaseWarrantsWeightedAverageExercisePrice_iS_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zCIIfTMOckmg" title="Weighted average exercise price, Outstanding at beginning of period" style="width: 11%; text-align: right"><ix:nonFraction name="enob:CommonStockPurchaseWarrantsWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_custom_CommonStockPurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.30</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zv3rR8L068Gg" title="Weighted Average remaining life, Outstanding"><ix:nonNumeric contextRef="From2021-07-012021-12-31_custom_CommonStockPurchaseWarrantsMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">1.02</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -7.5pt; padding-left: 7.5pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_pdd" title="Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1210">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_pdd" title="Weighted average exercise price, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1212">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -7.5pt; padding-left: 7.5pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zB52Y3Ttqu28" title="Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-07-012021-12-31_custom_CommonStockPurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_pdd" title="Weighted average exercise price, Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-07-012021-12-31_custom_CommonStockPurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.30</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-indent: -7.5pt; padding-left: 7.5pt">Cancelled/Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_pdd" title="Cancelled/Expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1218">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_pdd" title="Weighted average exercise price, Expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1220">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -7.5pt; padding-left: 7.5pt">Outstanding and exercisable at end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_ecustom--CommonStockPurchaseWarrants_iE_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zkRP1ohvISY1" title="Outstanding at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="enob:CommonStockPurchaseWarrants" contextRef="AsOf2021-12-31_custom_CommonStockPurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--CommonStockPurchaseWarrantsWeightedAverageExercisePrice_iE_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_ztXqZ0x7Fqid" title="Weighted average exercise price, Outstanding at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="enob:CommonStockPurchaseWarrantsWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_CommonStockPurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.30</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210701__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zigm8gzxpg7b" title="Weighted Average remaining life, Outstanding"><ix:nonNumeric contextRef="From2021-07-012021-12-31_custom_CommonStockPurchaseWarrantsMember" format="ixt-sec:duryear" name="enob:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm">.53</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A8_ztBWvfXlr8ya" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellspacing="0" cellpadding="0" id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zFTDqvRgnJ3e" summary="xdx: Disclosure - STOCKHOLDERS&apos; EQUITY (Details 4)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span id="xdx_8B2_zVUzfdARlrC" style="display: none">Summary of common stock purchase warrants</span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="7" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Underlying Warrants</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Outstanding</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Equivalent Shares Exercisable</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Exercise Prices</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Equivalent Shares</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average Remaining Contractual Life (years)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average Exercise Price</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Number Exercisable</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average Exercise Price</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_988_ecustom--ExercisePrices_c20210701__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_pdd" title="Exercise Prices" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="enob:ExercisePrices" contextRef="From2021-07-012021-12-31_us-gaap_WarrantMember_custom_ExercisePriceRange4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.30</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_pdd" title="Equivalent Shares Underlying Warrants Outstanding, Equivalent Shares" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_WarrantMember_custom_ExercisePriceRange4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_909_ecustom--EquivalentSharesUnderlyingWarrantsOutstandingWeightedAverageRemainingContractualLifeYears_dtY_c20210701__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zVtOx71vEb16" title="Equivalent Shares Underlying Warrants Outstanding, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2021-07-012021-12-31_us-gaap_WarrantMember_custom_ExercisePriceRange4Member" format="ixt-sec:duryear" name="enob:EquivalentSharesUnderlyingWarrantsOutstandingWeightedAverageRemainingContractualLifeYears">.53</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_pdd" title="Equivalent Shares Underlying Warrants Outstanding, Weighted Average Exercise Price" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_WarrantMember_custom_ExercisePriceRange4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.30</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_pdd" title="Equivalent Shares Exercisable, Number Exercisable" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-12-31_us-gaap_WarrantMember_custom_ExercisePriceRange4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_pdd" title="Equivalent Shares Exercisable, Weighted Average Exercise Price" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_WarrantMember_custom_ExercisePriceRange4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.30</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
</table>
</ix:nonNumeric><p id="xdx_8A1_zxLSsaOTAL53" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The exercise price of certain
warrants and the number of shares underlying the warrants are subject to adjustment for stock dividends, subdivisions of the outstanding
shares of Common Stock and combinations of the outstanding shares of Common Stock. For so long as the warrants remain outstanding,
we are required to keep reserved from our authorized and unissued shares of Common Stock a sufficient number of shares to provide
for the issuance of the shares underlying the warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_23E_zEQCxOw9zfB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 20; Value: 1 -->
    <div id="xdx_238_zzYWXCLSG5cl" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_237_zjtDPLYaPxPg" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_231_zdtTjO2UyGOi" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_23F_zuQH2EoziQNg" style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zJo9YLasTim3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zr8ZiXmwPqKb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 7 &#8212; STOCKHOLDERS&#8217; EQUITY
(Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zmVdjnxjT75i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Restricted Stock Units (RSUs)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognized stock-based compensation
expense related to RSUs of $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_pp0p0_c20211001__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zSX2kFCPfqy6" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-10-012021-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">255,340</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zYkhATHEFxe3" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-07-012021-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">258,331</ix:nonFraction></span> for the three and six months ended December 31, 2021, respectively. The Company
recognized stock-based compensation expense related to the RSUs of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20201001__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcMphSiuq8ei" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-10-012020-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,860</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--ShareBasedCompensation_c20200701__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pp0p0" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-07-012020-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,066</ix:nonFraction></span> for the three and six months ended December
31, 2020, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">A summary of the status of Restricted Stock Units
outstanding at December 31, 2021 is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"><table cellspacing="0" cellpadding="0" id="xdx_893_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zTsnrkAgRm71" summary="xdx: Disclosure - STOCKHOLDERS&apos; EQUITY (Details 5)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: white">
    <td><span id="xdx_8BF_zQSgEv2aWg8h" style="display: none">Summary of restricted stock units outstanding</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt">&#160;<b>Shares</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average Issuance</b></span><br />
<span style="font-size: 10pt"><b>Price</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average Remaining</b></span><br />
<span style="font-size: 10pt"><b>Life</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average Intrinsic</b></span><br />
<span style="font-size: 10pt"><b>Value</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 32%"><span style="font-size: 10pt">Outstanding at beginning of period</span></td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9Ao8j6N3y0d" title="Outstanding at beginning of period" style="width: 12%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2021-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_981_ecustom--RestrictedStockUnitsWeightedAverageExercisePrice_iS_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7MIRR8ei1zb" title="Weighted average exercise price, Outstanding at beginning of period" style="width: 12%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="enob:RestrictedStockUnitsWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.15</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvw9g2OVtsqb" title="Weighted Average remaining life, Outstanding"><ix:nonNumeric contextRef="From2021-07-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">.02</ix:nonNumeric></span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvpgmvxPFyJg" title="Weighted Average Intrinsic Value, Outstanding at Beginning of period" style="width: 12%; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1262">&#8212;</span></span></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Granted" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-07-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,266</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Weighted average exercise price, Granted" style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1266">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_982_ecustom--WeightedAverageIntrinsicValueGranted_pp0p0_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1HUQGhnXooj" title="Weighted Average Intrinsic Value, granted" style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1268">&#8212;</span></span></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Exercised</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zX0OuxAdDVE2" title="Exercised" style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-07-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,266</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Weighted average exercise price, Exercised" style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1272">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_ecustom--WeightedAverageIntrinsicValueExercised_pp0p0_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zy9fIu45OI7j" title="Weighted Average Intrinsic Value, exercised" style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1274">&#8212;</span></span></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Cancelled/Expired</span></td>
    <td>&#160;</td>
    <td style="border-bottom: windowtext 1pt solid">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Cancelled/Expired" style="border-bottom: windowtext 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1276">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: windowtext 1pt solid">&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Weighted average exercise price, Expired" style="border-bottom: windowtext 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1278">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: windowtext 1pt solid">&#160;</td>
    <td style="border-bottom: windowtext 1pt solid; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: windowtext 1pt solid">&#160;</td>
    <td id="xdx_983_ecustom--WeightedAverageIntrinsicValueCancelledExpired_pp0p0_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfxoE3ZfpDZi" title="Weighted Average Intrinsic Value, cancelled/ expired" style="border-bottom: windowtext 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1280">&#8212;</span></span></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Outstanding at end of period</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt">&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvYcr63baUAc" title="Outstanding at end of period" style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt">&#160;</td>
    <td id="xdx_98C_ecustom--RestrictedStockUnitsWeightedAverageExercisePrice_iE_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0xFGugBA937" title="Weighted average exercise price, Outstanding at end of period" style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="enob:RestrictedStockUnitsWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.15</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNspXunRvaDf" title="Weighted Average remaining life, Exercisable end of period"><ix:nonNumeric contextRef="From2021-07-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">.02</ix:nonNumeric></span></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0p0_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgpUnp4Z2L5e" title="Weighted Average Intrinsic Value, Outstanding at end of period" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1288">&#8212;</span></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
</ix:nonNumeric><p id="xdx_8A6_zrgAOIA4Kbs5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zmxz88tLAVDd" summary="xdx: Disclosure - STOCKHOLDERS&apos; EQUITY (Details 6)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span id="xdx_8B3_zdJ4CYrhLgk" style="display: none">Summary of restricted stock units activity</span></td><td style="font-weight: bold">&#160;</td>
    <td colspan="9" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restricted Stock Units&#160;Outstanding</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Grant Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Units</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (years)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Issuance Price</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantPrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_pdd" title="Grant Price" style="border-bottom: Black 2.5pt double; width: 19%; text-align: right"><ix:nonFraction name="enob:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantPrice" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_ExercisePriceRange5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6.15</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 2.5pt">&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_pdd" title="Stock Units" style="width: 20%; text-align: right; padding-bottom: 2.5pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_ExercisePriceRange5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></td><td style="width: 5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 20%; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210701__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zklhWfaBqTw4" title="Weighted Average remaining life, Outstanding"><ix:nonNumeric contextRef="From2021-07-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_ExercisePriceRange5Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">.02</ix:nonNumeric></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_pdd" title="Weight Average Issuance Price" style="border-bottom: Black 2.5pt double; width: 20%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_ExercisePriceRange5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.15</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A8_z67Jt0KnUkf4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<ix:exclude><p id="xdx_23E_zEtMcQojSnv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 21; Value: 1 -->
    <div id="xdx_23D_zjJS6hJhI8i5" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_232_zdLzQmOfHra" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_23F_zohrKcSOocAe" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_231_zDvaSPMqRPb5" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zFhopIGOAy3e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zuSzPRfox4Gj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES<br />
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zp8PVrzWGqQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zzzCkkvRwIPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 8 &#8212; <span id="xdx_82F_z3lFzl9tYPRe">COMMITMENTS AND CONTINGENCIES</span>
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On July 9, 2018, the Company
entered into a consulting agreement with G-Tech Bio, LLC, a California limited liability company (&#8220;G-Tech&#8221;) to assist
the Company with the development of the gene therapy and cell therapy modalities for the prevention, treatment, and amelioration
of HIV in humans, and with the development of a genetically enhanced Dendritic Cell for use as a wide spectrum platform for various
diseases (including but not limited to cancers and infectious diseases) (the &#8220;G-Tech Agreement&#8221;). G-Tech was entitled
to consulting fees for 20 months, with a monthly consulting fee of not greater than $130,000 per month. Upon the completion of
the 20 months, the monthly consulting fee of $<span id="xdx_901_ecustom--MonthlyConsultingFee_c20210701__20211231__us-gaap--InvestmentTypeAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember_pp0p0" title="Monthly consulting fee"><ix:nonFraction name="enob:MonthlyConsultingFee" contextRef="From2021-07-012021-12-31_custom_ConsultingAgreementMember_custom_GTechMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,000</ix:nonFraction></span> continued for scientific consulting and knowledge transfer on existing HIV
experiments and will continue until the services are no longer rendered or the agreement is terminated. G-Tech is controlled by
certain members of Weird Science. For the three and six months ended December 31, 2021, $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20211001__20211231__us-gaap--InvestmentTypeAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember_z0yMZFRxMw75" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-10-012021-12-31_custom_ConsultingAgreementMember_custom_GTechMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,000</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210701__20211231__us-gaap--InvestmentTypeAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember_z40v4NegCSoj" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-07-012021-12-31_custom_ConsultingAgreementMember_custom_GTechMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,000</ix:nonFraction></span>, was charged to research
and development expenses in our Condensed Consolidated Statements of Operations related to this consulting agreement, respectively.
For the three and six months ended December 31, 2020, $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20201001__20201231__us-gaap--InvestmentTypeAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember_zj6ShA8HYJgg" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-10-012020-12-31_custom_ConsultingAgreementMember_custom_GTechMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,000</ix:nonFraction></span> and <span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20200701__20201231__us-gaap--InvestmentTypeAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember_zF0U9EdhBEQ5" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-07-012020-12-31_custom_ConsultingAgreementMember_custom_GTechMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">125,000</ix:nonFraction></span>, was charged to research and development expenses in
our Condensed Consolidated Statements of Operations related to this consulting agreement, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On January 31, 2020, the
Company entered into a Statement of Work &amp; License Agreement (the &#8220;HBV License Agreement&#8221;) by and among the Company,
G-Tech , and G Health Research Foundation, a not for profit entity organized under the laws of California doing business as Seraph
Research Institute (&#8220;SRI&#8221;), whereby the Company acquired a perpetual, sublicensable, exclusive license (the &#8220;HBV
License&#8221;) for a treatment under development (the &#8220;Treatment&#8221;) aimed to treat Hepatitis B Virus (HBV) infections
in accordance with its agreement in principle with G-Tech and SRI.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The HBV License Agreement
contains customary representations, warranties and covenants of the parties with respect to the development of the Treatment and
the HBV License. G-Tech and SRI are each controlled by certain members of Weird Science, LLC, a shareholder of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The cash funding for research
costs pursuant to the HBV License Agreement consists of monthly payments amounting to $<span id="xdx_904_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20210701__20211231__us-gaap--InvestmentTypeAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember_pp0p0" title="Monthly research costs"><ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2021-07-012021-12-31_custom_ConsultingAgreementMember_custom_GTechMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">144,500</ix:nonFraction></span> that cover scientific staffing resources
to complete the project, as well as periodic payments for materials and equipment needed to complete the project. For the three
and six months ended December 31, 2021, the Company paid a total of $<span id="xdx_90D_ecustom--PaymentForScientificStaffingResources_pp0p0_c20211001__20211231__us-gaap--InvestmentTypeAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember_zgKOqtmeccS1" title="Payment for scientific staffing resources"><ix:nonFraction name="enob:PaymentForScientificStaffingResources" contextRef="From2021-10-012021-12-31_custom_ConsultingAgreementMember_custom_GTechMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">433,500</ix:nonFraction></span> and $<span id="xdx_903_ecustom--PaymentForScientificStaffingResources_pp0p0_c20210701__20211231__us-gaap--InvestmentTypeAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember_zXen6QAksyC2" title="Payment for scientific staffing resources"><ix:nonFraction name="enob:PaymentForScientificStaffingResources" contextRef="From2021-07-012021-12-31_custom_ConsultingAgreementMember_custom_GTechMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">867,000</ix:nonFraction></span>, respectively for scientific staffing
resources, R&amp;D and IND Enabling studies. During the three and six months ended December 31, 2021, respectively the Company
paid zero and a $<span id="xdx_901_ecustom--MilestonePayments_c20210701__20211231_pp0p0" title="Milestone payments"><ix:nonFraction name="enob:MilestonePayments" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,500,000</ix:nonFraction></span> for the milestone completion of a Pre-Investigational New Drug (IND) process following receipt of written
comments in accordance with the HBV License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On April 18, 2021, the Company
entered into a Statement of Work and License Agreement (the &#8220;License Agreement&#8221;), by and among the Company, G-Tech
and SRI, whereby the Company acquired a perpetual sublicensable, exclusive license (the &#8220;Development License&#8221;) to research,
develop, and commercialize certain formulations which are aimed at preventing and treating pan-coronavirus or the potential combination
of the pan-coronavirus and pan-influenza, including the SARS-coronavirus that causes COVID-19 and pan-influenza (the &#8220;Prevention
and Treatment&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p>

<ix:exclude><p id="xdx_233_zrvtt7nbTRFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 22; Value: 1 -->
    <div id="xdx_239_zgCMWWJl2Nb5" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23A_zmUFEtMF7n45" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_235_zP1gwd14jiNh" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_232_zO0cjZ6B8kzj" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zIQwhc2QBxZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zNuAipvgQuwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES<br />
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_234_zqyYurPsPwQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The License Agreement was
entered into pursuant to the existing Framework Agreement between the parties dated November 15, 2019. The License Agreement states
that in consideration for the Development License, the Company shall provide cash funding for research costs and equipment and
certain other in-kind funding related to the Prevention and Treatment over a 24-month period. Additionally, the License Agreement
provides for an up-front payment of $<span id="xdx_90F_ecustom--UpfrontPayment_pp0p0_c20191103__20191115_zFmcWxACm2f3" title="Up-front payment"><ix:nonFraction name="enob:UpfrontPayment" contextRef="From2019-11-032019-11-15" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,000,000</ix:nonFraction></span> and a $<span id="xdx_904_ecustom--PaymentForExpenditures_c20191115_pp0p0" title="Payment for expenditures"><ix:nonFraction name="enob:PaymentForExpenditures" contextRef="AsOf2019-11-15" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">760,000</ix:nonFraction></span> payment for expenditures to date prior to the effective date related
to research towards the Prevention and Treatment within 60 days of April 18, 2021. The License Agreement provides for additional
payments upon the occurrence of certain benchmarks in the development of the technology set forth in the License Agreement, in
each case subject to the terms of the License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The License Agreement provides
for cooperation related to the development of intellectual property related to the Prevention and Treatment and for a 3% royalty
to G-Tech on any net sales that may occur under the License Agreement. For the three and six months ended December 31, 2021, the
Company paid $<span id="xdx_905_ecustom--UpfrontPayment_pp0p0_c20211001__20211231_zSzQoOeq539i" title="Up-front payment"><ix:nonFraction name="enob:UpfrontPayment" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,000</ix:nonFraction></span> and $<span id="xdx_902_ecustom--UpfrontPayment_pp0p0_c20210701__20211231_zAGvWlWHq3w6"><ix:nonFraction name="enob:UpfrontPayment" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,000</ix:nonFraction></span>, respectively, related to the Prevention and Treatment research.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">G-Tech is controlled by
Dr. Serhat G&#252;mr&#252;kc&#252; and Anderson Wittekind, shareholders of the Company, and SRI is controlled by Dr. Serhat G&#252;mr&#252;kc&#252;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Shares held for non-consenting
shareholders</i></b><i> &#8211; </i>The 17,414 remaining shares of Common Stock related to the Acquisition of Enochian Denmark
have been reflected as issued and outstanding in the accompanying financial statements.&#160;There were zero shares of Common Stock
issued to such&#160;non-consenting shareholders during the three and six months ended December 31, 2021 (see Note 7.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Service Agreements</b>
<i>&#8211;</i>The Company has a consulting agreement for services of a Senior Medical Advisor for up to $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210701__20211231__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember_zHNSx1hW3Abi" title="Issued for services amount"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-07-012021-12-31_us-gaap_ServiceAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,000</ix:nonFraction></span> per year on a
part-time basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>Contingencies </b>&#8211;
The Company is from time to time involved in routine legal and administrative proceedings and claims of various types. While any
proceeding or claim contains an element of uncertainty, management does not expect a material impact on our results of operations
or financial position from such proceedings or claims.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_ztws3GagoRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 9&#160;&#8212;&#160;<span id="xdx_827_zWGPBWMq7B6e">RELATED PARTY TRANSACTIONS</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company paid G-Tech
$<span id="xdx_904_eus-gaap--RelatedPartyCosts_pp0p0_c20211001__20211231_z8Mbo3aiInB4" title="Related party costs"><ix:nonFraction name="us-gaap:RelatedPartyCosts" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">718,500</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--RelatedPartyCosts_pp0p0_c20210701__20211231_zEGXpDgkoXp5" title="Related party costs"><ix:nonFraction name="us-gaap:RelatedPartyCosts" contextRef="From2021-07-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,537,000</ix:nonFraction></span>, which included payments for consulting agreements related to HIV, contractual costs related to the HBV
License and the Development License (See Note 8), and security expenses, for the three and six months ended December 31, 2021,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-07-01to2021-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_zu3ouQY4zVgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 10 &#8212; <span id="xdx_828_zdzaosTppNu7">SUBSEQUENT EVENTS</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In accordance with ASC 855-10,
the Company performed a review of events subsequent to the balance sheet date and through the date of this report and determined
that there were no such events requiring recognition or disclosure.</p>

</ix:nonNumeric><p id="xdx_81A_zTUN1CX2Bbpf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_009"></span>Item 2. Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Forward-Looking Statement Notice </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Certain statements made
in this Quarterly Report on Form 10-Q are &#8220;forward-looking statements&#8221; (within the meaning of the Private Securities
Litigation Reform Act of 1995) regarding the plans and objectives of management for future operations. Such statements involve
known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of Enochian
Biosciences Inc. (&#8220;Enochian&#8221;, and together with its subsidiaries, the &#8220;Company&#8221;, &#8220;we&#8221; or &#8220;us&#8221;)
to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties.
Our actual future results and trends may differ materially depending on a variety of factors, including, but not limited to, the
risks and uncertainties discussed in Part I, Item 1A, &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K as filed with
the SEC on September 24, 2021. The Company&#8217;s plans and objectives are based, in part, on assumptions involving the continued
expansion of the business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future
economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict
accurately and many of which are beyond the control of the Company. Although the Company believes its assumptions underlying the
forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance
the forward-looking statements included in this Quarterly Report will prove to be accurate. In light of the significant uncertainties
inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation
by the Company or any other person that the objectives and plans of the Company will be achieved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">We
are a pre-clinical stage biotechnology company committed to using our genetically modified cell, gene, and immune therapy technologies
to potentially prevent or cure HIV, HBV, influenza and coronavirus infections, as well as to provide potentially long-term or life-long
cancer remission in some of the deadliest cancers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Over the past several years,
Enochian Biosciences Inc. has expanded the pipeline from a single potential cure for HIV (autologous transplantation with gene-modified
cells; ENOB-HV-01) to three additional potential cures for HIV, a potential cure for Hepatitis B Virus (HBV), potential inhaled
treatment and prophylaxis/prevention of all variants of SARS-CoV-1 and -2 (the cause of the COVID-19 pandemic), and potential cures
for many solid tumors, beginning with pancreatic cancer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our integrated platforms
encompass innovative interventions in gene and immune therapies that provide hope for cures or life-long remissions for devastating
diseases. Our platforms can potentially streamline and accelerate pre-clinical, regulatory, clinical, and production pathways.
Because of the relative ease of administration, our potentially groundbreaking interventions could be used throughout the world.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><i>Platforms: </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt"><i>Hijack RNA</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">Our novel approach
tricks the virus into sending suicide signals to the infected cell instead of turning the cell into a virus factory. The technology
is delivered by vectors that would allow it to rapidly treat an infection, or to lay and wait in ambush until a cell becomes infected,
which would prevent (prophylaxis, similar to taking drugs to protect from becoming infected with malaria or HIV) future infections.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">The delivery mechanism
can be adapted for aerosol (e.g., respiratory infections like the virus that causes COVID-19 and influenza), intravenous or other
delivery mechanisms (e.g. for Hepatitis B Virus and HIV).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: 18pt"><i>Allogeneic Cell
Therapy</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: 18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">The human immune
system is designed to recognize &#8220;self&#8221; and destroy &#8220;otherness&#8221; or &#8220;non-self&#8221;, such as bacteria,
viruses and cancer cells.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">Alloreactivity
(reacting against another person&#8217;s cells) is the most powerful response the immune system generates. Several of our technologies
take advantage of the alloreactivity to hyperstimulate a person&#8217;s immune response to better attack a chronic infection (e.g.
HIV) or solid tumors. In certain treatments (e.g. HIV and cancer), cells taken from healthy donors are sometimes genetically modified
to further boost the immune system to seek and kill diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">In addition to
those platforms, Enochian Biosciences has an innovative approach to remove cells from a person living with HIV and genetically
modify them so they cannot be infected with HIV. The unique innovation is an additional genetic alteration to increase the ability
of those cells to survive and expand when they are given back to the same person (autologous transplantation).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Respiratory Diseases</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">In
April 2021, Enochian Biosciences acquired the exclusive license to a potential pan-SARS-Cornavirus-1 and-2 (SARS-CoV) and pan-Influenza
inhaled treatment and prophylaxis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">SARS-CoV-2
has caused the most devastating global pandemic in a century &#8211; COVID-19. Using the Hijack RNA platform technology, <i>in
vitro</i> and <i>in vivo </i>results showing rapid killing of infected cells, but not uninfected cells were presented at the important
Conference on Retroviruses and Opportunistic Infections in March 2021. Since that time, there has been substantial progress with
a Pre-IND (as defined below) submission expected in the near term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Influenza
has caused dozens of major global pandemics; the most notable in 1918 that killed 50 to 100 million people. There was an H1N1 threat
as recently as 2009. The Hijack RNA also has shown promising <i>in vitro</i> results that were presented at the Annual Conference
of the American Society of Gene and Cell Therapy (ASGCT) in May 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">A
leading scientist and public health expert serves on our Scientific Advisory Board focused on respiratory diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Human Immunodeficiency
Virus (HIV), and Acquired Immunodeficiency Syndrome (AIDS)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">HIV
attacks the human immune system, specifically killing off CD4+ cells, or T cells, which play a central, controlling role in the
immune system. Left untreated, HIV dramatically reduces the number of T cells in the body, devastates the immune system, leading
to AIDS, a condition where the immune system cannot fight off life-threatening infections and cancers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Currently
there are over 30 antiretroviral drugs, or ART, approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) to treat
HIV but these drugs are expensive, require daily adherence, and can have significant side effects over time. In addition, on a
global basis, as many as 1 million people, including persons in high-income countries, continue to die each year from HIV/AIDS
due to drug-resistant HIV or lack of access to treatment. To date, there are no treatments that can eliminate the reservoir of
immune cells that are infected with HIV from the body. Consequently, treatment for HIV is life-long.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">There
have been several efforts to cure HIV by re-engineering a person&#8217;s own T-cells so that these cells no longer express a special
protein (C-C chemokine co-receptor type 5 or CCR5), which HIV uses to gain entry to them. A naturally occurring mutation that blocks
expression of CCR5 on T cells occurs in ~1% of persons living in or from Northern Europe with no known adverse effects. The &#8220;Berlin
patient&#8221;, and more recently the &#8220;London patient&#8221; were HIV-positive persons who developed cancer and were treated
with a bone marrow transplant with cells donated from persons with this naturally occurring mutation of CCR5. The Berlin and London
patients seem to have been effectively cured from HIV providing proof-of-concept that HIV can be cured. However, because the transplanted
cells come from another person, such transplants carry high risk and can result in death in a significant proportion of patients.
Given the success with these two patients, several researchers and companies have attempted to replicate this experience by genetically
modifying T cells of HIV-positive patients to render them unable to be infected by HIV and then returning them to the patient.
Because the transplanted cells are from the same person, the risks to the patient are much lower. The uptake, or engraftment of
the modified T cells, however, has not been optimal, leading to failure to achieve a cure. In addition, the transplant pre-treatment
that has been used is bone marrow-destroying chemotherapy, which wipes out the patient&#8217;s immune system and can have long-term
side effects including the risk of developing cancer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></p>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">ENOB-HV-01
is a novel, proprietary approach with the potential to overcome the failures of recent efforts to develop a cure for HIV. The intervention
provides gene-modified T cells with a competitive advantage over non-modified cells in the HIV-positive person, with the potential
to significantly increase engraftment; and avoid the need for chemotherapy that substantially depletes the bone marrow and could
potentially be given as an outpatient treatment. The Company met with the FDA INTERACT team on June 2, 2020. INTERACT is the first
available FDA interaction and is a key step in the process towards a potential Investigational New Drug Application (IND) to study
First-in-Human products potentially leading to marketing authorization via Biologics License Application (BLA). The FDA Center
for Biologics Evaluation and Research (CBER) has numerous INTERACT requests and grants meetings that are deemed appropriate for
this early FDA engagement. The Enochian management team considered the meeting to be successful with strong alignment between Enochian&#8217;s
approach to developing ENOB-HV-01 and the comments of the FDA reviewers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">Initial
scientific findings from a mouse study on the ENOB-HV-01 approach were presented at the annual ASCGT conference in May 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">We
are also developing ENOB-HV-11 and ENOB-HV-12 that will utilize a novel cellular- and immunotherapy approach that could potentially
provide both preventative and therapeutic vaccines for HIV. A non-human primate study is in process and on schedule. Preliminary
results could potentially be available by the latter part of 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our co-founder and inventor,
Dr. Serhat G&#252;mr&#252;kc&#252;, who is also the Director of Seraph Research Institute (SRI), submitted Pre-IND for ENOB-HV-21,
an innovative treatment of Natural Killer (NK) and Gamma Delta T-Cells (GDT) collected from another person. It is believed that
the GDT cells, a small subset of immune cells that can be infected with HIV, could be a key factor in controlling the virus. The
initial scientific findings were presented during the ASCGT Conference this past May. Enochian Biosciences has an exclusive license
to use the underlying patent to develop ENOB-HV-21 for the prevention, treatment, and/or amelioration of and/or therapy exclusively
for HIV in humans, and research and development exclusively relating to HIV in humans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">We
are in the development phase of additional product candidates related to our HIV pipeline. ENOB-HV-31, which is an <i>in vivo </i>gene
therapy, and ENOB-HV-32, which is a peptide drug for packaging and distribution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Hepatitis B (HBV) </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Despite the availability
of an effective vaccine and treatment that can control infection if it is taken daily for life, hepatitis B virus (HBV) is the
world&#8217;s most common serious liver infection. While vaccines are increasingly required for children, many adults have not
been vaccinated. Life-long treatment can be difficult for certain people and access can be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">In that regard, HBV remains
the leading cause of liver cancer and the second leading cause of cancer deaths in the world. Two billion people have been infected
with HBV, approximately 350 million have chronic HBV infection, and nearly one million people die every year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Current efforts to develop
novel treatment or cure largely focus on approaches to deplete the pool of a certain type of HBV DNA. Enochian Biosciences has
collaborated with SRI to develop an innovative approach to co-opt HBV polymerase, a key expanding factor that the virus needs to
reproduce itself, to induce the death of liver cells infected with the virus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On July 27, 2020, Enochian
Biosciences announced the creation of an HBV Scientific Advisory Board comprised of distinguished leaders in HBV disease, treatment
and cure. On August 23, 2021, we announced the addition of a third leading expert with substantial experience in HBV clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On September 27, 2021, the
Company announced the completion of a Pre-Investigational New Drug (IND) process following receipt of written comments from the
U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies
(OTAT) for ENOB-HB-01.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The initial <i>in vitro
</i>and <i>in vivo </i>work was presented at the biannual HEP DART meeting in December of 2019, where it was selected as one of
the best new therapies/novel strategies. Additional data was presented at the annual ASCGT conference in May 2020. A proof-of-concept,
<i>in vivo</i> cure study is in advanced stages. A Pre-IND request has been completed with productive comments and insights. An
IND could potentially be submitted towards the end of 2022 with potential for enrollment in a clinical trial to begin by the end
of 2022 or in 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Cancer</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">Based on learning from peer-reviewed publications
of Phase I/IIa trials, we have designed an innovative therapeutic vaccination platform that could potentially be used to induce
life-long remissions from some of the deadliest solid tumors. Initial preclinical <i>in vitro </i>studies have been encouraging.
We initially plan to target pancreatic cancer, triple-negative breast cancer, glioblastoma, and renal cell carcinoma. The platform
might also allow for non-specific immune enhancement that could have impact against a broad array of solid tumors. As with HIV,
our approach would potentially allow for outpatient therapy without ablating or significantly impairing the patient&#8217;s immune
system, as many current approaches require.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">Through a collaboration with a leader in the
field of pancreatic cancer, our first cancer-related therapeutic target, we are developing the pipeline with <i>in vitro </i>and
<i>in vivo </i>proof-of-concept studies to evaluate the potential to induce long-term remission or cure. Results are expected in
first half 2022. If the results are promising, a potential Pre-IND and an IND with potential for enrollment in a clinical trial
maybegin in 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">To
date, our operations have been funded by sales of our securities and the issuance of debt. We have never generated any sales revenue,
and we expect this to continue until our therapies or products are approved for marketing in the United States and/or Europe. Even
if we are successful in having our therapies or products approved for sale in the United States and/or Europe, we cannot guarantee
that a market for the therapies or products will develop. We may never be profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Corporate History</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On February 16, 2018, we
completed our acquisition of Enochian Biopharma pursuant to an acquisition agreement, dated January 12, 2018, by and among the
Registrant, its wholly owned subsidiary DanDrit Acquisition Sub, Inc., Enochian Biopharma and Weird Science with Enochian Biopharma
surviving as a wholly owned subsidiary of the Registrant. As consideration for the acquisition, the stockholders of Enochian Biopharma
received (i) 18,081,962 shares of Common Stock and (ii) the right to receive contingent shares pro rata upon the exercise or conversion
of warrants, which were outstanding at closing (see Note 7.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>COVID-19 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">The COVID-19 pandemic continues
to evolve, and to date has led to the implementation of various mitigation responses, including government-imposed quarantines,
travel restrictions and other public health safety measures, as well as leading to reported adverse impacts on healthcare resources,
facilities and providers across the United States and in other countries. COVID-19 may cause delays in our research activities.
To date, it has not materially affected our operations; however it has caused delays in the conduct of experiments due to limitations
of various organizations, in particular those conducting experiments related to COVID-19. There have also been increases in the
cost to conduct animal studies due to staffing and other limitations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">The full extent to which
the COVID-19 pandemic may impact our business and operations is subject to future developments, which are uncertain and difficult
to predict. Further quarantines, shelter-in-place or similar restrictions and other actions taken or imposed by foreign, federal,
state and local governments could adversely impact our or our partners&#8217; clinical, research and development, regulatory and
manufacturing operations or timelines.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We continue to monitor the
impact of the COVID-19 pandemic on our business and operations and will seek to adjust our activities as appropriate. In addition,
the pandemic could result in significant and prolonged disruption of global financial markets, reducing our ability to access capital,
which could in the future negatively affect the financial resources available to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;<b>Results of Operations
for the three and six months ended December 31, 2021 compared to the three and six months ended December 31, 2020</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;The following table
sets forth our revenues, expenses and net loss for the three and six months ended December 31, 2021 and 2020. The financial information
below is derived from our unaudited condensed consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="color: black; font-weight: bold">&#160;</td>
    <td colspan="7" style="color: black; font-weight: bold; text-align: center">For the Three Months Ended</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="color: black; font-weight: bold">&#160;</td>
    <td colspan="7" style="color: black; font-weight: bold; text-align: center">For the Six Months Ended</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">December 31,</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">Increase/(Decrease)</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">December 31,</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">Increase/(Decrease)</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2021</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2020</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">$</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">%</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2021</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2020</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">$</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; font-weight: bold; text-align: left">Operating Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 28%; color: black; text-align: left">General and administrative expenses</td><td style="width: 2%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 5%; color: black; text-align: right">4,154,901</td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 2%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 5%; color: black; text-align: right">1,939,988</td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 2%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 5%; color: black; text-align: right">2,214,913</td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 2%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 5%; color: black; text-align: right">114</td><td style="width: 1%; color: black; text-align: left">%</td><td style="width: 2%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 5%; color: black; text-align: right">8,621,598</td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 2%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 5%; color: black; text-align: right">3,717,911</td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 2%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 5%; color: black; text-align: right">4,903,687</td><td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 2%; color: black">&#160;</td>
    <td style="width: 1%; color: black; text-align: left">&#160;</td><td style="width: 5%; color: black; text-align: right">132</td><td style="width: 1%; color: black; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; text-align: left">Research and development expenses</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">2,144,085</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">1,334,468</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">809,617</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">61</td><td style="color: black; text-align: left">%</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">5,150,328</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">2,384,844</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">2,765,484</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">116</td><td style="color: black; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">Depreciation and amortization</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">31,805</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">30,760</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">1,045</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">3</td><td style="padding-bottom: 1pt; color: black; text-align: left">%</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">63,538</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">61,218</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">2,320</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">4</td><td style="padding-bottom: 1pt; color: black; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; text-align: left">Total Operating Expense</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">6,330,791</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">3,305,216</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">3,025,575</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">92</td><td style="padding-bottom: 1pt; color: black; text-align: left">%</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">13,835,464</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">6,163,973</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">7,671,491</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">124</td><td style="padding-bottom: 1pt; color: black; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; font-weight: bold; text-align: left">LOSS FROM OPERATIONS</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(6,330,791</td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(3,305,216</td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(3,025,575</td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">92</td><td style="padding-bottom: 1pt; color: black; text-align: left">%</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(13,835,464</td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(6,163,973</td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(7,671,491</td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">124</td><td style="padding-bottom: 1pt; color: black; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; font-weight: bold; text-align: left">Other Income (Expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">Change in fair value of contingent consideration</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(167,255</td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">493,411</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(660,666</td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(134</td><td style="color: black; text-align: left">)%</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(2,991,897</td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">920,811</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(3,912,708</td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(425</td><td style="color: black; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; text-align: left">Interest expense</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(93,382</td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(93,426</td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">44</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">&#8212;</td><td style="color: black; text-align: left">%</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(183,121</td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(185,739</td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">2,618</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(1</td><td style="color: black; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">Gain (Loss) on currency transactions</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">&#8212;</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(32,289</td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">32,289</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">100</td><td style="color: black; text-align: left">%</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">9</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(32,289</td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">32,298</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">100</td><td style="color: black; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; text-align: left">Interest income</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">8,487</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">3,066</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">5,421</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">177</td><td style="padding-bottom: 1pt; color: black; text-align: left">%</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">15,597</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">7,372</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">8,225</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">112</td><td style="padding-bottom: 1pt; color: black; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; text-align: left">Total Other (expense) income</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(252,150</td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">370,762</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(622,912</td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(168</td><td style="padding-bottom: 1pt; color: black; text-align: left">)%</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(3,159,412</td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">710,155</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(3,869,567</td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(545</td><td style="padding-bottom: 1pt; color: black; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; font-weight: bold; text-align: left">Loss Before Income Taxes</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">$</td><td style="color: black; text-align: right">(6,582,941</td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">$</td><td style="color: black; text-align: right">(2,934,454</td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">$</td><td style="color: black; text-align: right">(3,648,487</td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">124</td><td style="color: black; text-align: left">%</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">$</td><td style="color: black; text-align: right">(16,994,876</td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">$</td><td style="color: black; text-align: right">(5,453,818</td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">$</td><td style="color: black; text-align: right">(11,541,058</td><td style="color: black; text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">212</td><td style="color: black; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="color: black; font-weight: bold; text-align: left">Income Tax Benefit</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">1,158</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(1,158</td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(100</td><td style="padding-bottom: 1pt; color: black; text-align: left">)%</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(34</td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">123,952</td><td style="padding-bottom: 1pt; color: black; text-align: left">&#160;</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">$</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(123,986</td><td style="padding-bottom: 1pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; color: black; text-align: right">(100</td><td style="padding-bottom: 1pt; color: black; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: black; font-weight: bold; text-align: left">NET LOSS</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right">(6,582,941</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right">(2,933,296</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right">(3,649,645</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right">124</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">%</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right">(16,994,910</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right">(5,329,866</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right">(11,665,044</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">)</td><td style="color: black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: black; text-align: right">219</td><td style="padding-bottom: 2.5pt; color: black; text-align: left">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Revenues</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We are a pre-revenue, pre-clinical biotechnology company. We have
never generated revenues and have incurred losses since inception. We do not anticipate earning any revenues until our therapies
or products are approved for marketing and sale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Expenses </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our operating expenses for
the three months ended December 31, 2021, and December 31, 2020 were <span style="background-color: white">$6,330,791 and $3,305,216
respectively, representing an increase of $3,025,575, or approximately 92%</span>. The increase in operating expenses primarily
relate to general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our operating expenses for
the six months ended December 31, 2021, and December 31, 2020, were $13,835,464 and $6,163,973, respectively, representing an increase
of $7,671,491 or approximately 124%. The change is primarily related to the increase in general and administrative expenses of
$4,903,687, and an increase in R&amp;D expenses of $2,747,984.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">General and administrative
expenses for the three months ended December 31, 2021, and December 31, 2020, were $4,154,901 and $1,939,988, respectively, representing
an increase of $2,214,914 or approximately 114%. The variance is primarily related to an increase in stock-based compensation of
$1,683,901, an increase in compensation and related expenses of $301,743, and an increase in lab expenses of $160,618.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">General and administrative
expenses for the six months ended December 31, 2021, and December 31, 2020, were $8,621,598 and $3,717,911, respectively, representing
an increase of $4,903,687 or approximately 132%. The largest contributors to the increase in general and administrative expenses
were the increases in stock-based compensation of $4,085,720, officer compensation of $436,062, salaries expense of $196,065, laboratory
expenses of $171,847, and recruiting expenses of $117,233, offset by a decrease in security expenses of $139,175.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Research and development
expenses for the three months ended December 31, 2021, and December 31, 2020, were $2,144,085 and $1,334,468, respectively, representing
a decrease of $809,617 or approximately 61%. The variance is primarily driven by $684,939 contract development and manufacturing
company&#160;(&#8220;CDMO&#8221;) partner expenses related to CV-01, $75,000 related to COVID license payments that were not established
in prior year, and $33,000 in new contract research organization (&#8220;CRO&#8221;) payments. All other R&amp;D costs remained
relatively flat.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Research and development
expenses for the six months ended December 31, 2021, and December 31, 2020, were $5,150,328 and $2,384,844, respectively, representing
an increase of $2,765,484 or approximately 116%. The largest contributors to the increase in research and development expenses
were the increases in license costs related to ENOB HB-01 of $1,500,000 for achievement of milestone, costs incurred for ENOB HV-21
of $600,000, newly incurred costs with CDMO and CRO partners totaling $765,939, new COVID license payments of $150,000, offset
by a reduction in license costs related to ENOB-HB-01 totaling $400,000 that were incurred in the prior period only.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company recorded other
(expense) of $252,150 for three months ended December 31, 2021, compared to other income of $370,762 for the three months ended
December 31, 2020, representing an increase in other (expense) of $622,912 or 168%. The variance is primarily due to the change
in fair value of the contingent consideration liability expense of $660,666.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company recorded other
(expense) of $3,159,412 for the six months ended December 31, 2020, compared to other income of $710,155 for the six months ended
December 31, 2020, representing an increase in other (expense) of $3,869,567 or 545%. The variance is primarily due to the change
in fair value of the contingent consideration liability expense of $3,912,708.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Net Loss </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Net loss for the three months
ended December 31, 2021, and 2020, was $6,582,941 and $2,933,296, respectively, representing an increase in loss of $3,649,645
or approximately 124%. The increase in net loss was primarily due to an increase in general and administrative expenses of $2,214,913,
an increase in research and development expenses of $809,617, and the change in the change in fair value of the contingent consideration
of $660,666.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Net loss for the six months
ended December 31, 2021, and 2020, was $16,994,910 and $5,329,866, respectively, representing an increase in loss of $11,665,044
or approximately 219%. The increase in net loss was primarily due to the increase in general and administrative expenses of $4,903,687,
an increase in research and development costs of $2,765,484, and an increase in expense related to the change in fair value of
the contingent consideration of $3,912,708.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Liquidity and Capital Resources </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We have historically satisfied
our capital and liquidity requirements through funding from shareholders, the sale of our Common Stock and warrants, and debt financing.
We have never generated any sales revenue to support our operations and we expect this to continue until our therapies or products
are approved for marketing in the United States and/or Europe. Even if we are successful in having our therapies or products approved
for sale in the United States and/or Europe, we cannot guarantee that a market for the therapies or products will develop. We may
never be profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">At this time, we believe
we have sufficient liquidity and access to committed funds to fund our operations for the next twelve months. We may need additional
funds for (a) the purchase of equipment, (b) increases in personnel, and, (c) research and development, specifically to advance
towards an Investigational New Drug Application (IND) following Pre-IND readouts from the FDA for ENOB-CV-01, ENOB-HB-01, ENOB-HV-01,
and ENOB-HV-21. We will also require additional funding to continue our research and development of ENOB-HV-11/12, ENOB-DC-11,
ENOB-FL-01 and -11 and ENOB-CV-11, to fund the Coronavirus and Influenza Indications License Agreement in furtherance of treatment
related to all coronaviruses, and for possible future strategic acquisitions of businesses, products or technologies complementary
to our business. If additional funds are required, we may raise such funds from time to time through public or private sales of
our equity or debt securities. Such financing may not be available on acceptable terms, or at all, and our failure to raise capital
when needed could materially adversely affect our growth plans and our financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">As of December 31, 2021,
the Company had $13,707,907 in cash and working capital of $8,416,386 as compared to $20,664,410 in cash and working capital of
$19,013,100 as of June 30, 2021, a decrease of 34 % and 56%, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Assets</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Total assets at December
31, 2021, were $183,136,138 compared to $189,605,225 as of June 30, 2021. The decrease in total assets was primarily due to the
decrease in cash of $6,956,503. The change in cash is primarily attributed to $5,150,328 in research and development costs related
to the HBV license agreement, costs related to ENOB-CV-01 for related CDMO and CRO costs, and ENOB-HV-21 studies along with approximately
$3,710,286 in general and administrative expenses, net of non-cash items, offset by an increase in funding totaling $3,178,339
related to warrants exercised during the period and drawdowns from the LPC equity line.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Liabilities </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Total liabilities at December
31, 2021, were $17,516,675 compared to $14,942,286 as of June 30, 2021. The increase in total liabilities was primarily related
to an increase of $2,991,897 in the contingent consideration liability as a result of mark-to-market adjustment, and an increase
in other current liabilities of $409,273 related to a financing arrangement for a new insurance policy, partially offset by the
reduction in accrued expenses of $677,940, and the reduction of accounts payable of $153,809 due to timing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The following is a summary
of the Company&#8217;s cash flows (used by) or provided by operating, investing, and financing activities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months <br /> Ended <br />
    December 31,<br /> 2021</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months<br /> Ended December
    31,<br /> 2020</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left; text-indent: -7.5pt; padding-left: 7.5pt">Net Cash (Used in) Operating Activities</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(9,897,151</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(5,251,828</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -7.5pt; padding-left: 7.5pt">Net Cash (Used in) Investing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,156</td><td style="text-align: left">)</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(10,721</td><td style="color: black; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -7.5pt; padding-left: 7.5pt">Net Cash Provided by Financing Activities</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">2,950,741</td><td style="color: black; text-align: left">&#160;</td><td style="color: black">&#160;</td>
    <td style="color: black; text-align: left">&#160;</td><td style="color: black; text-align: right">(40,408</td><td style="color: black; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -7.5pt; padding-left: 7.5pt">(Loss) Gain&#160;on Currency Translation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,937</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,646</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -7.5pt; padding-left: 7.5pt">Change in Cash and Cash Equivalents</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,956,503</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,271,311</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cash Flows</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Cash used in operating activities
for the six months ended December 31, 2021, and 2020 was ($9,897,151) and ($5,251,828), respectively. Cash used in operating activities
during the current period included $5,150,328 in research and development costs related to the HBV license agreement, costs related
to ENOB-CV-01 for related CDMO and CRO costs, and ENOB-HV-21 studies along with approximately $3,710,286 in general and administrative
expenses, net of non-cash items.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Cash provided by financing
activities for the six months ended December 31, 2021, was $2,950,741 as compared to cash used by financing activities of $40,408
during the six months ended December 31, 2020. During the six months ended December 31, 2021, the Company received financing from
the drawdown of its LPC equity line of $3,048,339 and the exercise of warrants held by shareholders of $130,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Off-Balance Sheet Arrangements </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company does not have
any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company&#8217;s
financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures
or capital resources that is material to investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Significant Accounting Policies and Critical
Accounting Estimates </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The methods, estimates,
and judgments that we use in applying our accounting policies have a significant impact on the results that we report in our financial
statements. Some of our accounting policies require us to make difficult and subjective judgments, often as a result of the need
to make estimates regarding matters that are inherently uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">For a full explanation of
our accounting policies, see Note 1 to the unaudited condensed consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_010"></span>Item 3. Quantitative and Qualitative Disclosures
About Market Risk. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">As a &#8220;smaller reporting
company&#8221; as defined by Rule 12b-2 of the Securities Exchange Act of 1934, the Company is not required to provide the information
required by this Item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_011"></span>Item 4. Controls and Procedures.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Evaluation of Disclosure Controls and Procedures
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Our Principal Executive
Officer and Chief Financial Officer (the &#8220;Certifying Officers&#8221;) are responsible for establishing and maintaining disclosure
controls and procedures for the Company. The Certifying Officers have designed such disclosure controls and procedures to ensure
that material information is made known to them, particularly during the period in which this Report was prepared.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Certifying Officers
are responsible for establishing and maintaining adequate internal control over financial reporting for the Company and used the
&#8220;Internal Control over Financial Reporting Integrated Framework&#8221; issued by the Committee of Sponsoring Organizations
(&#8220;COSO&#8221;) to conduct an extensive review of the Company&#8217;s &#8220;disclosure controls and procedures&#8221; (as
defined in the Exchange Act, Rules 13a-15(e) and 15-d-15(e)) as of the end of each of the periods covered by this Report (the &#8220;Evaluation
Date&#8221;). Based upon that evaluation, the Certifying Officers concluded that, as of December 31, 2021, our disclosure controls
and procedures were not effective in ensuring that the information we were required to disclose in reports that we file or submit
under the Securities and Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods
specified in SEC rules and forms. The deficiency is attributed to the fact that the Company does not have an adequate number of
persons to whom it can segregate accounting tasks within the Company so as to ensure the segregation&#160;of duties between those
persons who approve and issue payment from those persons who are responsible to record and reconcile such transactions within the
Company&#8217;s accounting system. This control deficiency will be monitored and attention will be given to this matter as we increase
our personnel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Certifying Officers
based their conclusion on the fact that the Company has identified a material weakness in controls over financial reporting, detailed
above. We expect to be deficient in our disclosure controls and procedures until sufficient capital is available to hire the appropriate
internal accounting staff.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>Changes in Internal Controls </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">There have been no changes
in our internal controls over financial reporting during the three months ended December 31, 2021 that have materially affected
or are reasonably likely to materially affect our internal controls.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_012"></span>PART II &#8212; OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_013"></span>Item 1. Legal Proceedings.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">There are presently no material
pending legal proceedings other than in the ordinary course of business to which the Company or any of its subsidiaries, is a party
or as to which any of its property is subject, and no such proceedings are known to the Company to be threatened or contemplated
against it.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_014"></span>Item 1A. Risk Factors.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Risk factors that may affect
our business and financial results are discussed within Item 1A&#160;&#8221;Risk Factors&#8221; of our annual report for the fiscal
year ended June 30, 2021 on Form 10-K (&#8220;2021 Form 10-K&#8221;) filed with the&#160;SEC on September 24, 2021.&#160;There
have been no material changes to the disclosures relating to this item from those set forth in our 2021 Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_015"></span>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_016"></span>Item 3. Defaults Upon Senior Securities. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_017"></span>Item 4. Mine Safety Disclosures. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_018"></span>Item 5. Other Information.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_019"></span>Item 6. Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(a)</span></td>
    <td><span style="font-size: 10pt">Exhibits required by Item 601 of Regulation S-K.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 10%"><span style="font-size: 10pt">Exhibit&#160;No.</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 89%; text-align: justify"><span style="font-size: 10pt">Description </span></td></tr>
<tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">31.1**</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="e3501_ex31-1.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934</a></span></td></tr>
<tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
<tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">31.2**</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="e3501_ex31-2.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934</a></span></td></tr>
<tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
<tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">32.1***</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="e3501_ex32-1.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350</a></span></td></tr>
<tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
<tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">32.2***</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="e3501_ex32-2.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350</a></span></td></tr>
<tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
<tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">101.INS </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">XBRL Instance Document</span></td></tr>
<tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
<tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">101.SCH </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Schema</span></td></tr>
<tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
<tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">101.CAL </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Calculation Linkbase</span></td></tr>
<tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
<tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">101.DEF </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase</span></td></tr>
<tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
<tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">101.LAB </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Label Linkbase</span></td></tr>
<tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
<tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">101.PRE </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Presentation Linkbase</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
<tr style="vertical-align: top; background-color: transparent">
    <td style="width: 29px"><span style="font-size: 10pt">**</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Filed herewith.&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: transparent">
    <td><span style="font-size: 10pt">***</span></td>
    <td><span style="font-size: 10pt">Furnished herewith.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_020"></span>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Date: February 14, 2022</span></td>
    <td colspan="2"><span style="font-size: 10pt"><b>ENOCHIAN BIOSCIENCES INC. </b></span></td></tr>
<tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 45%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By: </span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><i>/s/ Mark Dybul </i></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Mark Dybul </span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer </span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(Principal Executive Officer) </span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By: </span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><i>/s/ Luisa Puche </i></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Luisa Puche</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Financial Officer </span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(Principal Financial and Accounting Officer) </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">31</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 3pt; margin-bottom: 3pt"><div style="border-top: Black 2pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
[{"type": "10-Q", "sequence": "1", "filename": "e3501_10-q.htm", "description": "FORM 10-Q", "secsgml_size_bytes": 796702}]
{"company-data": {"conformed-name": "Enochian Biosciences Inc", "cik": "0001527728", "assigned-sic": "2834", "irs-number": "452259340", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "10-Q", "act": "34", "file-number": "001-38758", "film-number": "22634857"}, "business-address": {"street1": "CENTURY CITY MEDICAL PLAZA", "street2": "2080 CENTURY CITY EAST", "city": "SUITE 906 LOS ANGELES", "state": "CA", "zip": "90067", "phone": "45 39179840"}, "mail-address": {"street1": "CENTURY CITY MEDICAL PLAZA", "street2": "2080 CENTURY CITY EAST", "city": "SUITE 906 LOS ANGELES", "state": "CA", "zip": "90067"}, "former-company": [{"former-conformed-name": "DanDrit Biotech USA, Inc.", "date-changed": "20140214"}, {"former-conformed-name": "Putnam Hills Corp.", "date-changed": "20110810"}]}
U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-Q
☒
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the quarterly period ended
December 31, 2021
OR
☐
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the transition period from ________ to ________
Commission
file number
001-38758
Enochian Biosciences Inc.
(Exact
name of registrant as specified in its charter)
Delaware
45-2259340
(State or other jurisdiction of
(I.R.S. Employer
incorporation or organization)
Identification Number)
2080 Century Park East
,
Suite 906
Los Angeles
,
CA
90067
(Address of principal executive offices)
(Zip Code)
+1
(305)
918-1980
(Registrant's
telephone number, including area code)
N/A
(Former
name, former address and former fiscal year, if changed since last report)
Securities
registered pursuant to Section 12(b) of the Act:
Title
    of Each Class
Trading
    Symbol
Name
    of Each Exchange on Which Registered
Common Stock, par value $0.0001 per
    share
ENOB
The
Nasdaq
Stock Market LLC
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.
Yes
☒ No ☐
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files).
Yes
☒ No ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging
growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting
company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☒
Emerging growth company
☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐
No
☒
As
of February 14, 2022, the number of shares of the registrant's common stock outstanding was
52,633,267
.
ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
- INDEX -
Page
PART I – FINANCIAL INFORMATION:
1
Item 1.
Financial Statements (Unaudited):
1
Condensed Consolidated Balance Sheets as of December 31, 2021 (Unaudited) and June 30, 2021
2
Condensed Consolidated Statements of Operations for the Three and Six Months Ended December 31, 2021 and 2020 (Unaudited)
3
Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended December 31, 2021 and 2020 (Unaudited)
4
Condensed Consolidated Statements of Stockholders' Equity for the Three and Six Months Ended December 31, 2021 and 2020 (Unaudited)
5
Condensed Consolidated Statements of Cash Flows for the Six Months Ended December 31, 2021 and 2020 (Unaudited)
6
Notes to the Condensed Consolidated Financial Statements (Unaudited)
7
Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
22
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
29
Item 4.
Controls and Procedures
29
PART II – OTHER INFORMATION:
30
Item 1.
Legal Proceedings
30
Item 1A.
Risk Factors
30
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
30
Item 3.
Defaults Upon Senior Securities
30
Item 4.
Mine Safety Disclosures
30
Item 5.
Other Information
30
Item 6.
Exhibits
30
Signatures
31
i
PART I – FINANCIAL INFORMATION
Item 1. Financial Statements.
The accompanying financial
statements have been prepared in accordance with generally accepted accounting principles for interim financial information and
in accordance with the instructions for Form 10-Q. Accordingly, they do not include all of the information and footnotes required
by generally accepted accounting principles for complete financial statements.
In the opinion of management,
the financial statements contain all material adjustments, consisting only of normal recurring adjustments necessary to present
fairly the financial condition, results of operations, and cash flows of the Company for the interim periods presented.
The results for the period
ended December 31, 2021 are not necessarily indicative of the results of operations for the full year. These financial statements
and related footnotes should be read in conjunction with the financial statements and footnotes thereto included in the Company's
Form 10-K for the fiscal year ended June 30, 2021, filed with the Securities and Exchange Commission on September 24, 2021.
1
ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
December 31,
June 30,
2021
2021
(Unaudited)
ASSETS
CURRENT ASSETS:
Cash
$
13,707,907
$
20,664,410
Other receivables
—
1,640
Prepaid expenses
910,637
232,943
Total Current Assets
14,618,544
20,898,993
Property and equipment, net
668,723
719,364
OTHER ASSETS:
Definite life intangible assets, net
55,413
65,906
Indefinite life intangible assets
154,824,000
154,824,000
Goodwill
11,640,000
11,640,000
Deposits and other assets
31,494
20,984
Operating lease rights-of-use assets
1,297,964
1,435,978
Total Other Assets
167,848,871
167,986,868
TOTAL ASSETS
$
183,136,138
$
189,605,225
LIABILITIES
CURRENT LIABILITIES:
Accounts payable – trade
$
166,750
$
320,559
Accrued expenses
504,383
1,182,323
Other current liabilities
499,875
90,602
Notes payable, net
4,727,662
—
Current portion of operating lease liabilities
303,488
292,409
Total Current Liabilities
6,202,158
1,885,893
NON-CURRENT LIABILITIES:
Contingent consideration liability
9,029,842
6,037,945
Convertible notes payable
1,200,000
1,200,000
Notes payable, net
—
4,579,114
Operating lease liabilities, net of current portion
1,084,675
1,239,334
Total Liabilities
17,516,675
14,942,286
Commitments and Contingencies
$
—
—
STOCKHOLDERS' EQUITY:
Preferred stock, $
0.0001
par value;
10,000,000
shares authorized;
no
shares issued and outstanding
—
—
Common stock, par value $
0.0001
,
100,000,000
shares authorized,
52,633,267
shares issued and outstanding at December 31, 2021, and
52,219,661
shares issued and outstanding at June 30, 2021
5,263
5,222
Additional paid-in capital
273,539,732
265,580,356
Accumulated deficit
(
107,906,715
)
(
90,911,805
)
Accumulated other comprehensive loss
(
18,817
)
(
10,834
)
Total Stockholders' Equity
165,619,463
174,662,939
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
$
183,136,138
$
189,605,225
See accompanying notes to the unaudited condensed
consolidated financial statements.
2
ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
For the Three Months Ended
For the Six Months Ended
December 31,
December 31,
2021
2020
2021
2020
Operating Expenses
General and administrative
$
4,154,901
$
1,939,988
8,621,598
3,717,911
Research and development
2,144,085
1,334,468
5,150,328
2,384,844
Depreciation and amortization
31,805
30,760
63,538
61,218
Total Operating Expenses
6,330,791
3,305,216
13,835,464
6,163,973
LOSS FROM OPERATIONS
(
6,330,791
)
(
3,305,216
)
(
13,835,464
)
(
6,163,973
)
Other Income (Expense)
Change in fair value of contingent consideration
(
167,255
)
493,411
(
2,991,897
)
920,811
Interest expense
(
93,382
)
(
93,426
)
(
183,121
)
(
185,739
)
Gain on currency transactions
—
(
32,289
)
9
(
32,289
)
Interest and other income
8,487
3,066
15,597
7,372
Total Other Income (Expense)
(
252,150
)
370,762
(
3,159,412
)
710,155
Loss Before Income Taxes
(
6,582,941
)
(
2,934,454
)
(
16,994,876
)
(
5,453,818
)
Income Tax (Provision) Benefit
—
1,158
(
34
)
123,952
NET LOSS
$
(
6,582,941
)
$
(
2,933,296
)
(
16,994,910
)
(
5,329,866
)
BASIC AND DILUTED LOSS PER SHARE
$
(
0.13
)
$
(
0.06
)
(
0.33
)
(
0.11
)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED
52,321,982
46,660,304
52,270,821
46,632,711
See accompanying notes to the unaudited condensed
consolidated financial statements
3
ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS
OF COMPREHENSIVE LOSS
(UNAUDITED)
For the Three Months Ended
For the Six Months Ended
December 31,
December 31,
2021
2020
2021
2020
Net Loss
$
(
6,582,941
)
$
(
2,933,296
)
(
16,994,910
)
(
5,329,866
)
Foreign Currency Translation, Adjustments
(
3,990
)
9,933
(
7,983
)
38,322
Comprehensive Loss
$
(
6,586,931
)
$
(
2,923,363
)
(
17,002,893
)
(
5,291,544
)
See accompanying notes to the unaudited condensed
consolidated financial statements.
4
ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS'
EQUITY
(UNAUDITED)
# of Shares
Common Shares
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Income
Total
July 1, 2021
52,219,661
$
5,222
$
265,580,356
$
(
90,911,805
)
$
(
10,834
)
$
174,662,939
Stock-based Compensation
—
—
2,727,975
—
—
2,727,975
Net Loss
—
—
—
(
10,411,969
)
—
(
10,411,969
)
Foreign Currency Translation Adjustment
—
—
—
—
(
3,993
)
(
3,993
)
September 30, 2021
52,219,661
5,222
268,308,331
(
101,323,774
)
(
14,827
)
166,974,952
Stock Issued Pursuant to Warrants Exercised
100,000
10
129,990
—
—
130,000
Shares Issued Pursuant to LPC Purchase Agreement
277,340
28
3,048,311
—
—
3,048,339
Stock-Based Compensation
—
—
2,043,292
—
—
2,043,292
Shares issued for fully vested RSUs
1,266
—
9,811
—
—
9,811
Restricted shares converted to shares for services rendered
35,000
3
(
3
)
—
—
—
Net Loss
—
—
—
(
6,582,941
)
—
(
6,582,941
)
Currency Translations
—
—
—
—
(
3,990
)
(
3,990
)
December 31, 2021
52,633,267
$
5,263
$
273,539,732
$
(
107,906,715
)
$
(
18,817
)
$
165,619,463
# of Shares
Common Shares
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Income
Total
July 1, 2020
46,497,409
$
4,650
$
230,497,225
$
(
64,188,198
)
$
(
41,416
)
$
166,272,261
Stock-Based Compensation
—
—
326,156
—
—
326,156
Issuance of Commitment Shares Related to LPC Purchase Agreement
139,567
14
(
14
)
—
—
—
Net Loss
—
—
—
(
2,396,570
)
—
(
2,396,570
)
Currency Translations
—
—
—
—
28,389
28,389
September 30, 2020
46,636,976
4,664
230,823,367
(
66,584,768
)
(
13,027
)
164,230,236
Stock Issued Pursuant to Warrants Exercised
63,122
6
82,050
82,056
Contingent Shares Issued Pursuant to Acquisition Agreement
63,122
6
192,516
192,522
Stock-based Compensation
—
—
359,391
—
—
359,391
Net Loss
—
—
—
(
2,933,296
)
—
(
2,933,296
)
Currency Translations
—
—
—
—
9,933
9,933
December 31, 2020
46,763,220
$
4,676
$
231,457,324
$
(
69,518,064
)
$
(
3,094
)
$
161,940,842
See accompanying notes to the unaudited condensed
consolidated financial statements.
5
ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH
FLOWS
(UNAUDITED)
For the
    Six Months Ended
December
    31,
2021
2020
NET
    LOSS
$
(
16,994,910
)
$
(
5,329,866
)
ADJUSTMENTS
    TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:
Depreciation
    and amortization
63,538
61,218
Change
    in contingent consideration liability
2,991,897
(
920,811
)
Stock
    based compensation expense
4,771,267
685,547
Right-of-use assets
138,014
132,611
Amortization
    of discount of notes payable
148,548
147,957
CHANGES
    IN OPERATING ASSETS AND LIABILITIES:
Other
    receivables
1,640
1,982
Prepaid expenses/deposits
(
11,812
)
374,154
Accounts
    payable
(
153,810
)
(
403,953
)
Accrued
    expenses
(
677,939
)
132,542
Other
    current liabilities
(
30,004
)
—
Operating
    lease liabilities
(
143,580
)
(
133,209
)
NET
    CASH USED IN OPERATING ACTIVITIES
(
9,897,151
)
(
5,251,828
)
CASH
    FLOWS FROM INVESTING ACTIVITIES:
Purchase
    of property and equipment
(
5,156
)
(
10,721
)
NET
    CASH USED IN INVESTING ACTIVITIES
(
5,156
)
(
10,721
)
CASH
    FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise
    of warrants
130,000
82,056
Repayment
    of finance agreement
(
227,598
)
(
122,464
)
Proceeds
    from LPC equity agreement
3,048,339
—
NET
    CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES
2,950,741
(
40,408
)
Effect
    of exchange rates on cash
(
4,937
)
31,646
NET
    CHANGE IN CASH
(
6,956,503
)
(
5,271,311
)
CASH,
    BEGINNING OF PERIOD
20,664,410
8,696,361
CASH,
    END OF PERIOD
$
13,707,907
$
3,425,050
SUPPLEMENTAL
    DISCLOSURES OF CASH FLOW INFORMATION
Cash
    paid during the quarter end for:
Interest
$
36,462
$
42,365
Income
    Taxes
$
34
$
37
SUPPLEMENTAL DISCLOSURES
    OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Contingent Shares issued pursuant
    to Acquisition Agreement
$
—
$
192,522
Finance agreement entered into in exchange
    for prepaid assets
$
666,875
$
607,250
See accompanying notes to the unaudited condensed
consolidated financial statement.
6
ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS
NOTE 1 —
THE BUSINESS AND SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES
Business
–
Enochian
Biosciences Inc., ("Enochian", or "Registrant", and together with its subsidiaries, the "Company",
"we" or "us") engages in the research and development of pharmaceutical and biological products for the
human treatment of HIV, HBV, influenza and coronavirus infections, and cancer with the intent to manufacture and commercialize
said products.
Basis of Presentation
-
The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in the United
States of America ("U.S. GAAP") and follows the rules and regulations of the U.S. Securities and Exchange Commission
("SEC"). The accompanying financial statements are unaudited. In the opinion of management, all adjustments (which
include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows
at December 31, 2021 and 2020 and for the periods then ended have been made. Certain information and footnote disclosures normally
included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited
condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included
in the Company's June 30, 2021, audited financial statements. The results of operations for the periods ended December 31,
2021 and 2020 are not necessarily indicative of the operating results for the full year.
Consolidation
- For
the three and six months ended December 31, 2021 and 2020, the condensed consolidated financial statements include the accounts
and operations of the Registrant and its subsidiaries. All material inter-company transactions and accounts have been eliminated
in the consolidation.
Accounting Estimates
- The preparation of financial statements in conformity with generally accepted accounting principles requires management to
make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets
and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period.
Actual results could differ from those estimated. Significant estimates include the fair value and potential impairment of intangible
assets, and fair value of equity instruments issued.
COVID-19
-
The pandemic
continues to evolve, and to date has led to the implementation of various mitigation responses, including government-imposed quarantines,
travel restrictions and other public health safety measures, as well as leading to reported adverse impacts on healthcare resources,
facilities and providers across the United States and in other countries. COVID-19 may cause delays in our research activities.
To date, it has not materially affected our operations; however, it has caused delays in the conduct of experiments due to limitations
of various organizations, in particular those conducting experiments related to COVID-19. There have also been increases in the
cost to conduct animal studies due to staffing and other limitations.
The full extent to which
the COVID-19 pandemic may impact our business and operations is subject to future developments, which are uncertain and difficult
to predict. Further quarantines, shelter-in-place or similar restrictions and other actions taken or imposed by foreign, federal,
state and local governments could adversely impact our or our partners' clinical, research and development, regulatory and
manufacturing operations or timelines.
We continue to monitor the
impact of the COVID-19 pandemic on our business and operations and will seek to adjust our activities as appropriate. In addition,
the pandemic could result in significant and prolonged disruption of global financial markets, reducing our ability to access capital,
which could in the future negatively affect the financial resources available to us.
Functional Currency &
Foreign Currency Translation
- The functional currency of Enochian Denmark is the Danish Kroner ("DKK"). The Company's
reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company's balance sheet accounts
are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars
at the average exchange rates prevailing during the periods ended December 31, 2021 and 2020. Translation gains and losses are
deferred and accumulated as a component of other comprehensive income in stockholders' equity. Transaction gains and losses
that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included
in the statement of operations as incurred.
7
ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 — THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES (Continued)
Cash and Cash Equivalents
—The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash
equivalents. The Company had balances held in financial institutions in Denmark and in the United States in excess of federally
insured amounts at December 31, 2021 and June 30, 2021 of $
13,423,820
and $
20,287,212
, respectively.
Property and Equipment
— Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives
of property and equipment are capitalized and depreciated upon being placed in service. Expenditures for maintenance and repairs
are charged to expense as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the
estimated useful lives of the assets, which range from four to ten years (see Note 3).
Intangible Assets
-
The
Company has both definite and indefinite life intangible assets.
Definite life intangible
assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards
Board ("FASB") Accounting Standards Codification ("ASC") Topic 350, "Goodwill and Other Intangible
Assets". Intangible assets are recorded at cost. Patent costs consist of costs incurred to acquire the underlying patent.
If it is determined that a patent will not be issued, the related remaining capitalized patent costs are charged to expense. Intangible
assets are amortized on a straight-line basis over their estimated useful life. The estimated useful life of patents is twenty
years from the date of application.
Indefinite life intangible
assets include license agreements and goodwill. The Company accounts for indefinite life intangible assets in accordance with ASC
350, "Goodwill and Other Intangible Assets". License agreement costs represent the fair value of the license agreement
on the date acquired and are tested annually for impairment, as well as whever events or changes in circumstances indicate the
carrying value may not be recoverable. The fair value analysis performed on the license agreements, and the fair value analysis
performed on goodwill supported that both indefinite life intangible assets are not impaired as of June 30, 2021 (see Note 4.)
Goodwill
—Goodwill
is not amortized but is evaluated for impairment annually as of June 30
th
of each fiscal year or whenever events or
changes in circumstances indicate the carrying value may not be recoverable.
Impairment of Goodwill and Indefinite Lived
Intangible Assets
– We test for goodwill impairment at the reporting unit level, which is one level below the operating
segment level. Our detailed impairment testing involves comparing the fair value of each reporting unit to its carrying value,
including goodwill. Fair value reflects the price a market participant would be willing to pay in a potential sale of the reporting
unit and is based on discounted cash flows or relative market-based approaches. If the carrying value of the reporting unit exceeds
its fair value, we record an impairment loss for such excess. The carrying value of in-process research and development ("IPR&D")
and goodwill at December 31, 2021, were $
154,824,000
and $
11,640,000
, respectively.
For indefinite-lived intangible assets, such
as licenses acquired as an IPR&D asset, on an annual basis we determine the fair value of the asset and record an impairment
loss, if any, for the excess of the carrying value of the asset over its fair value. The fair value analysis performed on the license
agreement, and the annual fair value analysis performed on goodwill supported that both indefinite life intangible assets are not
impaired as of June 30, 2021, and no impairment is deemed necessary as of December 31, 2021 (see Note 4.)
8
ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 — THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES (Continued)
Impairment of Long-Lived
Assets
-
Long-lived assets, such as property and equipment and definite life intangible assets are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances
which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant
adverse changes in the business climate or legal factors; current period cash flow or operating losses combined with a history
of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will
more likely than not be sold or disposed of significantly before the end of its estimated useful life.
Recoverability of assets
to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows
expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows,
an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.
Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or
fair value less costs to sell and would no longer be depreciated. The depreciable basis of assets that are impaired and continue
in use are their respective fair values.
Leases
— In
accordance with ASC Topic 842, the Company determined the initial classification and measurement of its right-of-use assets and
lease liabilities at the lease commencement date and thereafter. The lease terms include any renewal options and termination options
that the Company is reasonably assured to exercise, if applicable. The present value of lease payments is determined by using the
implicit interest rate in the lease, if that rate is readily determinable; otherwise, the Company develops an incremental borrowing
rate based on the information available at the commencement date in determining the present value of the future payments.
Rent expense for operating
leases is recognized on a straight-line basis, unless the operating lease right of use assets have been impaired, over the reasonably
assured lease term based on the total lease payments and is included in operating expense in the condensed consolidated statements
of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease
right-of-use assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative
expenses in the unaudited condensed consolidated statements of operations.
The Company has elected
the practical expedient to not separate lease and non-lease components. The Company's non-lease components are primarily
related to property maintenance, insurance and taxes, which vary based on future outcomes, and thus are recognized in general and
administrative expenses when incurred (see Note 5.)
Research and Development
Expenses
— The Company expenses research and development costs incurred in formulating, improving, validating, and creating
alternative or modified processes related to and expanding the use of the HIV, HBV, Coronaviruses and Oncology therapies and technologies
for use in the prevention, treatment, amelioration of and/or therapy for HIV, HBV, Coronaviruses and Oncology. Research and development
expenses for the three and six months ended December 31, 2021, amounted to $
2,144,085
and $
5,150,328
, respectively. Research and
development expenses for the three and six months ended December 31, 2020, amounted to $
1,334,468
, and $
2,384,844
, respectively
Income Taxes
—
The Company accounts for income taxes in accordance with FASB ASC Topic 740, "Accounting for Income Taxes", which requires
an asset and liability approach for accounting for income taxes.
Loss Per Share
—
The Company calculates earnings/ (loss) per share in accordance with FASB Topic ASC 260, "Earnings Per Share". Basic
earnings per common share (EPS) are based on the weighted average number of shares of Common Stock outstanding during each period.
Diluted earnings per common share are based on shares outstanding (computed as under basic EPS) and potentially dilutive shares
of Common Stock. Potential shares of Common Stock included in the diluted earnings per share calculation include in-the-money stock
options that have been granted but have not been exercised. Because of the net loss for the three and six months ended December
31, 2021 and 2020, the dilutive shares for both periods were excluded from the Diluted EPS calculation as the effect of these potential
shares of Common Stock is anti-dilutive. The Company had
7,125,894
and
4,072,275
potential shares of Common Stock excluded from
the Diluted EPS calculation as of December 31, 2021 and December 31, 2020, respectively.
9
ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 — THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES (Continued)
Fair Value of Financial
Instruments
—The Company accounts for fair value measurements for financial assets and financial liabilities in accordance
with FASB ASC Topic 820, "Fair Value Measurements". The authoritative guidance, which, among other things, defines
fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability
category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing
the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between
market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market
participants would use in pricing an asset or liability (see Note 2.)
Stock Options and
Restricted Share Units
—The Company has granted stock options, restricted share units ("RSUs") and warrants.
The Company accounts for options in accordance with the provisions of FASB ASC Topic 718, "Compensation - Stock Compensation".
Stock-Based Compensation
—The
Company records stock-based compensation in accordance with ASC Topic 718, "Compensation - Stock Compensation". All
transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted
for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever
is more reliably measurable. Equity instruments issued to consultants and the cost of the services received as consideration are
measured and recognized based on the fair value of the equity instruments issued and are recognized over the required service
period, which is generally the vesting period. Stock based compensation costs for the vesting of options and RSUs granted for the
three and six months ended December 31, 2021, were $
2,043,292
and $
4,771,267
, respectively. Stock-based compensation costs for
the vesting of the options and RSUs granted for the three and six months ended December 31, 2020 were $
359,391
and $
668,482
, respectively.
(see Note 7.)
Recently Adopted Accounting
Pronouncements
—
Recent accounting pronouncements issued by the FASB do not or are not believed by management to
have a material impact on the Company's present or future financial statements.
10
ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 —
FAIR VALUE
MEASUREMENTS
— The Company accounts for fair value measurements for financial assets and financial liabilities in accordance
with FASB ASC Topic 820, "Fair Value Measurements". The authoritative guidance, which, among other things, defines
fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability
category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing
the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between
market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market
participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes
a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
●
Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;
●
Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and
●
Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
There were no Level 1, 2
or 3 assets, nor any Level 1 or 2 liabilities as of December 31, 2021.
Level 3 liabilities held
as of December 31, 2021 consisted of a contingent consideration liability related to the February 16, 2018 acquisition of Enochian
Biopharma Inc. (the "Acquisition"). As consideration for the Acquisition, the stockholders of Enochian Biopharma received
(i)
18,081,962
shares of Common Stock, and (ii) the right to receive contingent shares pro rata upon the exercise of warrants,
which were outstanding at closing. The contingent consideration liability was recorded at fair value of $
21,516,000
at the time
of acquisition and is subsequently remeasured to fair value at the end of each reporting period. At December 31, 2021, there were
1,250,000
contingent shares were issuable in connection with the Acquisition of Enochian Biopharma.
The fair value of the contingent
consideration liability is estimated using an option-pricing model. The key inputs to the model are all contractual or observable
with the exception being volatility, which is computed, based on the Company's underlying stock. The key inputs to valuing
the contingent consideration liability as of December 31, 2021, include the Company's stock price on the valuation date of
$
7.29
; the exercise price of the warrants of $
1.30
, the risk-free rate of
0.20
% the expected volatility of the Company's
Common Stock of
88.4
%, the digital call rate of
99
%, and the
1,250,000
contingent shares remaining at the end of the period. Fair
Value measurements are highly sensitive to changes in these inputs and significant changes in these inputs could result in a significantly
higher or lower fair value.
Unless otherwise disclosed,
the fair value of the Company's financial instruments including cash, accounts receivable, prepaid expenses, investments,
accounts payable, accrued expenses, capital lease obligations and notes payable approximate their recorded values due to their
short-term maturities.
The following table sets
forth the Level 3 liability at December 31, 2021, which is recorded on the balance sheet at fair value on a recurring basis. As
required, this liability is classified based on the lowest level of input that is significant to the fair value measurement:
Fair Value Measurements at
Reporting Date Using
Quoted Prices in
Active Markets for Identical Assets Inputs
Significant Other
Observable Inputs
Significant Other Unobservable Inputs
(Level 1)
(Level 2)
(Level 3)
The roll forward of the contingent consideration liability is as follows:
Balance June 30, 2021
—
—
$
6,037,945
Contingent Shares issued pursuant to the Acquisition Agreement
—
—
—
Fair value adjustment
—
—
2,991,897
Contingent Consideration Liability at December 31, 2021
—
—
$
9,029,842
11
ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 3 —
PROPERTY AND EQUIPMENT
Useful Life
December 31, 2021
June 30, 2021
Lab Equipment and Instruments
4
-
7
$
583,421
$
583,421
Leasehold Improvements
10
224,629
224,629
Furniture Fixtures and Equipment
4
-
7
177,131
171,975
Total
985,181
980,025
Less Accumulated Depreciation
(
316,457
)
(
260,661
)
Net Property and Equipment
$
668,723
$
719,364
Depreciation expense amounted
to $
27,990
, and $
55,796
for the three and six months ended December 31, 2021 respectively, and $
26,813
and $
53,358
for the three
and six months ended December 31, 2020.
NOTE 4 —
INTANGIBLE ASSETS
At December 31, 2021 and
June 30, 2021, definite-life intangible assets, net of accumulated amortization, consisted of patents on the Company's products
and processes of $
55,413
and $
65,906
, respectively. The patents are recorded at cost and amortized over twenty years from the date
of application. Amortization expense for the three and six months ended December 31, 2021, was $
3,814
and $
7,741
, respectively.
Amortization expense for the three and six months ended December 31, 2020 was $
3,947
and $
7,859
, respectively.
At December 31, 2021 and
2020, indefinite life intangibles assets consisted of a license agreement classified as In-Process Research and Development ("IPR&D")
intangible assets, which are not amortizable until the intangible asset provides economic benefit, and goodwill.
At December 31, 2021 and
June 30, 2021, definite and indefinite-life intangible assets consisted of the following:
Useful Life
June 30,
2021
Period Change
Effect of Currency Translation
December 31 ,
2021
Definite Life Intangible Assets
Patents
20
Years
$
316,115
$
—
$
(
14,145
)
$
301,970
Less Accumulated Amortization
(
250,209
)
(
7,741
)
11,393
(
246,557
)
Net Definite-Life Intangible Assets
$
65,906
$
(
7,741
)
$
(
2,752
)
$
55,413
Indefinite Life Intangible Assets
License Agreement
$
154,824,000
—
—
$
154,824,000
Goodwill
11,640,000
—
—
11,640,000
Total Indefinite Life Intangible Assets
$
166,464,000
—
—
$
166,464,000
Expected future amortization
expense is as follows:
Year ending June 30,
2022
$
4,661
2023
15,154
2024
15,154
2025
15,154
2026
5,290
Thereafter
—
Total
$
55,413
During February 2018, the
Company acquired a License Agreement (as licensee) to an HIV therapy which consists of a perpetual, fully paid-up, royalty-free,
sub-licensable, and sole and exclusive worldwide license to research, develop, use, sell, have sold, make, have made, offer for
sale, import and otherwise commercialize certain intellectual property in cellular therapies for the prevention, treatment, amelioration
of and/or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans. Because the
HIV License Agreement is considered an IPR&D intangible asset it is classified as an indefinite life asset that is tested annually
for impairment.
Impairment – Following
the fourth quarter of each year, management performs its annual test of impairment of intangible assets by performing a quantitative
assessment and determines if it is more likely than not that, the fair value of the asset is greater than or equal to the carrying
value of the asset. The results of the quantitative assessment supported Management's conclusion that an impairment adjustment
was not required as of June 30, 2021, and no impairment is deemed necessary as of December 31, 2021.
12
ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS
NOTE 5 —
LEASES
Operating
Leases
—
On November 13, 2017, Enochian entered into a Lease Agreement for a term of five years and two months from November
1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company (the "Landlord"), as landlord,
pursuant to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increases
by 3% each year, and ranges from approximately $8,719 per month for the first year to $10,107 per month for the two months of the
sixth year
.
On June 19, 2018, the Registrant
entered into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc.,
pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, the Registrant entered
into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to
include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from
$17,770 per month for the first year to $23,186 per month for the tenth year. The equalized monthly lease payment for the term
of the lease is $20,050
.
The Company identified and
assessed the following significant assumptions in recognizing the right-of-use asset and corresponding liabilities:
Expected lease term
— The expected lease term includes both contractual lease periods and, when applicable, cancelable option periods when it
is reasonably certain that the Company would exercise such options. The Company's leases have remaining lease terms between
12 months and 68 months. As of December 31, 2021, the weighted-average remaining term is
5.28
years.
Incremental borrowing
rate
— The Company's lease agreements do not provide an implicit rate. As the Company does not have any external
borrowings for comparable terms of its leases, the Company estimated the incremental borrowing rate based on the U.S. Treasury
Yield Curve rate that corresponds to the length of each lease. This rate is an estimate of what the Company would have to pay if
borrowing on a collateralized basis over a similar term in an amount equal to the lease payments in a similar economic environment.
As of December 31, 2021, the weighted-average discount rate is
4.01
%.
Lease and non-lease
components
— In certain cases the Company is required to pay for certain additional charges for operating costs,
including insurance, maintenance, taxes, and other costs incurred, which are billed based on both usage and as a percentage of
the Company's share of total square footage. The Company determined that these costs are non-lease components and they are
not included in the calculation of the lease liabilities because they are variable. Payments for these variable, non-lease components
are considered variable lease costs and are recognized in the period in which the costs are incurred.
Lease expense charged to
general and administrative expenses for the three and six months ended December 31, 2021, amounted to $
84,113
and $
168,196
, respectively.
Lease expense charged to general and administrative expenses for the three and six months ended December 31, 2020 amounted
to $
88,690
and $
178,374
, respectively.
Below are the lease commitments
for the next 5 years and thereafter:
Year Ending June 30
th
Lease Expense
2022
$
175,419
2023
298,305
2024
246,004
2025
253,384
2026
260,985
Thereafter
313,836
Less imputed interest
(
159,770
)
Total
$
1,388,163
13
ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 6 —
NOTES PAYABLE
Convertible Notes Payable
— On
February 6, 2020, the Company issued two Convertible Notes (the "Convertible Notes") to an existing stockholder of
the Company each with a face value amount of $
600,000
, convertible into shares of the Company's Common Stock. The outstanding
principal amount of the Convertible Notes is due and payable on
February 6, 2023
. Interest on the Convertible Notes commenced accruing
on the date of issuance at six percent (
6
%) per annum, computed on the basis of twelve 30-day months, and is compounded monthly
on the final day of each calendar month based upon the Principal and all accrued and unpaid interest outstanding as of such compound
date. The interest is payable in cash on a semi-annual basis.
The holder of the Convertible
Notes had the right at any time prior to the date that is twelve months from issuance to convert all or any part of the outstanding
and unpaid principal and all unpaid interest into shares of the Company's Common Stock. The conversion price is equal to
$
12.00
per share of Common Stock. The holder did not exercise the conversion feature that expired on February 6, 2021. The Company
evaluated the Convertible Notes in accordance with ASC 470-20 and identified that they each contain an embedded conversion feature
that shall not be bifurcated from the host document (i.e., the Convertible Notes) as they are not deemed to be readily convertible
into cash. All proceeds received from the issuance have been recognized as a liability on the balance sheet. The Convertible Notes
balance as of December 31, 2021 and 2020 was $
1,200,000
. As of December 31, 2021 and 2020, the Company recorded accrued interest
in the amount of $
24,181
, which is included in accrued expenses for each period. For the three and six months ended December 31,
2021 and 2020, the interest expense related to the Convertible Notes amounted to $
18,181
and $
36,453
, respectively.
Note Payable
— On March 30, 2020
(the "Issuance Date"), the Company issued a Promissory Note in the principal amount of $
5,000,000
(the "Unsecured
Note") to Paseco APS, a Danish limited company and an existing stockholder of the Company. The principal amount of the Note
was originally payable on
November 30, 2021
(the "Maturity Date") and bears interest at a fixed rate of
6
% per annum,
computed based on the number of days between the Issuance Date and the Maturity Date, which was prepaid by the Company in full
on the Issuance Date through the issuance of
188,485
shares of the Company's Common Stock based on the closing market price
on that date for a total value of $
501,370
. The Company evaluated the Unsecured Note and PIK interest in accordance with ASC 470-Debt
and ASC 835-Interest, respectively. Pursuant to ASC 470-20, proceeds received from the issuance are to be recognized at their relative
fair value, thus the liability was shown net of the corresponding discount of $
493,192
, which is the relative fair value of the
shares issued for the PIK interest on the closing date using the effective interest method. The discount of $
493,192
is being accreted
over the life of the Unsecured Note.
On February 11, 2021, the
Company entered into an amendment to the Unsecured Note in the principal amount of $
5,000,000
that extends the Maturity Date out
to November 30, 2022. All other terms of the Unsecured Note remain the same. The change in Maturity Date required an additional
year of interest at the fixed rate of
6
% per annum, which was prepaid by the Company in full on the date of the amendment through
the issuance of
74,054
shares of the Company's Common Stock based on the closing market price on that date for a total value
of $
298,178
. For the three and six months ended December 31, 2021, respectively, discount amortization of $
74,274
and $
148,548
was charged to interest expense. For the three and six months ended December 31, 2020, discount amortization of $
73,979
and $
147,958
,
respectively was charged to interest expense. The Unsecured Note balance, net of discount at December 31, 2021 was $
4,727,662
,
and is reflected in current liabilities
Finance Agreement
— On November
30, 2021, the Company entered into a premium finance agreement (the "Agreement") with a principal amount of $
666,875
at
3.99
% interest per annum. The repayment of the Agreement will be made in nine equal monthly installments of $
56,469
.
For the three and six months
ended December 31, 2021, the Company recorded total interest expense in the amount of $
927
. This amount is reflected in other income
and expenses.
Total interest expense recorded
for the three and six months ended December 31, 2021, was $
93,382
and $
183,121
, respectively. Interest expense recorded for the
three and six months ended December 31, 2020, $
93,426
and $
185,739
, respectively.
14
ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 7 —
STOCKHOLDERS' EQUITY
Preferred Stock
—The
Company has
10,000,000
authorized shares of Preferred Stock, par value $
0.0001
per share. At December 31, 2021 and June 30, 2021,
there were zero shares issued and outstanding.
Common Stock
—The
Company has
100,000,000
authorized shares of Common Stock, par value $
0.0001
per share. At December 31, 2021 and June 30, 2021,
there were
52,633,267
and
52,219,661
shares issued and outstanding, respectively
Voting —
Holders
of Common Stock are entitled to one vote for each share held of record on each matter submitted to a vote of stockholders, including
the election of directors, and do not have any right to cumulate votes in the election of directors.
Dividends —
Holders
of Common Stock are entitled to receive ratably such dividends as the Board from time to time may declare out of funds legally
available.
Liquidation Rights —
In the event of any liquidation, dissolution or winding up of affairs of the Company, after payment of all of our debts and liabilities,
the holders of Common Stock will be entitled to share ratably in the distribution of any of our remaining assets.
Purchase Agreement with Lincoln Park Capital
On July 8, 2020, we entered
into a purchase agreement (the "Purchase Agreement") with Lincoln Park Capital Fund, LLC ("Lincoln Park"),
pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $
20,000,000
of shares of our Common Stock from time to time through August 1, 2023.
Under the Purchase Agreement,
we may direct Lincoln Park, at our sole discretion subject to certain conditions, to purchase up to
200,000
shares of Common Stock
on any business day (a "Regular Purchase"). The amount of a Regular Purchase may be increased under certain circumstances
up to
125,000
shares of Common Stock, provided that Lincoln Park's committed obligation for Regular Purchases on any business
day shall not exceed $
1,000,000
. In the event we direct Lincoln Park to purchase the full amount allowed for a Regular Purchase
on any given business day, we may also direct Lincoln Park to purchase additional amounts as accelerated and additional accelerated
purchases. The purchase price of shares of Common Stock related to the future funding will be based on the then prevailing market
prices of such shares at the time of sales as described in the Purchase Agreement.
Our sale of shares of Common
Stock to Lincoln Park subsequent to the Amendment Date is
limited to 12,016,457 shares of Common Stock, representing 19.99%
of
the shares of the Common Stock outstanding on the Amendment Date unless (i) stockholder approval is obtained, (ii) the average
price of all applicable sales to Lincoln Park under the Purchase Agreement equals or exceeds the lesser of (A) the closing price
of the Common Stock on the Nasdaq Capital Market immediately preceding the date of the Purchase Agreement or (B) the average of
the closing prices on the Nasdaq Capital Market for the five Business Days immediately preceding the date of the Purchase Agreement
or (iii) to the extent it would cause Lincoln Park to beneficially own more than 9.99% of the Company's outstanding shares
of Common Stock at any given time.
In consideration for entering
into the Purchase Agreement, we issued
139,567
shares of Common Stock to Lincoln Park as a commitment fee on July 21, 2020.
During the three and six
months ended December 31, 2021, we issued
277,340
shares of Common Stock to Lincoln Park under the Purchase Agreement for a purchase
price of $
3,048,339
.
15
ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 7 — STOCKHOLDERS' EQUITY
(Continued)
Common Stock Issuances
—
In the three and six months ended December 31, 2021, there were
413,606
shares of Common Stock issued, respectively.
In the three and six months ended December 31, 2020, there were
126,244
and
265,811
shares of Common Stock issued, respectively.
Acquisition of Enochian
Biopharma Inc. / Contingently issuable shares
—
On February 16, 2018, the Acquisition was completed when the subsidiary
merged with and into Enochian Biopharma, with Enochian Biopharma as the surviving corporation. As consideration for the Acquisition,
the stockholders of Enochian Biopharma received (i) 18,081,962 shares of Common Stock, and (ii) the right to receive contingent
shares pro rata upon the exercise or conversion of warrants, which were outstanding at closing. At December 31, 2021,
1,250,000
contingent shares are issuable in connection with the Acquisition of Enochian Biopharma.
Acquisition of Enochian
Denmark
—
At December 31, 2021 and June 30, 2021, the Company maintained a reserve of
17,414
shares of Common
Stock of the Registrant held in escrow according to Danish law (the "Escrow Shares"), , all of which are reflected
as issued and outstanding in the accompanying financial statements. The Escrow Shares are reserved to acquire the shares of Enochian
Denmark held by non-consenting shareholders of Enochian Denmark on both December 31, 2021 and June 30, 2021, in accordance with
Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark. There have been
167,639
shares of Common
Stock issued to non-consenting shareholders of Enochian Denmark as of December 31, 2021. During the three and six months ended
December 31, 2021, the Company issued zero shares of Common Stock to such non-consenting shareholders of Enochian Denmark. There
is no impact on outstanding shares as these shares are reflected as issued and outstanding.
16
ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 7 — STOCKHOLDERS' EQUITY (Continued)
Stock-based Compensation
The Company recognizes compensation
costs for stock option awards to employees and directors based on their grant-date fair value. The value of each stock option is
estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate
the fair values of the stock options granted using the Black-Scholes option-pricing model are as follows:
Enochian
Biosciences Inc.
Expected term (in years)
5.0
–
6.5
Volatility
82.39
%-
90.21
%
Risk free interest rate
0.77
%-
1.33
%
Dividend yield
0
%
The Company recognized stock-based compensation expense related
to the options of $
2,043,292
and $
4,771,267
for the three and six months ended December 31, 2021, respectively. The Company recognized
stock-based compensation expense related to the options of $
359,391
and $
668,482
for the three and six months ended December 31,
2020, respectively. At December 31, 2021, the Company had approximately $
8,571,250
of unrecognized compensation cost related to
non-vested options.
Plan Options
On February 6, 2014, the
Board adopted the Company's 2014 Equity Incentive Plan (the "2014 Plan"), and the Company had reserved
1,206,000
shares of Common Stock for issuance in accordance with the terms of the 2014 Plan.
On October 30, 2019, the
Board approved and on October 31, 2019, the Company's shareholders adopted Enochian's 2019 Equity Incentive Plan (the
"2019 Plan"), which replaced the 2014 Plan. The 2019 Plan authorized options to be awarded to not exceed the sum of
(1) 6,000,000 new shares of Common Stock, and (2) the number of shares of Common Stock available for the grant of awards as of
the effective date under the 2014 Plan that, after the effective date of the 2019 Plan, expires, or is terminated, surrendered,
or forfeited for any reason without issuance of shares. The remaining shares of Common Stock available for grant related to the
2014 Plan was 655,769 as of the effective date; this amount along with the new 6,000,000 shares totals 6,655,769 shares of
Common Stock were available to grant immediately after the effective date of the 2019 Plan.
Pursuant to the 2019 Plan,
the Company granted options to purchase
120,900
and
3,130,200
shares of Common Stock to employees with a
three-year vesting period during the three and six months ended December 31, 2021, respectively. For the three and six months ended
December 31, 2020, the Company granted options to purchase
9,201
shares of Common Stock to employees with a
three-year vesting period. Options are exercisable at the market price of the
Company's Common Stock on the date of the grant.
During the three and six
months ended December 31, 2021, the Company granted options to purchase
36,727
and
63,462
shares of Common stock, respectively,
to the Board of Directors and Scientific Advisory Board Members with a one-year vesting period. For the three and six months ended
December 31, 2020, the Company granted annual options to purchase
63,435
and
87,631
shares of Common Stock, respectively to members
of the Board of Directors and Scientific Advisory Board with a one-year vesting period. Options are exercisable at the market price
of the Company's Common Stock on the date of the grant.
The Company issued options
to purchase
21,979
shares of Common Stock with immediate vesting, issued options to purchase
17,500
shares of Common Stock with
a one-year vesting period, and issued options to purchase
60,000
shares of Common Stock with a three-year vesting period for consulting
services during the three and six months ended December 31, 2021.
To date the Company has
granted options under the Plan ("Plan Options") to purchase
4,629,294
shares of Common Stock.
17
ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 7 — STOCKHOLDERS' EQUITY
(Continued)
A summary of the status
of the Plan Options outstanding at December 31, 2021 is presented below:
Options Outstanding
Options Exercisable
Exercise Price Ranges
Number Outstanding
Weighted Average Remaining Contractual Life (years)
Weighted Average Exercise Price
Number Exercisable
Weighted Average Remaining Contractual Life (years)
Weighted Average Exercise Price
$
2.00
–
4.50
285,043
8.69
$
3.23
197,637
8.49
$
3.12
$
4.51
–
6.50
3,538,330
9.21
$
4.80
455,999
7.09
$
6.16
$
6.51
–
8.00
797,521
8.70
$
7.95
556,094
8.20
$
7.93
Total
4,620,894
9.09
$
5.25
1,209,730
7.83
$
6.48
A summary of the status
of the Plan Options at December 31, 2021 and changes since July 1, 2021 are presented below:
Shares
Weighted Average Exercise
Price
Average Remaining Life
Weighted Average Intrinsic
Value
Outstanding at beginning of period
1,329,153
$
6.24
8.42
$
511,239
Granted
3,300,141
$
4.85
10.0
$
—
Exercised
—
$
—
—
$
—
Forfeited
—
$
—
—
$
—
Expired
(
8,400
)
$
—
—
$
—
Outstanding at end of period
4,620,894
$
5.25
9.09
$
9,997,233
Exercisable end of period
1,209,730
$
6.48
7.83
$
1,352,948
At December 31, 2021, the
Company had
1,209,730
exercisable Plan Options outstanding. The total intrinsic value of options exercisable at December 31, 2021,
was $
1,352,948
. Intrinsic value is measured using the fair market value at the date of exercise (for shares exercised) or at December
31, 2021 (for outstanding options), less the applicable exercise price.
Common Stock Purchase Warrants
A summary of the warrants
outstanding at December 31, 2021, are presented below:
Shares
Weighted Average Exercise
Price
Weighted Average Remaining
Life
Outstanding at beginning of period
1,350,000
$
1.30
1.02
Granted
—
$
—
—
Exercised
(
100,000
)
$
1.30
—
Cancelled/Expired
—
$
—
—
Outstanding and exercisable at end of period
1,250,000
$
1.30
.53
Underlying Warrants
Outstanding
Equivalent Shares Exercisable
Exercise Prices
Equivalent Shares
Weighted Average Remaining Contractual Life (years)
Weighted Average Exercise Price
Number Exercisable
Weighted Average Exercise Price
$
1.30
1,250,000
.53
$
1.30
1,250,000
$
1.30
The exercise price of certain
warrants and the number of shares underlying the warrants are subject to adjustment for stock dividends, subdivisions of the outstanding
shares of Common Stock and combinations of the outstanding shares of Common Stock. For so long as the warrants remain outstanding,
we are required to keep reserved from our authorized and unissued shares of Common Stock a sufficient number of shares to provide
for the issuance of the shares underlying the warrants.
18
NOTE 7 — STOCKHOLDERS' EQUITY
(Continued)
Restricted Stock Units (RSUs)
The Company recognized stock-based compensation
expense related to RSUs of $
255,340
and $
258,331
for the three and six months ended December 31, 2021, respectively. The Company
recognized stock-based compensation expense related to the RSUs of $
7,860
and $
17,066
for the three and six months ended December
31, 2020, respectively.
A summary of the status of Restricted Stock Units
outstanding at December 31, 2021 is presented below:
Shares
Weighted Average Issuance
Price
Weighted Average Remaining
Life
Weighted Average Intrinsic
Value
Outstanding at beginning of period
5,000
$
6.15
.02
$
—
Granted
36,266
—
—
—
Exercised
(
36,266
)
—
—
—
Cancelled/Expired
—
—
—
—
Outstanding at end of period
5,000
6.15
.02
$
—
Restricted Stock Units Outstanding
Grant Price
Stock Units
Weighted Average Remaining Contractual Life (years)
Weighted Average Issuance Price
6.15
5,000
.02
$
6.15
19
ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 8 —
COMMITMENTS AND CONTINGENCIES
On July 9, 2018, the Company
entered into a consulting agreement with G-Tech Bio, LLC, a California limited liability company ("G-Tech") to assist
the Company with the development of the gene therapy and cell therapy modalities for the prevention, treatment, and amelioration
of HIV in humans, and with the development of a genetically enhanced Dendritic Cell for use as a wide spectrum platform for various
diseases (including but not limited to cancers and infectious diseases) (the "G-Tech Agreement"). G-Tech was entitled
to consulting fees for 20 months, with a monthly consulting fee of not greater than $130,000 per month. Upon the completion of
the 20 months, the monthly consulting fee of $
25,000
continued for scientific consulting and knowledge transfer on existing HIV
experiments and will continue until the services are no longer rendered or the agreement is terminated. G-Tech is controlled by
certain members of Weird Science. For the three and six months ended December 31, 2021, $
75,000
and $
150,000
, was charged to research
and development expenses in our Condensed Consolidated Statements of Operations related to this consulting agreement, respectively.
For the three and six months ended December 31, 2020, $
75,000
and
125,000
, was charged to research and development expenses in
our Condensed Consolidated Statements of Operations related to this consulting agreement, respectively.
On January 31, 2020, the
Company entered into a Statement of Work & License Agreement (the "HBV License Agreement") by and among the Company,
G-Tech , and G Health Research Foundation, a not for profit entity organized under the laws of California doing business as Seraph
Research Institute ("SRI"), whereby the Company acquired a perpetual, sublicensable, exclusive license (the "HBV
License") for a treatment under development (the "Treatment") aimed to treat Hepatitis B Virus (HBV) infections
in accordance with its agreement in principle with G-Tech and SRI.
The HBV License Agreement
contains customary representations, warranties and covenants of the parties with respect to the development of the Treatment and
the HBV License. G-Tech and SRI are each controlled by certain members of Weird Science, LLC, a shareholder of the Company.
The cash funding for research
costs pursuant to the HBV License Agreement consists of monthly payments amounting to $
144,500
that cover scientific staffing resources
to complete the project, as well as periodic payments for materials and equipment needed to complete the project. For the three
and six months ended December 31, 2021, the Company paid a total of $
433,500
and $
867,000
, respectively for scientific staffing
resources, R&D and IND Enabling studies. During the three and six months ended December 31, 2021, respectively the Company
paid zero and a $
1,500,000
for the milestone completion of a Pre-Investigational New Drug (IND) process following receipt of written
comments in accordance with the HBV License Agreement.
On April 18, 2021, the Company
entered into a Statement of Work and License Agreement (the "License Agreement"), by and among the Company, G-Tech
and SRI, whereby the Company acquired a perpetual sublicensable, exclusive license (the "Development License") to research,
develop, and commercialize certain formulations which are aimed at preventing and treating pan-coronavirus or the potential combination
of the pan-coronavirus and pan-influenza, including the SARS-coronavirus that causes COVID-19 and pan-influenza (the "Prevention
and Treatment").
20
ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
The License Agreement was
entered into pursuant to the existing Framework Agreement between the parties dated November 15, 2019. The License Agreement states
that in consideration for the Development License, the Company shall provide cash funding for research costs and equipment and
certain other in-kind funding related to the Prevention and Treatment over a 24-month period. Additionally, the License Agreement
provides for an up-front payment of $
10,000,000
and a $
760,000
payment for expenditures to date prior to the effective date related
to research towards the Prevention and Treatment within 60 days of April 18, 2021. The License Agreement provides for additional
payments upon the occurrence of certain benchmarks in the development of the technology set forth in the License Agreement, in
each case subject to the terms of the License Agreement.
The License Agreement provides
for cooperation related to the development of intellectual property related to the Prevention and Treatment and for a 3% royalty
to G-Tech on any net sales that may occur under the License Agreement. For the three and six months ended December 31, 2021, the
Company paid $
75,000
and $
150,000
, respectively, related to the Prevention and Treatment research.
G-Tech is controlled by
Dr. Serhat Gümrükcü and Anderson Wittekind, shareholders of the Company, and SRI is controlled by Dr. Serhat Gümrükcü.
Shares held for non-consenting
shareholders
–
The 17,414 remaining shares of Common Stock related to the Acquisition of Enochian Denmark
have been reflected as issued and outstanding in the accompanying financial statements. There were zero shares of Common Stock
issued to such non-consenting shareholders during the three and six months ended December 31, 2021 (see Note 7.)
Service Agreements
–
The Company has a consulting agreement for services of a Senior Medical Advisor for up to $
210,000
per year on a
part-time basis.
Contingencies
–
The Company is from time to time involved in routine legal and administrative proceedings and claims of various types. While any
proceeding or claim contains an element of uncertainty, management does not expect a material impact on our results of operations
or financial position from such proceedings or claims.
NOTE 9 —
RELATED PARTY TRANSACTIONS
The Company paid G-Tech
$
718,500
and $
3,537,000
, which included payments for consulting agreements related to HIV, contractual costs related to the HBV
License and the Development License (See Note 8), and security expenses, for the three and six months ended December 31, 2021,
respectively.
NOTE 10 —
SUBSEQUENT EVENTS
In accordance with ASC 855-10,
the Company performed a review of events subsequent to the balance sheet date and through the date of this report and determined
that there were no such events requiring recognition or disclosure.
21
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations.
Forward-Looking Statement Notice
Certain statements made
in this Quarterly Report on Form 10-Q are "forward-looking statements" (within the meaning of the Private Securities
Litigation Reform Act of 1995) regarding the plans and objectives of management for future operations. Such statements involve
known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of Enochian
Biosciences Inc. ("Enochian", and together with its subsidiaries, the "Company", "we" or "us")
to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties.
Our actual future results and trends may differ materially depending on a variety of factors, including, but not limited to, the
risks and uncertainties discussed in Part I, Item 1A, "Risk Factors" in our Annual Report on Form 10-K as filed with
the SEC on September 24, 2021. The Company's plans and objectives are based, in part, on assumptions involving the continued
expansion of the business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future
economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict
accurately and many of which are beyond the control of the Company. Although the Company believes its assumptions underlying the
forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance
the forward-looking statements included in this Quarterly Report will prove to be accurate. In light of the significant uncertainties
inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation
by the Company or any other person that the objectives and plans of the Company will be achieved.
Our Business
We
are a pre-clinical stage biotechnology company committed to using our genetically modified cell, gene, and immune therapy technologies
to potentially prevent or cure HIV, HBV, influenza and coronavirus infections, as well as to provide potentially long-term or life-long
cancer remission in some of the deadliest cancers.
Over the past several years,
Enochian Biosciences Inc. has expanded the pipeline from a single potential cure for HIV (autologous transplantation with gene-modified
cells; ENOB-HV-01) to three additional potential cures for HIV, a potential cure for Hepatitis B Virus (HBV), potential inhaled
treatment and prophylaxis/prevention of all variants of SARS-CoV-1 and -2 (the cause of the COVID-19 pandemic), and potential cures
for many solid tumors, beginning with pancreatic cancer.
Our integrated platforms
encompass innovative interventions in gene and immune therapies that provide hope for cures or life-long remissions for devastating
diseases. Our platforms can potentially streamline and accelerate pre-clinical, regulatory, clinical, and production pathways.
Because of the relative ease of administration, our potentially groundbreaking interventions could be used throughout the world.
Platforms:
Hijack RNA
Our novel approach
tricks the virus into sending suicide signals to the infected cell instead of turning the cell into a virus factory. The technology
is delivered by vectors that would allow it to rapidly treat an infection, or to lay and wait in ambush until a cell becomes infected,
which would prevent (prophylaxis, similar to taking drugs to protect from becoming infected with malaria or HIV) future infections.
The delivery mechanism
can be adapted for aerosol (e.g., respiratory infections like the virus that causes COVID-19 and influenza), intravenous or other
delivery mechanisms (e.g. for Hepatitis B Virus and HIV).
Allogeneic Cell
Therapy
The human immune
system is designed to recognize "self" and destroy "otherness" or "non-self", such as bacteria,
viruses and cancer cells.
22
Alloreactivity
(reacting against another person's cells) is the most powerful response the immune system generates. Several of our technologies
take advantage of the alloreactivity to hyperstimulate a person's immune response to better attack a chronic infection (e.g.
HIV) or solid tumors. In certain treatments (e.g. HIV and cancer), cells taken from healthy donors are sometimes genetically modified
to further boost the immune system to seek and kill diseases.
In addition to
those platforms, Enochian Biosciences has an innovative approach to remove cells from a person living with HIV and genetically
modify them so they cannot be infected with HIV. The unique innovation is an additional genetic alteration to increase the ability
of those cells to survive and expand when they are given back to the same person (autologous transplantation).
Respiratory Diseases
In
April 2021, Enochian Biosciences acquired the exclusive license to a potential pan-SARS-Cornavirus-1 and-2 (SARS-CoV) and pan-Influenza
inhaled treatment and prophylaxis.
SARS-CoV-2
has caused the most devastating global pandemic in a century – COVID-19. Using the Hijack RNA platform technology,
in
vitro
and
in vivo
results showing rapid killing of infected cells, but not uninfected cells were presented at the important
Conference on Retroviruses and Opportunistic Infections in March 2021. Since that time, there has been substantial progress with
a Pre-IND (as defined below) submission expected in the near term.
Influenza
has caused dozens of major global pandemics; the most notable in 1918 that killed 50 to 100 million people. There was an H1N1 threat
as recently as 2009. The Hijack RNA also has shown promising
in vitro
results that were presented at the Annual Conference
of the American Society of Gene and Cell Therapy (ASGCT) in May 2020.
A
leading scientist and public health expert serves on our Scientific Advisory Board focused on respiratory diseases.
Human Immunodeficiency
Virus (HIV), and Acquired Immunodeficiency Syndrome (AIDS)
HIV
attacks the human immune system, specifically killing off CD4+ cells, or T cells, which play a central, controlling role in the
immune system. Left untreated, HIV dramatically reduces the number of T cells in the body, devastates the immune system, leading
to AIDS, a condition where the immune system cannot fight off life-threatening infections and cancers.
Currently
there are over 30 antiretroviral drugs, or ART, approved by the U.S. Food and Drug Administration ("FDA") to treat
HIV but these drugs are expensive, require daily adherence, and can have significant side effects over time. In addition, on a
global basis, as many as 1 million people, including persons in high-income countries, continue to die each year from HIV/AIDS
due to drug-resistant HIV or lack of access to treatment. To date, there are no treatments that can eliminate the reservoir of
immune cells that are infected with HIV from the body. Consequently, treatment for HIV is life-long.
There
have been several efforts to cure HIV by re-engineering a person's own T-cells so that these cells no longer express a special
protein (C-C chemokine co-receptor type 5 or CCR5), which HIV uses to gain entry to them. A naturally occurring mutation that blocks
expression of CCR5 on T cells occurs in ~1% of persons living in or from Northern Europe with no known adverse effects. The "Berlin
patient", and more recently the "London patient" were HIV-positive persons who developed cancer and were treated
with a bone marrow transplant with cells donated from persons with this naturally occurring mutation of CCR5. The Berlin and London
patients seem to have been effectively cured from HIV providing proof-of-concept that HIV can be cured. However, because the transplanted
cells come from another person, such transplants carry high risk and can result in death in a significant proportion of patients.
Given the success with these two patients, several researchers and companies have attempted to replicate this experience by genetically
modifying T cells of HIV-positive patients to render them unable to be infected by HIV and then returning them to the patient.
Because the transplanted cells are from the same person, the risks to the patient are much lower. The uptake, or engraftment of
the modified T cells, however, has not been optimal, leading to failure to achieve a cure. In addition, the transplant pre-treatment
that has been used is bone marrow-destroying chemotherapy, which wipes out the patient's immune system and can have long-term
side effects including the risk of developing cancer.
23
ENOB-HV-01
is a novel, proprietary approach with the potential to overcome the failures of recent efforts to develop a cure for HIV. The intervention
provides gene-modified T cells with a competitive advantage over non-modified cells in the HIV-positive person, with the potential
to significantly increase engraftment; and avoid the need for chemotherapy that substantially depletes the bone marrow and could
potentially be given as an outpatient treatment. The Company met with the FDA INTERACT team on June 2, 2020. INTERACT is the first
available FDA interaction and is a key step in the process towards a potential Investigational New Drug Application (IND) to study
First-in-Human products potentially leading to marketing authorization via Biologics License Application (BLA). The FDA Center
for Biologics Evaluation and Research (CBER) has numerous INTERACT requests and grants meetings that are deemed appropriate for
this early FDA engagement. The Enochian management team considered the meeting to be successful with strong alignment between Enochian's
approach to developing ENOB-HV-01 and the comments of the FDA reviewers.
Initial
scientific findings from a mouse study on the ENOB-HV-01 approach were presented at the annual ASCGT conference in May 2020.
We
are also developing ENOB-HV-11 and ENOB-HV-12 that will utilize a novel cellular- and immunotherapy approach that could potentially
provide both preventative and therapeutic vaccines for HIV. A non-human primate study is in process and on schedule. Preliminary
results could potentially be available by the latter part of 2022.
Our co-founder and inventor,
Dr. Serhat Gümrükcü, who is also the Director of Seraph Research Institute (SRI), submitted Pre-IND for ENOB-HV-21,
an innovative treatment of Natural Killer (NK) and Gamma Delta T-Cells (GDT) collected from another person. It is believed that
the GDT cells, a small subset of immune cells that can be infected with HIV, could be a key factor in controlling the virus. The
initial scientific findings were presented during the ASCGT Conference this past May. Enochian Biosciences has an exclusive license
to use the underlying patent to develop ENOB-HV-21 for the prevention, treatment, and/or amelioration of and/or therapy exclusively
for HIV in humans, and research and development exclusively relating to HIV in humans.
We
are in the development phase of additional product candidates related to our HIV pipeline. ENOB-HV-31, which is an
in vivo
gene
therapy, and ENOB-HV-32, which is a peptide drug for packaging and distribution.
Hepatitis B (HBV)
Despite the availability
of an effective vaccine and treatment that can control infection if it is taken daily for life, hepatitis B virus (HBV) is the
world's most common serious liver infection. While vaccines are increasingly required for children, many adults have not
been vaccinated. Life-long treatment can be difficult for certain people and access can be limited.
In that regard, HBV remains
the leading cause of liver cancer and the second leading cause of cancer deaths in the world. Two billion people have been infected
with HBV, approximately 350 million have chronic HBV infection, and nearly one million people die every year.
Current efforts to develop
novel treatment or cure largely focus on approaches to deplete the pool of a certain type of HBV DNA. Enochian Biosciences has
collaborated with SRI to develop an innovative approach to co-opt HBV polymerase, a key expanding factor that the virus needs to
reproduce itself, to induce the death of liver cells infected with the virus.
On July 27, 2020, Enochian
Biosciences announced the creation of an HBV Scientific Advisory Board comprised of distinguished leaders in HBV disease, treatment
and cure. On August 23, 2021, we announced the addition of a third leading expert with substantial experience in HBV clinical trials.
On September 27, 2021, the
Company announced the completion of a Pre-Investigational New Drug (IND) process following receipt of written comments from the
U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies
(OTAT) for ENOB-HB-01.
24
The initial
in vitro
and
in vivo
work was presented at the biannual HEP DART meeting in December of 2019, where it was selected as one of
the best new therapies/novel strategies. Additional data was presented at the annual ASCGT conference in May 2020. A proof-of-concept,
in vivo
cure study is in advanced stages. A Pre-IND request has been completed with productive comments and insights. An
IND could potentially be submitted towards the end of 2022 with potential for enrollment in a clinical trial to begin by the end
of 2022 or in 2023.
Cancer
Based on learning from peer-reviewed publications
of Phase I/IIa trials, we have designed an innovative therapeutic vaccination platform that could potentially be used to induce
life-long remissions from some of the deadliest solid tumors. Initial preclinical
in vitro
studies have been encouraging.
We initially plan to target pancreatic cancer, triple-negative breast cancer, glioblastoma, and renal cell carcinoma. The platform
might also allow for non-specific immune enhancement that could have impact against a broad array of solid tumors. As with HIV,
our approach would potentially allow for outpatient therapy without ablating or significantly impairing the patient's immune
system, as many current approaches require.
Through a collaboration with a leader in the
field of pancreatic cancer, our first cancer-related therapeutic target, we are developing the pipeline with
in vitro
and
in vivo
proof-of-concept studies to evaluate the potential to induce long-term remission or cure. Results are expected in
first half 2022. If the results are promising, a potential Pre-IND and an IND with potential for enrollment in a clinical trial
maybegin in 2022.
To
date, our operations have been funded by sales of our securities and the issuance of debt. We have never generated any sales revenue,
and we expect this to continue until our therapies or products are approved for marketing in the United States and/or Europe. Even
if we are successful in having our therapies or products approved for sale in the United States and/or Europe, we cannot guarantee
that a market for the therapies or products will develop. We may never be profitable.
Corporate History
On February 16, 2018, we
completed our acquisition of Enochian Biopharma pursuant to an acquisition agreement, dated January 12, 2018, by and among the
Registrant, its wholly owned subsidiary DanDrit Acquisition Sub, Inc., Enochian Biopharma and Weird Science with Enochian Biopharma
surviving as a wholly owned subsidiary of the Registrant. As consideration for the acquisition, the stockholders of Enochian Biopharma
received (i) 18,081,962 shares of Common Stock and (ii) the right to receive contingent shares pro rata upon the exercise or conversion
of warrants, which were outstanding at closing (see Note 7.)
COVID-19
The COVID-19 pandemic continues
to evolve, and to date has led to the implementation of various mitigation responses, including government-imposed quarantines,
travel restrictions and other public health safety measures, as well as leading to reported adverse impacts on healthcare resources,
facilities and providers across the United States and in other countries. COVID-19 may cause delays in our research activities.
To date, it has not materially affected our operations; however it has caused delays in the conduct of experiments due to limitations
of various organizations, in particular those conducting experiments related to COVID-19. There have also been increases in the
cost to conduct animal studies due to staffing and other limitations.
The full extent to which
the COVID-19 pandemic may impact our business and operations is subject to future developments, which are uncertain and difficult
to predict. Further quarantines, shelter-in-place or similar restrictions and other actions taken or imposed by foreign, federal,
state and local governments could adversely impact our or our partners' clinical, research and development, regulatory and
manufacturing operations or timelines.
We continue to monitor the
impact of the COVID-19 pandemic on our business and operations and will seek to adjust our activities as appropriate. In addition,
the pandemic could result in significant and prolonged disruption of global financial markets, reducing our ability to access capital,
which could in the future negatively affect the financial resources available to us.
25
Results of Operations
for the three and six months ended December 31, 2021 compared to the three and six months ended December 31, 2020
The following table
sets forth our revenues, expenses and net loss for the three and six months ended December 31, 2021 and 2020. The financial information
below is derived from our unaudited condensed consolidated financial statements.
For the Three Months Ended
For the Six Months Ended
December 31,
Increase/(Decrease)
December 31,
Increase/(Decrease)
2021
2020
$
%
2021
2020
$
%
Operating Expenses
General and administrative expenses
4,154,901
1,939,988
2,214,913
114
%
8,621,598
3,717,911
4,903,687
132
%
Research and development expenses
2,144,085
1,334,468
809,617
61
%
5,150,328
2,384,844
2,765,484
116
%
Depreciation and amortization
31,805
30,760
1,045
3
%
63,538
61,218
2,320
4
%
Total Operating Expense
$
6,330,791
$
3,305,216
$
3,025,575
92
%
$
13,835,464
$
6,163,973
$
7,671,491
124
%
LOSS FROM OPERATIONS
$
(6,330,791
)
$
(3,305,216
)
$
(3,025,575
)
92
%
$
(13,835,464
)
$
(6,163,973
)
$
(7,671,491
)
124
%
Other Income (Expense)
Change in fair value of contingent consideration
(167,255
)
493,411
(660,666
)
(134
)%
(2,991,897
)
920,811
(3,912,708
)
(425
)%
Interest expense
(93,382
)
(93,426
)
44
—
%
(183,121
)
(185,739
)
2,618
(1
)%
Gain (Loss) on currency transactions
—
(32,289
)
32,289
100
%
9
(32,289
)
32,298
100
%
Interest income
8,487
3,066
5,421
177
%
15,597
7,372
8,225
112
%
Total Other (expense) income
(252,150
)
370,762
(622,912
)
(168
)%
(3,159,412
)
710,155
(3,869,567
)
(545
)%
Loss Before Income Taxes
$
(6,582,941
)
$
(2,934,454
)
$
(3,648,487
)
124
%
$
(16,994,876
)
$
(5,453,818
)
$
(11,541,058
)
212
%
Income Tax Benefit
$
—
$
1,158
$
(1,158
)
(100
)%
$
(34
)
$
123,952
$
(123,986
)
(100
)%
NET LOSS
$
(6,582,941
)
$
(2,933,296
)
$
(3,649,645
)
124
%
$
(16,994,910
)
$
(5,329,866
)
$
(11,665,044
)
219
%
Revenues
We are a pre-revenue, pre-clinical biotechnology company. We have
never generated revenues and have incurred losses since inception. We do not anticipate earning any revenues until our therapies
or products are approved for marketing and sale.
Expenses
Our operating expenses for
the three months ended December 31, 2021, and December 31, 2020 were
$6,330,791 and $3,305,216
respectively, representing an increase of $3,025,575, or approximately 92%
. The increase in operating expenses primarily
relate to general and administrative expenses.
Our operating expenses for
the six months ended December 31, 2021, and December 31, 2020, were $13,835,464 and $6,163,973, respectively, representing an increase
of $7,671,491 or approximately 124%. The change is primarily related to the increase in general and administrative expenses of
$4,903,687, and an increase in R&D expenses of $2,747,984.
26
General and administrative
expenses for the three months ended December 31, 2021, and December 31, 2020, were $4,154,901 and $1,939,988, respectively, representing
an increase of $2,214,914 or approximately 114%. The variance is primarily related to an increase in stock-based compensation of
$1,683,901, an increase in compensation and related expenses of $301,743, and an increase in lab expenses of $160,618.
General and administrative
expenses for the six months ended December 31, 2021, and December 31, 2020, were $8,621,598 and $3,717,911, respectively, representing
an increase of $4,903,687 or approximately 132%. The largest contributors to the increase in general and administrative expenses
were the increases in stock-based compensation of $4,085,720, officer compensation of $436,062, salaries expense of $196,065, laboratory
expenses of $171,847, and recruiting expenses of $117,233, offset by a decrease in security expenses of $139,175.
Research and development
expenses for the three months ended December 31, 2021, and December 31, 2020, were $2,144,085 and $1,334,468, respectively, representing
a decrease of $809,617 or approximately 61%. The variance is primarily driven by $684,939 contract development and manufacturing
company ("CDMO") partner expenses related to CV-01, $75,000 related to COVID license payments that were not established
in prior year, and $33,000 in new contract research organization ("CRO") payments. All other R&D costs remained
relatively flat.
Research and development
expenses for the six months ended December 31, 2021, and December 31, 2020, were $5,150,328 and $2,384,844, respectively, representing
an increase of $2,765,484 or approximately 116%. The largest contributors to the increase in research and development expenses
were the increases in license costs related to ENOB HB-01 of $1,500,000 for achievement of milestone, costs incurred for ENOB HV-21
of $600,000, newly incurred costs with CDMO and CRO partners totaling $765,939, new COVID license payments of $150,000, offset
by a reduction in license costs related to ENOB-HB-01 totaling $400,000 that were incurred in the prior period only.
The Company recorded other
(expense) of $252,150 for three months ended December 31, 2021, compared to other income of $370,762 for the three months ended
December 31, 2020, representing an increase in other (expense) of $622,912 or 168%. The variance is primarily due to the change
in fair value of the contingent consideration liability expense of $660,666.
The Company recorded other
(expense) of $3,159,412 for the six months ended December 31, 2020, compared to other income of $710,155 for the six months ended
December 31, 2020, representing an increase in other (expense) of $3,869,567 or 545%. The variance is primarily due to the change
in fair value of the contingent consideration liability expense of $3,912,708.
Net Loss
Net loss for the three months
ended December 31, 2021, and 2020, was $6,582,941 and $2,933,296, respectively, representing an increase in loss of $3,649,645
or approximately 124%. The increase in net loss was primarily due to an increase in general and administrative expenses of $2,214,913,
an increase in research and development expenses of $809,617, and the change in the change in fair value of the contingent consideration
of $660,666.
Net loss for the six months
ended December 31, 2021, and 2020, was $16,994,910 and $5,329,866, respectively, representing an increase in loss of $11,665,044
or approximately 219%. The increase in net loss was primarily due to the increase in general and administrative expenses of $4,903,687,
an increase in research and development costs of $2,765,484, and an increase in expense related to the change in fair value of
the contingent consideration of $3,912,708.
Liquidity and Capital Resources
We have historically satisfied
our capital and liquidity requirements through funding from shareholders, the sale of our Common Stock and warrants, and debt financing.
We have never generated any sales revenue to support our operations and we expect this to continue until our therapies or products
are approved for marketing in the United States and/or Europe. Even if we are successful in having our therapies or products approved
for sale in the United States and/or Europe, we cannot guarantee that a market for the therapies or products will develop. We may
never be profitable.
At this time, we believe
we have sufficient liquidity and access to committed funds to fund our operations for the next twelve months. We may need additional
funds for (a) the purchase of equipment, (b) increases in personnel, and, (c) research and development, specifically to advance
towards an Investigational New Drug Application (IND) following Pre-IND readouts from the FDA for ENOB-CV-01, ENOB-HB-01, ENOB-HV-01,
and ENOB-HV-21. We will also require additional funding to continue our research and development of ENOB-HV-11/12, ENOB-DC-11,
ENOB-FL-01 and -11 and ENOB-CV-11, to fund the Coronavirus and Influenza Indications License Agreement in furtherance of treatment
related to all coronaviruses, and for possible future strategic acquisitions of businesses, products or technologies complementary
to our business. If additional funds are required, we may raise such funds from time to time through public or private sales of
our equity or debt securities. Such financing may not be available on acceptable terms, or at all, and our failure to raise capital
when needed could materially adversely affect our growth plans and our financial condition and results of operations.
27
As of December 31, 2021,
the Company had $13,707,907 in cash and working capital of $8,416,386 as compared to $20,664,410 in cash and working capital of
$19,013,100 as of June 30, 2021, a decrease of 34 % and 56%, respectively.
Assets
Total assets at December
31, 2021, were $183,136,138 compared to $189,605,225 as of June 30, 2021. The decrease in total assets was primarily due to the
decrease in cash of $6,956,503. The change in cash is primarily attributed to $5,150,328 in research and development costs related
to the HBV license agreement, costs related to ENOB-CV-01 for related CDMO and CRO costs, and ENOB-HV-21 studies along with approximately
$3,710,286 in general and administrative expenses, net of non-cash items, offset by an increase in funding totaling $3,178,339
related to warrants exercised during the period and drawdowns from the LPC equity line.
Liabilities
Total liabilities at December
31, 2021, were $17,516,675 compared to $14,942,286 as of June 30, 2021. The increase in total liabilities was primarily related
to an increase of $2,991,897 in the contingent consideration liability as a result of mark-to-market adjustment, and an increase
in other current liabilities of $409,273 related to a financing arrangement for a new insurance policy, partially offset by the
reduction in accrued expenses of $677,940, and the reduction of accounts payable of $153,809 due to timing.
The following is a summary
of the Company's cash flows (used by) or provided by operating, investing, and financing activities:
Six Months
Ended
December 31,
2021
Six Months
Ended December
    31,
2020
Net Cash (Used in) Operating Activities
$
(9,897,151
)
$
(5,251,828
)
Net Cash (Used in) Investing Activities
(5,156
)
(10,721
)
Net Cash Provided by Financing Activities
2,950,741
(40,408
)
(Loss) Gain on Currency Translation
(4,937
)
31,646
Change in Cash and Cash Equivalents
$
(6,956,503
)
$
(5,271,311
)
Cash Flows
Cash used in operating activities
for the six months ended December 31, 2021, and 2020 was ($9,897,151) and ($5,251,828), respectively. Cash used in operating activities
during the current period included $5,150,328 in research and development costs related to the HBV license agreement, costs related
to ENOB-CV-01 for related CDMO and CRO costs, and ENOB-HV-21 studies along with approximately $3,710,286 in general and administrative
expenses, net of non-cash items.
Cash provided by financing
activities for the six months ended December 31, 2021, was $2,950,741 as compared to cash used by financing activities of $40,408
during the six months ended December 31, 2020. During the six months ended December 31, 2021, the Company received financing from
the drawdown of its LPC equity line of $3,048,339 and the exercise of warrants held by shareholders of $130,000.
Off-Balance Sheet Arrangements
The Company does not have
any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company's
financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures
or capital resources that is material to investors.
28
Significant Accounting Policies and Critical
Accounting Estimates
The methods, estimates,
and judgments that we use in applying our accounting policies have a significant impact on the results that we report in our financial
statements. Some of our accounting policies require us to make difficult and subjective judgments, often as a result of the need
to make estimates regarding matters that are inherently uncertain.
For a full explanation of
our accounting policies, see Note 1 to the unaudited condensed consolidated financial statements.
Item 3. Quantitative and Qualitative Disclosures
About Market Risk.
As a "smaller reporting
company" as defined by Rule 12b-2 of the Securities Exchange Act of 1934, the Company is not required to provide the information
required by this Item.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Our Principal Executive
Officer and Chief Financial Officer (the "Certifying Officers") are responsible for establishing and maintaining disclosure
controls and procedures for the Company. The Certifying Officers have designed such disclosure controls and procedures to ensure
that material information is made known to them, particularly during the period in which this Report was prepared.
The Certifying Officers
are responsible for establishing and maintaining adequate internal control over financial reporting for the Company and used the
"Internal Control over Financial Reporting Integrated Framework" issued by the Committee of Sponsoring Organizations
("COSO") to conduct an extensive review of the Company's "disclosure controls and procedures" (as
defined in the Exchange Act, Rules 13a-15(e) and 15-d-15(e)) as of the end of each of the periods covered by this Report (the "Evaluation
Date"). Based upon that evaluation, the Certifying Officers concluded that, as of December 31, 2021, our disclosure controls
and procedures were not effective in ensuring that the information we were required to disclose in reports that we file or submit
under the Securities and Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods
specified in SEC rules and forms. The deficiency is attributed to the fact that the Company does not have an adequate number of
persons to whom it can segregate accounting tasks within the Company so as to ensure the segregation of duties between those
persons who approve and issue payment from those persons who are responsible to record and reconcile such transactions within the
Company's accounting system. This control deficiency will be monitored and attention will be given to this matter as we increase
our personnel.
The Certifying Officers
based their conclusion on the fact that the Company has identified a material weakness in controls over financial reporting, detailed
above. We expect to be deficient in our disclosure controls and procedures until sufficient capital is available to hire the appropriate
internal accounting staff.
Changes in Internal Controls
There have been no changes
in our internal controls over financial reporting during the three months ended December 31, 2021 that have materially affected
or are reasonably likely to materially affect our internal controls.
29
PART II — OTHER INFORMATION
Item 1. Legal Proceedings.
There are presently no material
pending legal proceedings other than in the ordinary course of business to which the Company or any of its subsidiaries, is a party
or as to which any of its property is subject, and no such proceedings are known to the Company to be threatened or contemplated
against it.
Item 1A. Risk Factors.
Risk factors that may affect
our business and financial results are discussed within Item 1A "Risk Factors" of our annual report for the fiscal
year ended June 30, 2021 on Form 10-K ("2021 Form 10-K") filed with the SEC on September 24, 2021. There
have been no material changes to the disclosures relating to this item from those set forth in our 2021 Form 10-K.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
None.
Item 6. Exhibits.
(a)
Exhibits required by Item 601 of Regulation S-K.
Exhibit No.
Description
31.1**
Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934
31.2**
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934
32.1***
Certification of Principal Executive Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350
32.2***
Certification of Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350
101.INS
XBRL Instance Document
101.SCH
XBRL Taxonomy Extension Schema
101.CAL
XBRL Taxonomy Extension Calculation Linkbase
101.DEF
XBRL Taxonomy Extension Definition Linkbase
101.LAB
XBRL Taxonomy Extension Label Linkbase
101.PRE
XBRL Taxonomy Extension Presentation Linkbase
**
Filed herewith.
***
Furnished herewith.
30
SIGNATURES
Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date: February 14, 2022
ENOCHIAN BIOSCIENCES INC.
By:
/s/ Mark Dybul
Mark Dybul
Chief Executive Officer
(Principal Executive Officer)
By:
/s/ Luisa Puche
Luisa Puche
Chief Financial Officer
(Principal Financial and Accounting Officer)
31